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Lung cancer
Lung cancer is the most commonly diagnosed form of cancer worldwide in both sexes 
combined. Of the 18.1 million new cancer cases in 2018, 2.1 million (11.6%) are estimated to 
be lung cancers [1]. It is also the most common cause of cancer deaths, with an estimated 1.8 
million (18.4%) deaths due to lung cancer out of 9.6 million cancer deaths worldwide. In the 
Netherlands, almost 14 000 new lung cancer cases have been diagnosed in 2018 (based on 
preliminary numbers) [2], and nearly 10 400 lung cancer patients died of lung cancer in 2017 
[3]. It is diagnosed more often in males than in females, and patients are mainly between 
60 and 74 years of age at diagnosis. Between 80% and 90% of lung cancer deaths in the 
United States are attributed to smoking and similar numbers likely apply to the Netherlands 
(Centers for Disease Control and Prevention [4]). Other risk factors include air pollution, 
ionizing radiation (e.g., from radon), other lung diseases (for example, tuberculosis, chronic 
obstructive pulmonary disease), and asbestos exposure.
The majority of lung cancers can be divided into two groups based on their pathological 
appearance: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Between 
80% to 85% of the lung cancers are NSCLC and they form the main topic of this thesis. 
The predicted outcome of a patient’s disease is based on staging according to the AJCC 
TNM cancer staging manual [5]. Staging indicates disease prognosis and assists physicians in 
determining an optimal treatment strategy. The overall cancer stage is based on the tumor 
location, the size and extent of the tumor (T stage), lymph node involvement (N stage) and 
metastasis status (M stage). The research cohorts in this thesis consist mainly of patients 
diagnosed with stage III (locally advanced) NSCLC. Stage III NSCLC comprises large tumors (>7 
cm), invasive tumors or tumors that have spread to regional lymph nodes. Overall survival 
in stage III NSCLC patients has improved over the years but is still only 57% one year after 
diagnosis, and 19% after five years [6]. The treatment strategy for these patients is typically 
a combination of surgery, chemotherapy, and radiation therapy with the recent addition of 
immunotherapy for selected patients [7].
Radiation oncology
Radiation therapy or radiotherapy, forms an integral part of the treatment strategy for 
many cancers. High-energy radiation, commonly comprising photons, protons or electrons 
in the megaelectronvolt range, is exploited for its capability to ionize atoms and molecules 
(ejecting electrons). Ionization can lead to the breakage of chemical bonds resulting in 
atoms or molecules with unpaired valence electrons, so-called free radicals. Free radicals 
are highly reactive and cause biological damage in living tissues. While most of this damage 
is corrected through cellular repair mechanisms, extensive damage to the DNA molecules 
can exceed the repair capabilities of the cells. Radiation can induce cellular senescence, 
which halts cell division and proliferation. Alternatively, sufficient DNA damage can lead to 
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cell death during subsequent cell divisions, termed mitotic catastrophe, or to programmed 
cell death, termed apoptosis [8].
The amount of energy deposited in a unit mass of material is called the absorbed dose 
and has the SI unit gray (Gy, equivalent to J/kg). Typical radiation doses for lung cancer 
treatments with curative intent are between 60-66 Gy and given in 30-33 daily fractions [9].
Administering radiation to a tumor inevitably leads to radiation dose in neighboring healthy 
tissues. The radiation dose to the tumor should be sufficiently high to kill all tumor cells 
and achieve local control, but be low enough in surrounding tissues to limit side effects 
induced by the radiation (i.e. toxicities). The tradeoff between tumor control and side 
effects as a function of the prescribed treatment dose is called the therapeutic window. The 
tolerances of healthy tissues have been thoroughly researched to determine the optimal 
radiation doses [10,11]. Common side effects in lung cancer patients are inflammation of 
the esophagus (esophagitis), leading to a sore throat and swallowing difficulty (dysphagia, 
odynophagia), and inflammation of the lungs (pneumonitis), leading to a dry cough or 
shortness of breath (dyspnea) [12]. 
The ability of cells to recover from radiation damage depends in part on the type of cells. 
Tumor cells typically recover more slowly from radiation damage than healthy tissues. This 
characteristic is utilized to enhance the therapeutic window by administering radiation 
therapy in multiple fractions over the course of many days. Additionally, the therapeutic 
window can be further enhanced through a variety of radiotherapy techniques. For most 
patients, radiotherapy is administered via external beam radiotherapy using photons. By 
applying sophisticated modulation techniques, such as intensity-modulated radiotherapy 
or volumetric-modulated arc therapy, volumes that are highly conformal to the tumor are 
irradiated while limiting the dose to surrounding healthy tissues. Depending on the tumor 
location, some cancers are eligible for internal radiation therapy using radioactive sources 
(such as gynecological, prostate, or skin cancers). This form of internal radiotherapy is 
called brachytherapy and can drastically limit the dose to the surrounding tissues. Another 
approach is to use protons instead of photons as the type of ionizing radiation. In photon 
radiotherapy, the treatment dose is deposited along the entire trajectory of the beam and is 
mainly reduced by attenuation and the inverse-square law. In contrast, protons deposit dose 
in a highly localized volume, allowing improved sparing of healthy tissues.
Generating highly conformal radiation distributions (high precision) is one part of the 
equation, but radiation treatments also need to be delivered at exactly the intended location 
(high accuracy). Towards this end, pre-treatment imaging of the patient is common practice, 
by using for example cone beam computed tomography. Before each irradiation, the internal 
anatomy can be assessed and the patient position can be accurately set and verified. Recent 
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introductions of systems combining radiation treatment and magnetic resonance imaging 
(MRI) devices offer imaging of the treatment region with unprecedented soft tissue contrast 
immediately prior to or even during treatment [13,14]. MRI-guided radiotherapy potentially 
allows for enhanced accuracy and precision of the radiation dose delivery, which can further 
reduce the dose to the healthy tissues and limit the risk of treatment-induced side effects.
Prediction modeling of patient outcomes
Prediction modeling concerns the practice of developing models that predict outcomes by 
using statistical analyses on input data. The generated models relate one or more available 
input variables with the observed outcome. Prediction models can be used to calculate a 
probability of observing a certain outcome depending on the individual patient values for 
the model variables. They are widely used in medical research to predict diagnosis, prognosis 
or treatment outcomes. In radiation oncology, for example, prediction models are used to 
estimate the probability of achieving tumor control or the risk of inducing side effects for a 
given treatment. Prediction models for treatment-induced side effects in healthy tissues or 
organs are called normal tissue complication probability (NTCP) models and form the main 
research topic of this thesis. 
One can distinguish between prognostic and predictive models. Prognostic models have 
input variables with values that are fixed for a patient (e.g., tumor stage) and do not allow 
any modification to influence the outcome prediction. In contrast, predictive models do 
contain variables whose values can be modified. For example, in models containing the 
planned radiotherapy doses to the tumor or surrounding healthy tissues as variables, the 
outcome predictions can be altered by adjusting the treatment plans. Such models can be 
used to individualize treatments by optimizing the tradeoff between tumor control and side 
effects. Prediction models are currently used in the Netherlands to stratify patients between 
proton and photon radiotherapy, the so-called ‘model-based approach’ [15,16].
It is useful to realize that prediction models do not establish causal relations but help 
demonstrate correlations between inputs and the outcome under investigation. A two-year 
survival model containing tumor stage as an input does not indicate that a higher tumor 
stage itself causes earlier mortality (higher tumor stage only indicates more advanced 
disease). Tumor staging is simply an artificial construct to achieve classification according 
to some protocol. A more trivial example: a crowing rooster does not cause the start of 
morning, but it surely correlates strongly with it. Nonetheless, strong correlations are 
extremely helpful since they can assist in revealing underlying causal relations and can allow 
accurate outcome prediction.
The process of developing prediction models is alternatively referred to as statistical 
learning, machine learning, or more broadly, artificial intelligence (AI). These terms are 
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closely related; there is no strict agreement on their precise definitions, and their use mostly 
varies depending on the research problem at hand. In general, they can be considered to 
convey the same meaning, and throughout this thesis prediction modeling and machine 
learning will be used synonymously.
The basics of prediction modeling methodology are described in more detail in the next 
chapter of this thesis.
The machine learning revolution
In the past decade the interest in machine learning and AI technologies has seen a dramatic 
increase, as evidenced by the explosive growth in AI related expenditures [17]. At first 
glance, machine learning seems like a recent invention; it is not much appreciated that 
the underlying methods have already been developed many decades ago. The field of AI 
research started in the 50s; illustrated by the invention of the perceptron in 1957, which 
is essentially a single-layer neural network consisting of multiple input neurons connected 
with one output neuron [18]. The widespread attention for machine learning that has 
developed in recent years can be attributed to a combination of several factors:
• Computing power: the doubling of central processing unit (CPU) transistors 
every two years (exponential growth, Moore’s Law), and similarly, recent strong 
performance gains in graphics processing units (GPUs), which are well suited for 
machine learning tasks due to their parallel architecture.
• Advent of the Big Data era: data storage technology improvements have enabled 
the collection of vast amounts of data. Similar to Moore’s Law for computing 
power, a doubling of the total amount of (transient) data is observed every two 
years (estimated by global market analyst IDC at 5 zettabytes (ZB = 1012 gigabytes) 
in 2014 and recently updated to an estimated 180 ZB in 2025 [19]).
• Improved implementations: advanced machine learning algorithms, such as deep 
learning [20], show increased interpretation of complex data representations 
including image or free text data.
• Accessible tools: free and open-source tools are widely available, e.g., the caret 
package for predictive modeling in R [21], the Anaconda distribution for scientific 
computing [22], the TensorFlow library for neural networks [23], and are easy to 
use thanks to large communities of users and developers.
• Successful applications: the use of machine learning has become mainstream for 
many applications, for instance, in natural language processing, for recommendation 
systems, in financial trading markets or for speech/image recognition [24].
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In healthcare, we are routinely collecting large quantities of patient data on, for example, 
genomics, imaging, blood biomarkers, treatment and follow-up [25]. The application 
of machine learning techniques in medicine has the potential to revolutionize personal 
medicine, i.e. it could help find treatments that are tailored towards single patients and 
maximize individual treatment benefits. Furthermore, machine learning algorithms can 
process large amounts of data and do so in short timespans, enabling a rapid learning 
healthcare system where newly collected data immediately contributes to the continuously 
growing medical knowledge database [26,27].
Focusing on radiation oncology, the published machine learning applications are numerous. 
Machine learning implementations have been published for, amongst others, automatic 
lesion detection, tumor characterization, image delineation, treatment planning and 
outcome prediction [28,29].
Distributed learning
Conventional machine learning is performed on data aggregated in one location (centralized 
learning). In contrast, distributed learning, or sometimes called federated learning, is 
machine learning research performed on data that is partitioned across multiple locations. 
The data remains at the locations of their respective owners and is not directly shared. The 
data is at no instance available all at once, and this necessitates “bringing the algorithm to 
the data, instead of the data to the algorithm” — a proverb commonly used to describe 
distributed learning [30].
Distributed learning is becoming increasingly popular for several reasons. Data separated 
over multiple locations requires a certain level of parallelization of the algorithms, which 
in turn can lead to significant speed improvements for the desired data analyses [31]. This 
approach is especially helpful in a world where the number of connected devices is rapidly 
increasing (e.g., distributed learning applied to mobile devices [32]). Additionally, because 
the data does not leave the institutes, distributed learning can effectively negate privacy 
concerns when performing multi-institutional machine learning studies in the healthcare 
domain.
Data can be horizontally partitioned, i.e. each data location contains a unique set of patients 
but all data locations cover a similar set of variables, or data can be vertically partitioned, 
i.e. each data location contains a different set of variables but for the same overall set of 
patients [33]. The distributed learning research described in this thesis concerns horizontally 
partitioned data and the data locations are formed by the institutes. Each institute makes 
a predetermined set of variables available for their own patients within the distributed 
learning infrastructure.
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A researcher performing a distributed learning study typically does not have direct access 
to the data and cannot inspect individual data elements. This requires conversions of 
conventional data analysis algorithms (e.g., algorithms that fit prediction models) so that 
they can operate within the distributed learning infrastructure [34,35]. The ultimate goal 
is that the converted algorithms produce results as if the data were centralized, or in other 
words, that they converge to identical solutions as would have been obtained when the data 
was aggregated and analyzed centrally.
Another important consequence of the inability of a researcher to inspect individual data 
elements is that (s)he can only validate data correctness through indirect means, such as 
algorithms calculating summary statistics. Conventionally, a human can infer semantics 
by looking at the data, but now the algorithms need to do this for us. Adhering to FAIR 
data principles (Findable, Accessible, Interoperable, Reusable [36]) is therefore especially 
important in a distributed infrastructure to ensure that the algorithms correctly interpret the 
data. A move away from conventional technologies, such as relational databases and SQL 
queries, and towards technologies that enrich data with meaning, such as Semantic Web, 
logically follows. A key role is reserved for the mapping of data using common ontologies, 
where concepts and relationships between concepts are explicitly coded into the data 
representation (for example, the Radiation Oncology Ontology [37]). Ontologies ensure that 
different data representations between institutes are comprehensible by the algorithms 
(e.g., biological sex might be encoded as M/F in institute A, but as 0/1 in institute B).
Thesis outline
In Chapter 2, the basic theory underlying prediction modeling is described. The process 
of creating a prediction model using regression techniques is illustrated. Important 
performance metrics for model evaluation and different approaches for model validation 
are clarified.
Chapter 3 presents a multivariable logistic regression NTCP model that was developed 
for prediction of acute esophageal toxicity in locally advanced NSCLC patients undergoing 
(chemo-)radiotherapy. This prediction model was externally validated in five new patient 
cohorts originating from four Dutch institutes to investigate its generalizability on new data 
(Chapter 4). The influence of the spatial dose distribution for the development of acute 
esophageal toxicity was investigated in Chapter 5. Two-dimensional dose distributions 
(dose-surface maps) were calculated for the esophagus, and spatio-dosimetric features 
were derived for evaluation of their added benefit to the predictive performance of the 
model presented in Chapter 3.
An empirical comparison of different machine learning algorithms for outcome classification 
is demonstrated in Chapter 6. Twelve radiotherapy datasets covering a range of tumor 
GENERAL INTRODUCTION AND THESIS OUTLINE 15
1
sites, treatment outcomes (toxicity, survival, tumor control) and features (clinical, blood 
biomarker, dosimetric) were collected in an attempt to establish a representative distribution 
of radiation oncology datasets. Six common classification algorithms (decision tree, random 
forest, neural network, support vector machine, elastic net logistic regression, LogitBoost) 
were compared in a nested cross-validation according to multiple performance metrics.
In Chapters 7 and 8, a distributed learning infrastructure was used to perform privacy-
preserving prediction modeling studies. A distributed logistic regression implementation 
was developed following two optimization algorithms. In Chapter 7 a two-year survival 
prognostic prediction model based on tumor staging classifications was developed and 
validated on more than 20 000 NSCLC patients from eight international healthcare institutes. 
Chapter 8 updates the acute esophageal toxicity model from Chapter 3 using data from four 
Dutch institutes and investigates the improvement in model performance with increased 
size of the training cohort.
In Chapter 9 the pitfalls of, and recommendations for, machine learning research in radiation 
oncology are discussed. The challenges and future perspectives of distributed learning and 
its potential to resolve the common machine learning pitfalls are described.
Table 1: Summary of the topics and characteristics of the studies presented in the different chapters 
of this thesis.
Chapter Content Modeling study type Disease Predicted outcome
Learning 
setting
1 Introduction
2 Theory
3
Original 
research
Development
NSCLC Acute esophageal toxicity
Centralized
4 Validation
5 Development
6 Algorithm 
comparison
NSCLC, 
HNC, larynx, 
meningioma
Survival, tumor control, 
toxicity, medication 
prescription
7 Development 
& validation
NSCLC
Survival
Distributed
8 Acute esophageal toxicity
9 Discussion
Abbreviations: NSCLC = non-small cell lung cancer, HNC = head and neck cancer.
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Chapter 2
Prediction modeling methodology
Frank J.W.M. Dankers, Alberto Traverso, Leonard Wee, Sander M.J. van Kuijk
Adapted from: Prediction Modeling Methodology. In: Kubben P, Dumontier 
M, Dekker A, editors. Fundamentals of Clinical Data Science, New York: 
Springer, Cham; 2019, p. 101–20.
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Statistical hypothesis testing
A statistical hypothesis is a statement that can be tested by collecting data and making 
observations. Before you start data collection and perform your research, you need to 
formulate your hypothesis. An example hypothesis could be for instance: “If I increase the 
prescribed radiation dose to the tumor, this will also lead to an increase of side-effects in 
surrounding healthy tissues”. The purpose of statistical hypothesis testing is to find out 
whether the observations are meaningful or can be attributed to noise or chance.
The null hypothesis (often denoted H0) generally states the currently accepted fact. Often 
it is formulated in such a way that two measured values have no relation with each other. 
The alternative hypothesis, H1, states that there is in fact a relation between the two values. 
Rejecting or disproving the null hypothesis gives support to the belief that there is a relation 
between the two values.
To quantify the probability that a measured value originates from the distribution stated 
under the null hypothesis statistical tests are used that produce a p-value (e.g., Z-test or 
student’s t-test). The p-value gives the probability of obtaining a value equal to or greater 
than the observed value if the null hypothesis is true. A high p-value indicates that the 
observed value is likely under the null assumption, vice versa a low p-value indicates that 
the observed value is unlikely given the null hypothesis, which can lead to its rejection.
There are common misconceptions regarding the interpretation of the p-value [1]:
• The p-value is not the probability that the null hypothesis is true
• The p-value is not the probability of falsely rejecting the null hypothesis (type I 
error, see below)
• A low p-value does not give support to the alternative hypothesis
The p-value is to be used in combination with the α level. The α level is a predefined 
significance level by the researcher which equals the probability of falsely rejecting the null 
hypothesis if it is true (type I error). It is the probability (s)he deems acceptable for making a 
type I error. If the p-value is smaller than the α level, the result is said to be significant at the 
α level and the null hypothesis is rejected. Commonly used values for α are 0.05 or 0.001.
Confidence levels serve a similar purpose as the α level, and by definition the confidence 
level + α level = 1. So an α level of 0.05 corresponds to a 95% confidence level.
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Figure 1:  Illustration of null hypothesis testing. The p-value represents the probability of obtaining a 
value equal or higher than the test value. The α level is predefined by the researcher and represents 
the accepted probability of making a type I error where the null hypothesis is falsely rejected. If the 
p-value of a statistical test is larger than the α level the null hypothesis is rejected.
Types of error
We distinguish between two types of errors in statistical testing [2]. If the null hypothesis 
is true but falsely rejected, this is called a type I error (comparable to a false positive, with 
a positive result indicating the rejection). The type I error rate, the probability of making a 
type I error, is equal to the α level since that is the significance level at which we reject the 
null hypothesis. Likewise, if the null hypothesis is false but not rejected, this is called a type II 
error (comparable to a false negative, with a negative result indicating the failed rejection).
Table 1: The two types of errors that can be made regarding the acceptance or rejection of the null 
hypothesis.
Null hypothesis truth
True False
Null hypothesis decision
Fail to reject Correct Type II error 
(false negative)
Reject Type I error 
(false positive)
Correct
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Creating a prediction model using regression techniques
Prediction modeling using linear and logistic regression
A prediction model tries to stratify patients for their probability of having a certain outcome. 
The model then allows you to identify patients that have an increased chance of an event and 
this may lead to treatment adaptations for the individual patient. For instance, if a patient 
has an increased chance of a tumor recurrence the doctor may opt for a more aggressive 
treatment, or, if a patient has a high risk of getting a side-effect a milder treatment might 
be indicated.
The outcome variable of the prediction model can be anything, e.g., the risk of getting a side 
effect, the chance of surviving at a certain time point, or the probability of having a tumor 
recurrence. We can distinguish outcome variables into continuous variables or categorical 
variables. Continuous variables are described by numerical values and regression models are 
used to predict them, e.g., linear regression. Categorical variables are restricted to a limited 
number of classes or categories and we use classification models for their prediction. If the 
outcome has two categories this is referred to as binary classification and typical techniques 
are decision trees and logistic regression (somewhat confusingly, this regression method is 
well suited for classification due to its function shape).
Fitting or training a linear or logistic prediction model is a matter of finding the function 
coefficients so that the model function optimally follows the data.
   
Figure 2: Examples of predictive modeling (blue line) for a continuous outcome using linear 
regression and for a binary outcome using logistic regression. The predictions in the logistic 
regression are rounded to either class A or B using a threshold (0.5 by default).
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Software and courses for prediction modeling
There are many different software packages available for generating prediction models, all 
of them with different advantages and disadvantages. Some packages are code-based and 
programming skills are required, e.g., Python, R or Matlab. There are integrated development 
environments available for improved productivity, like RStudio for R, and Spyder for Python. 
Additionally, they can have rich open-source libraries tailored specifically towards machine 
learning, for instance Caret for R [3] and Scikit-learn for Python [4]. Other packages have 
graphical user interfaces and being able to program is not mandatory, like SPSS, SAS or 
Orange. Some packages are only commercially available, but many are open-source and 
have a large user base for support.
Preference for a certain software package over others is very personal and the best advice 
is therefore to simply try several and find out for yourself. A special mention is reserved for 
the Anaconda Distribution [5], which hosts many of the most widely used software packages 
for prediction modeling in a single platform (RStudio, Spyder, Jupyter Notebook, Orange and 
more).
Table 2: A non-exhaustive overview of available software packages for prediction modeling and some 
of their features.
Name Reference Coding required
Development 
environments Open-source
Learn more 
(books/tutorials)
R [6] Yes RStudio [7] Yes [8]
Python [9] Yes
Spyder [10]
Jupyter notebooks 
[11]
Yes [12]
Matlab [13] Yes Matlab No [14]
SPSS [15] No N/A No [16]
SAS [17] No N/A Partly 
(students)
[18]
Orange [19] No Visual workflows Yes
Weka [20] No N/A Yes [21]
Rapidminer [22] No Visual workflows Partly
N/A = not applicable
There is a wealth of freely available information on the Web to help you get going. Providing 
a comprehensive overview is therefore an impossible task, but some excellent online courses 
(sometimes referred to as Massive Open Online Courses or MOOCs) are listed in Table 3.
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Table 3: Free online courses for prediction modeling and machine learning.
Course Organizer / link
Machine learning Andrew Ng, Stanford University, Coursera
https://www.coursera.org/learn/machine-learning
Machine learning Tom Mitchell, Carnegie Mellon University
http://www.cs.cmu.edu/~tom/10701_sp11/
Learning from data Yaser Abu-Mostafa, California Institute of Technology
https://work.caltech.edu/telecourse.html
Machine learning Nando de Freitas, University of Oxford
https://www.cs.ox.ac.uk/people/nando.defreitas/machinelearning/
A short word on modeling time-to-event outcomes
Many studies are interested not only in predicting a certain outcome, but additionally take 
into account the time it takes for this outcome to occur. This is referred to as time-to-event 
analysis and a typical example is survival analysis. Kaplan-Meier curves are widely used 
for investigation of the influence of categorical variables [23], whereas Cox regression (or 
sometimes called Cox proportional hazards model) additionally allows the investigation of 
quantitative variables [24].
Creating a model that performs well outside the training set
The bias-variance tradeoff
The bias-variance tradeoff explains the difficulty of a generated prediction model to 
generalize beyond the training set, i.e. perform well in an independent test set (also called 
the out-of-sample performance). The error of a model in an independent test set can be 
shown to be decomposable into a reducible component and an irreducible component. 
The irreducible component cannot be diminished, it will always be present no matter how 
good the model will be fitted to the training data. The origin of the irreducible error can, 
for instance, be an unmeasured but yet important variable for the outcome that is to be 
predicted.
The reducible error can be further decomposed into the error due to variance and the error 
due to bias [2]. The variance is the error due to the amount of overfitting done during 
model generation. If you use a very flexible algorithm, e.g., an advanced machine learning 
algorithm with lots of freedom to follow the data points in the training set very closely, this 
is more likely to overfit the data. The error in the training set will be small, but the error in 
the test set will be large. Another way to look at this is that a high variance will result in very 
different models during training if the model is fitted using different training sets.
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Bias relates to the error due to the assumptions made by the algorithm that is chosen for 
model generation. If a linear algorithm is chosen, i.e. a linear relation between the inputs 
and the outcome is assumed, this may cause large errors (large bias) if the underlying true 
relation is far from linear. Algorithms that are more flexible (e.g., neural networks) result in 
less bias since they can match the underlying true but complex relations more closely.
In general it can be said that:
• Flexible algorithms have low bias since they can more accurately match the 
underlying true relation, but have high variance since they are susceptible to 
overfitting
• Inflexible algorithms have low variance since they are less likely to overfit, but have 
high bias due to their problems of matching the underlying true relationship
From this we can conclude that the final test set error is a tradeoff between low bias and low 
variance. It is impossible to simultaneously achieve the lowest possible variance and bias. 
The challenge is to generate a model with (reasonably) low variance and low bias since that 
is most likely to generalize well to external sets. This model might have slightly decreased 
performance in the training set, but will have the best performance in subsequent test sets.
Figure 3: The bias-variance tradeoff. With increased model complexity the model can more 
accurately match the underlying relation at the risk of increasing the variance (amount of overfitting). 
The bias-variance tradeoff corresponds to minimizing the total prediction error (which is the sum of 
bias and variance).
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Techniques for making a general model
As we collect and expand our datasets we often score many features (parameters) so that 
we minimize the risk of potentially missing important features, i.e. features that are highly 
predictive of the outcome. This means that generally we deal with wide sets containing 
many features. However, many of these features are in fact redundant or not relevant for 
the outcome at all and can be safely omitted. Including a large number of features during 
model generation increases the possibility of chance correlations of features with the 
outcome (overfitting) and this results in models that do not generalize well. Dimensionality 
reduction [25], reducing the number of features, is therefore an important step prior to 
model generation. The main advantages are:
• Lowered chance of overfitting and improved model generalization
• Increased model interpretability (depending on the method of dimensionality 
reduction)
• Faster computation times and reduced storage needs
There are many useful dimensionality reduction techniques. The first category of methods 
to consider is that of feature selection, where we limit ourselves to a subset of the most 
important features prior to model generation. Firstly, if a feature has a large fraction of 
missing values it is unlikely to be predictive of the outcome and can often be safely removed. 
In addition, if a feature has zero or near zero variance, i.e. its values are all highly similar, this 
again indicates that the feature is likely to be irrelevant. Another simple step is to investigate 
the inter-feature correlation, e.g., by calculating the Pearson or Spearman correlation 
matrix. Features that are highly correlated with each other are redundant for predicting the 
outcome (multicollinearity). Even though a group of highly correlated features may all be 
predictive of the outcome, it is sufficient to only select a single feature as the others provide 
no additional information.
Traditionally, further feature selection is then performed by applying stepwise regression. 
In each step a feature is either added or removed and a regression model is fitted and 
evaluated based on some selection criterion. There are many choices for the criterion to 
choose between models, e.g., the Bayesian information criterion or the Akaike information 
criterion, both of which quantify the measure of fit of models and additionally add a penalty 
term for complex models comprising more parameters [26]. In forward selection, one 
starts with no features and the feature that improves the model the most is added to the 
model. This process is repeated until no significant improvement is observed. In backward 
elimination, one starts with a model containing all features, and features are removed 
that decrease the model performance the least, until no features can be removed without 
significantly decreasing performance. 
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With feature selection we limit ourselves to a subset of features that are already present in the 
dataset and this is a special case of dimensionality reduction [27]. In feature extraction the 
number of features are reduced by replacing the existing features by fewer artificial features 
which are combinations of the existing features. Popular techniques for feature extraction 
are principle component analysis, linear discriminant analysis and autoencoders [25].
More advanced machine learning algorithms often contain embedded methods for reducing 
model complexity to improve generalizability. An example is regularization where each 
added feature also comes with an added penalty or cost [8]. The addition of a feature may 
increase the model performance but, if the added cost is too high, it will not be included 
in the final model. This effectively performs feature selection and prevents overfitting. The 
severity of the cost is a hyperparameter that can be tuned (e.g., through cross-validation, see 
paragraph “Techniques for internal validation”). Popular regularization methods for logistic 
regression are LASSO (or L1 regularization) [28], ridge (or L2 regularization), or a combination 
of both using Elastic Net [29]. The main difference between L1 and L2 regularization is that 
in L1 regularization the coefficients of unimportant parameters shrink to zero, effectively 
performing feature selection and simplifying the final model.
Model performance metrics
General performance metrics
The performance of a prediction model is evaluated by the calculation of performance 
metrics. We want our model to have high discriminative ability, i.e. high probabilities should 
be predicted for observations having positive classes (e.g., alive after 2 years of treatment) 
and low probabilities for negative classes (dead after 2 years of treatment). There is no 
general best performance metric for model evaluation as this depends strongly on the 
underlying data as well as the intended application of the model.
Other often-used overall performance metrics are R-squared measures of goodness of fit 
(or R2, also called the coefficient of determination). The R2 can be interpreted as the amount 
of variance in the data that is explained by the model (explained variation). Higher R2s 
correspond to better models. Examples are Cox and Snell’s R2 or Nagelkerke’s R2. R-squared 
values are mainly used in regression models; for classification models it is more appropriate 
to look at performance metrics derived from the confusion matrix.
Another popular overall performance measure is the Brier score (or mean squared error) 
and it is defined as the average of the square of the difference between the predictions and 
observations. A low Brier score indicates that predictions match observations and we are 
dealing with a good model. 
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Confusion matrix
The confusion matrix is a very helpful tool in assessing model performance. It lists the correct 
and false predictions versus the actual observations and allows for the calculation of several 
insightful performance metrics. If the output of your prediction model is a probability (e.g., 
the output of a logistic regression model), then it needs to be dichotomized first by applying 
a threshold (typically 0.5) before the confusion matrix can be generated. An exemplary 
confusion matrix is shown in Table 4.
Table 4: Confusion matrix showing predictions and observations. Many useful performance metrics 
are derived from the values in the confusion matrix.
Observation
True False
Prediction
True
True positive
(TP)
False positive
(FP)
→ Positive predictive value (PPV)
False
False negative
(FN)
True negative
(TN)
→
Negative predictive value
(NPV)
↓ ↓
Sensitivity
(TPR)
Specificity
(TNR)
True positives, called hits, are cases that are correctly classified. True negatives are correctly 
rejected. False positives, or false alarm, are equivalent to a type I error. False negatives, or 
misses, are equivalent to a type II error.
Prevalence is defined as the number of positive observations with respect to the total 
observations. A balanced dataset has a prevalence close to 0.5, or 50%. Often, we have to 
deal with imbalanced datasets and this can lead to difficulties when interpreting certain 
performance metrics. Performance metrics can be high for poor models that are trained and 
tested on imbalanced datasets.
Prevalence = (TP + FN) / (TN + TP + FP + FN)
Performance metrics derived from the confusion matrix
Accuracy, defined as the proportion of correct predictions, is often reported in literature. 
Care has to be taken when using this metric in highly imbalanced datasets. Consider a 
dataset with only 10% positive observations. If the prediction model simply always predicts 
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the negative class it will be correct in 90% of the cases. The accuracy is high, but the model 
is useless since it cannot detect any positive cases.
Accuracy = (TN + TP) / (TN + TP + FP + FN)
Another option is to look at the proportion of correct positive predictions for the total number 
of positive observations. This is called the Positive Predictive Value (PPV) or precision. 
Similarly, the proportion of correct negative predictions for the total number of negative 
observations is called the Negative Predictive Value (NPV), respectively. These metrics are 
of interest to patients and clinicians as they give the probability that the prediction matches 
the observation (truth) for a patient. PPV and NPV are dependent on the prevalence in the 
dataset making their interpretation more difficult. A high prevalence will increase PPV and 
decrease NPV (while keeping other factors constant).
PPV = TP / (TP + FP)
NPV = TN / (TN + FN)
If we want to consider characteristics not of the population but of the prediction model 
when applied as a clinical test, we can evaluate sensitivity and specificity. Sensitivity, or 
True Positive Rate (TPR, or sometimes called recall or probability of detection), is defined as 
the probability of the model to make a positive prediction for the entire group of positive 
observations. It is a measure of avoiding false negatives, i.e. not missing any diseased 
patients.
Similarly, specificity is defined as the probability of the model to make a negative prediction 
for the entire group of negative observations. It is a measure of avoiding false positives, i.e. 
not including non-diseased patients.
TPR = TP / (TP + FN) (sensitivity)
TNR = TN / (TN + FP) (specificity)
Additionally, we can determine the False Positive Rate (FPR), or fall-out, and the False 
Negative Rate (FNR), which are the opposites of TPR and FPR, respectively. Note that these 
metrics are used in the next paragraph for the construction of the Receiver Operating 
Characteristic curve.
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FNR = 1 - TPR = 1 - sensitivity
FPR = 1 -TNR = 1 - specificity
The F1-score, or F-score, is a metric combining both PPV (precision) and TPR (recall or 
sensitivity). Unlike PPV and TPR separately, it takes both false positives and false negatives 
into account simultaneously. It does however still omit the true negatives. It is typically used 
instead of accuracy in the case of severe class imbalance in the dataset.
 F1 = 2 · (PPV · TPR) / (PPV + TPR)
Model discrimination - Receiver Operating Characteristic and Area Under the Curve
The performance of a prediction model is always a tradeoff between sensitivity and 
specificity. By changing the threshold that we apply to round our model predictions to 
positive or negative classes, we can change the sensitivity and specificity of our model. 
By decreasing this threshold, we are making it easier for the model to make positive 
predictions. The number of false negatives will go down but false positives will go up, 
increasing sensitivity but lowering specificity. By increasing the threshold, the model will 
make fewer positive predictions, the number of false negatives will go up and false positive 
will go down, decreasing sensitivity and increasing specificity (see Figure 4).
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Figure 4: Influence of the threshold that is used to round model prediction probabilities to 0 or 1. By 
using a low threshold the model will detect most of the patients with the outcome (high sensitivity), 
but many patients without the outcome will also be included (low specificity). For each value of the 
threshold sensitivity and specificity values can be calculated.
By evaluating different thresholds for rounding our model predictions, we can determine 
many sensitivity and specificity pairs. If we plot the sensitivity versus (1 - specificity) for all 
these pairs, i.e. the true positive rate versus the false positive rate, we obtain the Receiver 
Operating Characteristic curve (ROC) [30]. This curve can give great insight into model 
discrimination performance. It allows for determining the optimal sensitivity/specificity pair 
of a model so that it can support decision making, and also allows comparison of different 
models with each other.
Powerful models have ROC curves that approach the upper left corner, which indicates that 
the model achieves the maximum of 100% sensitivity and 100% specificity simultaneously. 
Conversely, a poor model with no predictive value will have an ROC curve close to the y = 
x or 45 degree line. This has led to the use of the Area Under the Curve (AUC) of the ROC 
curve (or concordance statistic, c) as a widely used metric for interpreting individual model 
performance but also for comparing between models. Strong performing models have 
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higher ROC curves and thus larger AUC values. A perfect model making correct predictions 
for every patient has an AUC of 1, whereas a useless model giving random predictions 
results in an AUC of 0.5. The AUC can be interpreted as the probability that the model will 
give a higher predicted probability to a randomly chosen positive patient than a randomly 
chosen negative patient.
Figure 5: ROC curve indicating discriminating performance of the model. Model predictions are 
rounded to 0 or 1 using many different thresholds resulting in sensitivity and specificity pairs that form 
the curve. AUC is indicated by the gray area under the curve. Higher values correspond to better model 
discrimination performance.
Model calibration
Historically, the focus in evaluating model performance has primarily been on discriminative 
performance, e.g., by calculating R2 metrics, confusion matrix metrics and performing ROC/
AUC analysis. Model calibration is however as important as discrimination and should always 
be evaluated and reported. Model calibration refers to the agreement between subgroups 
of predicted probabilities and their observed frequencies. For example, if we collect 100 
patients for which our model predicts 10% chance of having the outcome, and we find that 
in reality 10 patients actually have the outcome, then our model is well calibrated. Since the 
predicted probabilities can drive decision-making it is clear that we want the predictions to 
match the observed frequencies.
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A widely-used (but no so effective) way of determining model calibration is by performing the 
Hosmer-Lemeshow test for goodness of fit of logistic regression models. The test evaluates 
the correspondence between predictions and observations by dividing the probability range 
[0-1] into n subgroups. Typically, 10 subgroups are chosen, but this number is arbitrary and 
can have a big influence on the final p-value of the test.
A better approach is to generate a calibration plot [31]–[33]. It is constructed by ordering 
the predicted probabilities, dividing them into subgroups (again, typically 10 is chosen) 
and then plotting the average predicted probability versus the average outcome for each 
subgroup. The points should lie close to the ideal line of y = x indicating agreement between 
predictions and observed frequencies for each subgroup. Helpful additions are error bars, 
a trend line (often a LOESS smoother [34]), individual patient predictions versus outcomes 
and/or histograms of the distributions of positive and negative observations (the graph is 
then sometimes called a validation plot).
Figure 6: Calibration plot indicating agreement between model predictions and observed frequencies. 
Data points are subdivided into groups for which mean observation is plotted against mean model 
probability. Perfect model calibration corresponds with the y=x line. Additionally, individual data 
points are shown (with some added y-jitter to make them more clear), as well as histograms for the 
positive and negative classes [0,1].
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Validation of a prediction model
The importance of splitting training/test sets
In the previous paragraphs different metrics for evaluation of model performance have been 
discussed. As briefly discussed in paragraph “The bias-variance tradeoff” it is important to 
compute performance metrics not on the training dataset but on data that was not seen 
during the generation of the model, i.e. a test or validation set. This will ensure that you are 
not mislead into thinking you have a good performing model, while it may in fact be heavily 
overfitted on the training data. Overfitting means that the model is trained too well on the 
training set and starts to follow the noise in the data. This generally happens if we allow 
too many parameters in the final model. The performance on the training set is good, but 
on new data the model will fail. Underfitting corresponds to models that are too simplistic 
and do not follow the underlying patterns in the data, again resulting in poor performance 
in unseen data.
Properly evaluating your model on new/unseen data will improve the generalizability of 
the model. We differentiate between internal validation, where the dataset is split into a 
training set for model generation and a test set for model validation, and external validation, 
where the complete dataset is used for model generation and separate/other datasets are 
available for model validation.
Techniques for internal validation
If you only have a single dataset available you can generate a test set by slicing of a piece 
of the training set. The simplest approach is to use a random split, e.g., using 70% of the 
data for training and 30% for evaluation (sometimes called a hold-out set). It is important to 
stratify the outcome over the two sets, i.e. make sure the prevalence in both sets remains 
the same. The problem with this method is that we can never be sure that the calculated 
performance metric is a realistic estimate of the model performance on new data or due 
to a ‘(un)lucky’ randomization. This can be overcome by repeating for many iterations and 
averaging the performance metrics. This method is called Monte Carlo cross-validation [35].
38 CHAPTER 2
Figure 7: Schematic overview of a Monte Carlo cross-validation. A random stratified split is applied 
to separate a test set from the training set. A prediction model is trained on the training set and 
performance metrics on the test set are stored after which the process is repeated.
Another approach is the method of k-fold cross-validation [36]. In this method the data is 
split into k stratified folds. One of these folds is used as a test set, the others are combined 
and used for model training. We then iterate and use every fold as a test set once. A 
better estimate of the true model performance can be achieved by averaging the model 
performances on the test set. Typically, k=5 or k=10 is chosen for the number of folds.
Figure 8: Schematic overview of k-fold cross-validation. The dataset is randomly split into k stratified 
folds. Each fold is used as a test set once, while the other folds are temporarily combined to form a 
training set for model generation. Performance metrics on the test set are calculated and stored, and 
the process is repeated for the number of folds that have been generated.
The advantage of k-fold cross-validation is that each data point is used in a test set only 
once, whereas in Monte Carlo cross-validation it can be selected multiple times (and other 
points are not selected for a test set at all), possibly introducing bias. The disadvantage of 
k-fold cross-validation is that it only evaluates a limited number of splits whereas Monte 
Carlo cross-validation evaluates as many split as you desire by increasing the number of 
iterations (although you could iterate the entire k-fold cross-validation procedure as well 
which is commonly called repeated k-fold cross-validation).
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Note that in both Monte Carlo cross-validation and k-fold cross-validation we are generating 
many models instead of a single final model, e.g., because the feature selection algorithm 
might select different features or the regression produces different coefficients due to different 
training data. Cross-validation is used to identify the best method (i.e. data pre-processing, 
algorithm choice etc.) that is to be used to construct your final model. When you have identified 
the optimal method you can then train your model accordingly on all the available data.
A common mistake in any method where the dataset is split into training and test sets is 
to allow data leakage to occur [37]. This refers to using any data or information during 
model generation that is not part of the training set and can result in overfitting and overly 
optimistic model performance. It can happen for example when you do feature selection on 
the total dataset before applying the split. In general it is advised to perform any data pre-
processing steps after the data has been split. 
External validation
The true test of a prediction model is to evaluate its performance under external validation, or 
separate datasets from the training dataset. Preferably, this is performed on new data acquired 
from a different institution. It will indicate the generalizability of the model and show whether 
it is overfitted on the training data. If this can be performed on multiple external validation 
sets, this further strengthens the acceptance of the prediction model under evaluation.
It has to be noted that if the datasets intended to be used for external validation are 
collected by the same researchers that built the original prediction model, this is still not 
an independent validation. Independent external validation, by other researchers, is the 
ultimate test of the model generalizability. This requires open and transparent reporting 
of the prediction model, of inclusion and exclusion criteria for the training cohort and of 
data pre-processing steps. Additionally, it is encouraged to make the training data publicly 
available as this allows other researchers to verify your methodology and results and greatly 
improves reproducibility.
Further reading
The field of prediction modeling and machine learning is extremely broad and in this 
chapter we have only scratched the surface. A good place to start with further reading on 
the many aspects of prediction modeling is the book “Clinical Prediction Models - A Practical 
Approach to Development, Validation, and Updating” by Steyerberg [38]. If you are looking 
to improve your knowledge and simultaneously improve your practical modeling skills the 
book “An Introduction to Statistical Learning - with Applications in R” by James et al. is 
highly recommended [8]. Finally, if you want to go in-depth and understand the underlying 
principles of the many machine learning algorithms the go-to book is “The Elements of 
Statistical Learning - Data Mining, Inference, and Prediction” by Hastie et al [39].
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Abstract
Background and purpose
The majority of normal-tissue complication probability (NTCP) models for acute esophageal 
toxicity (AET) in advanced stage non-small cell lung cancer (AS-NSCLC) patients treated with 
(chemo-)radiotherapy are based on three-dimensional conformal radiotherapy (3D-CRT). 
Due to distinct dosimetric characteristics of intensity-modulated radiation therapy (IMRT), 
3D-CRT based models need revision. We established a multivariable NTCP model for AET in 
149 AS-NSCLC patients undergoing IMRT.
Materials and methods
An established model selection procedure was used to develop an NTCP model for Grade 
≥2 AET (53 patients) including clinical and esophageal dose-volume histogram parameters.
Results
The NTCP model predicted an increased risk of Grade ≥2 AET in case of: concurrent 
chemoradiotherapy (CCR) [adjusted odds ratio (OR) 14.08, 95% confidence interval (CI) 
4.70-42.19; p<0.001], increasing mean esophageal dose [D
mean
; OR 1.12 per Gy increase, 
95% CI 1.06-1.19; p<0.001], female patients (OR 3.33, 95% CI 1.36-8.17; p=0.008), and 
≥cT3 (OR 2.7, 95% CI 1.12-6.50; p=0.026). The AUC was 0.82 and the model showed good 
calibration.
Conclusions
A multivariable NTCP model including CCR, D
mean
, clinical tumor stage and gender predicts 
Grade ≥2 AET after IMRT for AS-NSCLC. Prior to clinical introduction, the model needs 
validation in an independent patient cohort.
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Introduction
The introduction of intensity-modulated radiation therapy (IMRT) and volumetric modulated 
arc therapy (VMAT) for advanced stage non-small cell lung cancer (NSCLC) patients allows 
for the delivery of highly conformal dose distributions enabling treatment of larger target 
volumes or the delivery of increased prescription doses [1,2]. Nevertheless, patients may 
still suffer from acute esophageal toxicity (AET) during and shortly after radiotherapy for 
advanced stage disease, because large high-dose volumes of centrally located tumors or 
involved mediastinal lymph nodes often border the esophagus [3,4]. 
Furthermore, AET is enhanced with concurrent chemoradiotherapy (CCR) [5]. Although CCR 
improves survival, the increased AET has a negative impact on the overall quality of life and 
may lead to hospitalization and treatment interruptions jeopardizing treatment outcome. 
Hence, predicting AET may be helpful in anticipating (chemo-)radiotherapy induced 
esophageal toxicity. 
Several studies have assessed the prevalence of AET in (non-small cell) lung cancer patients 
in relation to the dose delivered to the esophagus and other tumor and patient related 
characteristics [4,6-17]. Heterogeneous outcomes have been reported, particularly for the 
dosimetric variables predicting for AET [4,9,10,18,19]. Up till now, there is no consensus on 
the single best dose-volume histogram (DVH) parameter to predict AET with high accuracy and 
precision. Furthermore, most studies are based on patients treated with three-dimensional 
conformal radiotherapy (3D-CRT), while the vast majority of patients is being treated with 
IMRT or VMAT these days. These techniques can deliver more conformal dose distributions 
than 3D-CRT, however, often at the cost of increased target dose heterogeneity and larger 
proportions of surrounding healthy tissues receiving low doses [2,20]. As a consequence, 
the dosimetric differences between 3D-CRT and IMRT/VMAT may possibly influence the risk 
of AET and thus new predictive models for AET after IMRT/VMAT are needed.   
In this study we systematically investigated the relationship between DVH and clinical 
parameters to establish a predictive model for Grade ≥2 AET in advanced stage NSCLC 
patients treated with step-and-shoot IMRT or VMAT.
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Materials and Methods 
Patients and treatment characteristics
In this retrospective study, we assessed a cohort of 149 consecutive patients that had 
undergone (chemo-)radiotherapy for histopathologically confirmed advanced stage or 
inoperable NSCLC between March 2008 and June 2013. The study has been carried out 
in accordance with the national applicable rules concerning the review of research ethics 
committees and informed consent.
For staging purposes, every patient underwent a diagnostic 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET) scan combined with a low-dose computed tomography 
(CT) scan, and magnetic resonance imaging of the brain. CCR was only delivered to patients 
in good clinical condition; all others underwent sequential treatment or radiotherapy alone. 
For radiation treatment planning, an intravenous contrast-enhanced CT scan (Big Bore 
Brilliance CT scanner; Philips Medical Systems, Best, The Netherlands) of the thorax (3 mm 
slice thickness), directly followed by a slow-CT scan of the primary tumor, were acquired 
while the patient was in treatment position. Both CT data sets were transferred to the 
Pinnacle3 (Version 8.0-9.2; Philips Radiation Oncology Systems, Fitchburg, WI) treatment 
planning system (TPS). The primary tumor and suspicious lymph nodes (confirmed by 
histopathology after endobronchial/endoesophageal ultrasonography, enlarged or with 
malignant features on CT scan, and/or FDG-PET positive) were considered the gross tumor 
volume (GTV). Clinical target volumes (CTV) enclosed the GTV of the primary tumor and 
lymph nodes with 10 mm and 5 mm margins, respectively. Planning target volumes (PTVs) 
were created by an isotropic 5 mm expansion of the CTVs. Delineation of the organs at risk 
(OAR) such as lungs, heart and spinal cord (i.e., inner margin entire bony thoracic spinal 
canal) was automatically performed by the TPS and was adjusted manually if necessary. 
Because of the retrospective nature of this analysis and the importance of accurate DVH 
data concerning the esophagus, the outer rim of the esophageal wall (from the lower border 
of the cricoid cartilage to the gastro-esophageal junction) was re-contoured by one single 
physician (RW).
The prescribed dose to the PTV was 66 Gy in 33 (once-daily) fractions using IMRT (step and 
shoot until June 2011 or VMAT from April 2011 onwards). In 4 (2.7%) patients the prescribed 
dose could not be achieved without violating the normal-tissue dose constraints, and hence 
the number of fractions was reduced to 30 fractions. According to the ICRU 50/62 guidelines 
the -5% and +7% dose heterogeneity criteria for the PTV were aimed for [21,22]. A standard 
beam set-up (six co-planar 10 MV photon beams for IMRT and one 10 MV photon arc for 
VMAT) was used avoiding the contralateral uninvolved lung. Step-and-shoot IMRT was 
planned with a minimum of 10 monitor units per segment and a maximum of 60 segments. 
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Gantry angular spacing between control points was 4 degrees for the VMAT arc. Predicted 
dose deposition was calculated using a 3D collapsed-cone convolution superposition 
algorithm. Routine position verification prior to irradiation consisted of an off-line set-up 
and correction protocol.
The standard sequential chemotherapy regimen typically consisted of 3 (3-weekly) courses 
of gemcitabine (1250 mg/m2; on day 1 and 8) and cisplatinum (80 mg/m2; on day 1), whereas 
all patients undergoing CCR received 2 (3-weekly) courses of etoposide (100 mg/m2; on day 
1-3) and cisplatinum (50 mg/m2; on day 1 and 8). Due to local policy, some patients from 
a referring hospital received one additional course of gemcitabine/cisplatinum 3 weeks 
before start of CCR.
Toxicity scoring
The standard follow-up protocol consisted of weekly assessment of acute toxicity by the 
treating radiation oncologist, even though this may have varied according to the patients’ 
perceived well-being. In general, follow-up continued after the end of treatment until acute 
toxicity resolved. The Radiation Therapy Oncology Group acute radiation morbidity scoring 
criteria have been used by the treating radiation oncologist to evaluate esophageal toxicity [23].
Data collection and statistical analysis
All medical records were retrospectively reviewed. Anonymous patient and tumor 
characteristics together with the (maximum) AET scores (at any time point) were collected 
in a secured and audit trail-equipped database (OpenClinica, version 3.4, Waltham, MA). 
Full DVH data of the esophagus (solid organ including lumen) were retrieved from the TPS to 
extract the parameters: mean and maximum esophageal dose (D
mean
 and D
max
, respectively), 
and the relative volume receiving ≥5 Gy to ≥70 Gy (V
5Gy
 to V
70Gy
) in 5 Gy increments. To 
correct for spatial fractionation effects, these parameters were extracted from the DVHs 
after conversion from physical dose to 2 Gy per fraction equi-effective (EQD2) dose assuming 
α/β=10 Gy for acute toxicity.
Relevant clinical parameters and the abovementioned EQD2-corrected DVH parameters 
were evaluated for Grade ≥2 AET using univariate logistic regression analysis. The resulting 
significant parameters were tested for between-group (Grade ≥2 vs Grade ≤1 AET) differences 
using the Mann-Whitney-U or Chi-square test, where appropriate. A p-value of <0.05 was 
considered statistically significant.
Data exploration and predictive modeling
In accordance with the method of El Naqa et al. [24], a Spearman cross-correlation matrix 
of the DVH parameters was first calculated to assess the degree of multicollinearity 
between variables. In case of high inter-variable correlations (correlation coefficient ≥0.8), 
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a surrogate variable was selected before actual modeling was performed. Furthermore, the 
Lyman-Kutcher-Burman (LKB) normal-tissue complication probability (NTCP) model was 
fitted to the Grade ≥2 AET data using the EQD2-corrected DVHs to assess the volume effect 
[25]. After these data exploration steps, automated multivariable logistic regression model 
selection was performed using the MATLAB-based (version R2013b; The MathWorks, Natick, 
MA) Dose Response Explorer System (DREES; version 1.0 beta) [26]. First, the optimal model 
order was estimated by leave-one-out cross validation (2000 samples); i.e. the number of 
model parameters with the highest correlation coefficient for Grade ≥2 AET was selected 
as the optimal number of parameters. The second step comprised the estimation of the 
model parameters by logistic regression analysis with forward selection on 2000 bootstrap 
samples. From these bootstrap samples, the most frequently selected model was chosen as 
the optimal model. Odds ratios (OR) and the accompanying 95% confidence intervals (CI) 
were calculated for these parameters using SPSS software (version 20.0; Chicago, IL). 
The multivariable NTCP model for Grade ≥2 AET with k prognostic variables (x) is expressed 
by the multivariable logistic regression formula: 
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁(𝑥𝑥) =
1
1+𝑒𝑒−𝑆𝑆(𝑥𝑥)
 , 
𝑘𝑘𝑆𝑆(𝑥𝑥) = 𝛽𝛽0 + ∑𝑖𝑖𝑖1 𝛽𝛽𝑖𝑖 ∙ 𝑥𝑥𝑖𝑖 , 
 
(1)
where,
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁(𝑥𝑥) =
1
1+𝑒𝑒−𝑆𝑆(𝑥𝑥)
 , 
𝑘𝑘𝑆𝑆(𝑥𝑥) = 𝛽𝛽0 + ∑𝑖𝑖𝑖1 𝛽𝛽𝑖𝑖 ∙ 𝑥𝑥𝑖𝑖 , 
 
(2)
and βi are the regression coefficients.
The discriminative power of the model was assessed by calculating the area under the curve 
(AUC) of the receiver operating characteristic. As recommended by Steyerberg et al. [27], 
the AUC was corrected for optimism by a bootstrap sampling procedure. We used an in-
house software tool based on MATLAB to generate 5000 bootstrap cohorts by randomly 
drawing 149 samples (with replacement) and construct 5000 new predictive models, which 
were subsequently applied on the original patient cohort to acquire new AUCs. The mean 
difference in AUC between the original sample-based model and the bootstrap sample-
based models was considered the correction for optimism.
For calibration of the NTCP model, the agreement between the predicted complication risk 
and the observed outcome rates was assessed by generating a calibration plot according to 
[27] and by performing the Hosmer-Lemeshow test [28].
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Results
A total of 149 patients were evaluated (Table 1), of whom 72 (48.4%) patients had ≥cT3 
tumors and 129 (86.5%) patients suffered from advanced nodal disease (i.e., ≥cN2). 
Concurrent and sequential chemoradiation was delivered to 93 (62.4%) and 46 (30.9%) 
patients, respectively. Weekly AET assessment was available for 108 (72.5%) patients, only 5 
(3.4%) patients were seen less than 4 times during the six-week course of radiotherapy. One 
hundred and twenty-six (84.6%) patients had at least one follow-up contact after finishing 
radiotherapy, whereas for the remaining 23 (15.4%) the post-treatment AET scores were 
not available. The majority of these 23 patients (N=14, 61%) had Grade ≤1 AET during 
radiotherapy.
Grade 0, 1, 2 or 3 AET was scored in 18 (12.1%), 78 (52.4%), 40 (26.8%) and 13 (8.7%) 
patients, respectively. From Table 2, it is clear that the rate of Grade ≥2 AET was significantly 
higher (p<0.001) in patients receiving CCR (N=46) than in patients receiving sequential 
chemoradiation or radiotherapy alone (N=7). Univariate logistic regression analysis revealed 
a significant increase in Grade ≥2 AET in younger patients, in females, in those treated with 
VMAT, and when concurrent chemotherapy was administered (Table 3). Univariate logistic 
regression analysis of the DVH parameters (Supplemental material, Table S1) showed a 
significant increase in Grade ≥2 AET for all V
5Gy 
to V65Gy parameters, with the most significant 
increase for V
50Gy
, V
55Gy
 and V
60Gy 
(p<0.001, respectively). Also, the regression coefficient of 
D
mean
 was statistically significant (p=0.001). For V
70Gy
 and D
max
 the regression coefficients 
were not statistically significant.
Regarding the Spearman self-correlation matrix for the DVH parameters, all parameters 
were significantly correlated, most of them with correlation coefficients ≥0.8 (Supplemental 
material, Figure S1A). A strong correlation was also observed between D
mean
 and V
15Gy
 
through V
60Gy
, suggesting a high degree of multicollinearity. Fitting the LKB NTCP model to 
the DVH data displayed the following parameters: n = 1.04 (95% CI 0.48−5.49), m = 0.65 
(95% CI 0.27−1.03), and D50 = 32.84 Gy (95% CI 15.59−50.08 Gy). The volume parameter n 
appeared to be close to 1, indicating a large volume effect and thus implying that D
mean
 was a 
good predictor for Grade ≥2 AET. Since D
mean 
in our model was a good surrogate for the other 
DVH parameters, we decided to solely include this dosimetric parameter in the modeling 
procedure. 
Analyzing D
mean
 together with the clinical parameters presented in Table 3, the optimal 
model consisted of 4 parameters (Supplemental material, Figure S1B). In approximately 55% 
of the bootstrap samples, the model including CCR, advanced tumor stage (cT3/4), gender 
and D
mean
 was considered to be optimal (Supplemental material, Figure S1C). The regression 
coefficients and adjusted ORs for this optimal model indicated that patients had an increased 
risk of Grade ≥2 AET with increasing D
mean
, when they received CCR, were female or had 
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advanced tumor stage (Table 4). Based on these prognostic variables, a predicted NTCP 
estimate for individual patients could be calculated from (1) by substituting the variables 
and corresponding regression coefficients into Eq. (2).
The sample-based AUC was 0.84 (95% CI 0.77–0.91); the bootstrap optimism-corrected AUC 
was 0.82, indicating good discriminative ability and robustness of the model. The Hosmer-
Lemeshow test showed no significant difference (p=0.127), supporting the significant 
agreement between the predicted risk and observed NTCP rates for patients suffering 
from Grade ≥2 AET. The fit (loess smoother) of the actual outcome vs predictions in the 
calibration plot for Grade ≥2 AET (Supplemental material, Figure S2) was close to the ideal 
45° reference line. Nagelkerke’s R2 of this predictive model was 0.407.
Table 1. Patient, clinical and treatment characteristics.
Characteristics N=149
Gender (%)
Male 97 (65)
Female 52 (35)
Age (y) (range)
Median 63 (36-78)
Karnofsky Performance score (%)
≥ 90 95 (64)
≤ 80 54 (36)
Tumor cell type (%)
SCC 56 (37.6)
AC 59 (39.6)
NSCLC not otherwise specified 22 (14.8)
Other/Missing 6/6 (4/4)
Clinical Stage (%)
IIb 2 (1.3)
IIIa 94 (63.1)
IIIb 53 (35.6)
Tumor stage (%)
0 7 (4.7)
1 24 (16.1)
2 44 (29.6)
3 36 (24.2)
4 36 (24.2)
X 2 (1.3)
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Characteristics N=149
Nodal stage (%)
0 12 (8.1)
1 7 (4.7)
2 92 (61.7)
3 37 (24.8)
X 1 (0.7)
Chemotherapy (%)
Concurrent 93 (62.4)
Sequential 46 (30.9)
None 10 (6.7)
Radiation dose (2 Gy fractions) (%)
66 Gy 145 (97.3)
60 Gy 4 (2.7)
Radiotherapy technique (%)
IMRT 99 (66.4)
VMAT 50 (33.6)
Abbreviations: SCC = squamous cell carcinoma; AC = adenocarcinoma; NSCLC = non-small cell lung 
cancer; IMRT = intensity-modulated radiation therapy; VMAT = volumetric modulated arc therapy.
Table 2. Number of patients (whole group percentage is displayed between brackets) according to the 
maximum scored Acute Esophageal Toxicity (AET) grade divided by the allocated treatment.
RTOG AET grading CCR
SCR or 
radiotherapy 
alone
Total
0 (absence of symptoms) 8 (5.4%) 10 (6.7%) 18 (12.1%)
1 (requiring non-narcotic analgesics at most) 39 (26.2%) 39 (26.2%) 78 (52.4%)
2 (requiring narcotic analgesics or puree/liquid 
diet)
35 (23.5%) 5 (3.3%) 40 (26.8%)
3 (requiring nasogastric tube feeding or 
intravenous fluids)
11 (7.4%) 2 (1.3%) 13 (8.7%)
4 (esophageal obstruction, ulceration, 
perforation or fistula )
0 0 0
5 (death due to toxicity) 0 0 0
Abbreviations: RTOG = Radiation Therapy Oncology Group; AET = acute esophageal toxicity; CCR = 
concurrent chemoradiotherapy; SCR = sequential chemoradiotherapy.
Table 1. Continued. Patient, clinical and treatment characteristics.
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Table 3. Results from univariate logistic regression analysis for clinical parameters.
Clinical parameter Grade ≥2 AET
Coefficient Odds ratio (95% CI) p-value
Age -0.062 0.94 (0.90 - 0.98) 0.002
Gender (female vs male) 0.825 2.28 (1.13 - 4.59) 0.021
Concurrent chemotherapy (yes vs no) 1.924 6.85 (2.81 - 16.69) <0.001
VMAT vs IMRT 0.801 2.23 (1.10 - 4.50) 0.026
Radiation dose 0.086 1.09 (0.74 - 1.60) 0.66
Karnofsky Performance score ≥90 0.550 1.73 (0.84 - 3.57) 0.136
≥5% weight loss (pre-treatment) -0.170 0.84 (0.40 - 1.77) 0.653
≥cT3 0.314 1.37 (0.70 - 2.69) 0.360
≥cN2 0.494 1.64 (0.56 - 4.83) 0.371
Upper and middle lobes vs lower lobes -0.330 0.72 (0.34 - 1.53) 0.390
Abbreviations: AET = acute esophageal toxicity; CI = confidence interval; VMAT = volumetric 
modulated arc therapy; IMRT = intensity-modulated radiation therapy; cT = clinical Tumor stage and 
cN = clinical Nodal stage according to the 7th edition of the International Union Against Cancer TNM 
classification. In case of “x vs y”, the latter is the reference category.
 Table 4. Predictive parameters from multivariable logistic regression analysis of the final model.
Predictor Grade ≥2 AET
 Coefficient Adjusted Odds ratio  
(95% CI)
p-value
Concurrent chemotherapy (yes vs no)  2.645 14.08 (4.70 - 42.19) <0.001
D
mean
 (per Gy increase)  0.117 1.12 (1.06 - 1.19) <0.001
Gender (female vs male)  1.204 3.33 (1.36 - 8.17) 0.008
Tumor stage (cT3/4 vs cT1/2)  0.994 2.70 (1.12 - 6.50) 0.026
Constant -6.418   
Abbreviations: AET = acute esophageal toxicity; CI = confidence interval; Dmean = mean esophageal 
dose. In case of “x vs y”, the latter is the reference category.
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Discussion
Compared to 3D-CRT, the more conformal dose distributions of IMRT/VMAT and its 
influence on AET has not been well documented. This issue has been addressed in a study 
reported by Gomez et al. [29], showing Grade ≥3 AET in 28% of patients treated with IMRT 
(N=139) versus 8% (p<0.05) of patients treated with 3D-CRT (N=405). However, another 
study reported the contrary with equal risks of AET after IMRT or 3D-CRT [30]. Due to the 
dosimetric differences between 3D-CRT and IMRT it is hypothesized that established 3D-CRT 
toxicity prediction models are not suitable for predicting toxicity after IMRT. This hypothesis 
is supported by Beetz et al. [31], who showed that their NTCP model for xerostomia in head 
and neck cancer based on 3D-CRT data was less valid for patients treated with IMRT. These 
findings even more imply the need for this study as the increased conformality of IMRT paved 
the way for treatment intensification strategies such as dose escalation. These strategies 
may increase AET and therefore it is important to be able to adequately predict AET by 
means of a predictive model, in particular because model based predictions outperform the 
predictions of physicians [32]. Our IMRT-based predictive model for AET may guide future 
dose prescription and treatment planning to keep toxicity within acceptable levels. 
Using a validated systematic approach we constructed a predictive model for Grade ≥2 AET 
in advanced stage NSCLC patients treated with IMRT. The model comprises 4 prognostic 
variables: delivery of CCR, esophageal D
mean
, gender and clinical tumor stage, and displayed 
good predictive performance characteristics. However, from Figure S1B one may conclude 
that a model order of 2 may be equivalent to a model consisting of the abovementioned 4 
parameters for the correlation with AET is nearly equal. This was refuted after performing 
the likelihood-ratio test for nested models, as the addition of the parameters tumor stage 
and gender contributed significantly (p=0.003) to the predictions of the reduced model 
including only CCR and D
mean
 (the latter two parameters were deemed of greatest relevance 
based on the bootstrap sampling results, see Figure S1C).
Although there is a great diversity in predictors for AET as reported in previous studies, the 
esophageal D
mean
 and the administration of CCR as found in our study are in correspondence 
with earlier studies [7-9,11,33,34]. This can be well explained by radiosensitisation due to 
CCR and enhanced damage of the esophageal mucosa with increasing mean dose to the 
esophagus. These effects are reflected in our population by high adjusted ORs [14.08 and 
1.12 (per Gy increase), for CCR and D
mean
, respectively] for Grade ≥2 AET. According to our 
model, patients with advanced tumor stage (cT3/4) are at higher risk of Grade ≥2 AET, which 
may be due to the fact that the target volumes of these tumors do often border on the 
esophagus due to large tumor dimension or tumor extension into the mediastinum. Female 
patients showed an increased risk for Grade ≥2 AET as well. This was also reflected in the 
clinically validated (3D-CRT based) model for AET of Dehing-Oberije et al. [11], however, 
using a different grading scale and endpoint. 
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Besides CCR and esophageal D
mean
, univariate analysis revealed that radiotherapy technique 
(VMAT vs IMRT) and age were also significantly correlated with Grade ≥2 AET since more 
CCR was applied in younger patients and in those treated with VMAT (p<0.001 and p=0.007 
respectively). The explanation for this may be the fact that new insights into the added value 
of CCR above sequential treatment occurred together with the introduction of VMAT at our 
department resulting in relatively more patients receiving CCR with a VMAT technique. Only 
few elderly patients underwent CCR, most probably because they were considered unfit or 
had contraindications for chemotherapy.
In a meta-analysis by Palma et al. [18], data on 1082 patients who underwent CCR for locally 
advanced NSCLC were evaluated with the goal to design and validate a predictive model for 
AET. Even though the radiation technique (e.g., 3D-CRT vs IMRT) was not specified, it can 
be deducted from the literature references that the majority of patients most probably had 
been treated by 3D-CRT. The authors found the esophageal V
60Gy
 to provide the single best 
predictive value for AET. This DVH parameter was also highly significant in our univariate 
analysis. However, for model building, we decided to replace the significant esophageal DVH 
parameters by one single parameter (D
mean
) to circumvent the problem of multicollinearity 
that may lead to unrobust models. This approach seems adequate as the esophageal D
mean
 
was found to be most consistently predictive for AET in earlier reports [7]. Moreover, fitting 
of the LKB model to our DVH data revealed that this D
mean
 was a good predictor for AET. This 
is in line with an earlier report where the diverse DVH parameters were replaced by the 
esophageal D
mean
 resulting in a validated AET predictive model [11]. Thus, D
mean 
seems an 
adequate surrogate DVH parameter for non-stereotactic techniques, however, for modeling 
of AET after stereotactic radiotherapy for central lung tumors the maximum dose to the 
esophagus and doses to small volumes correlate best with AET [35].
For the modeling procedure we applied the systematic approach as described by El Naqa et 
al. [24] as this has been specifically tested for modeling of radiotherapy toxicity outcomes. 
Also, this approach allows assessment of multicollinearity and selection of the optimal 
model order. These are important issues in finding a model that is likely to fit well to other 
patient populations. Notwithstanding this, our evaluation has some drawbacks. Firstly, the 
retrospective nature of this study may lead to inclusion bias. To minimize this, all patients 
treated in a fixed time period were included. Secondly, the quality of the retrospectively 
retrieved toxicity data may be suboptimal, e.g., the duration of AET may not have been 
reported properly. To overcome these two problems, Niezink et al. [36] have developed 
a standardized program of prospective data acquisition for pulmonary radiotherapy, 
however, internal and external validation is still pending. This approach, together with the 
recently proposed international data exchange strategy, will further improve research upon 
treatment toxicity [37]. Thirdly, performance of a predictive model is overestimated when 
determined on the same population that was used to construct the model [27]. This was 
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the case in our study and therefore we performed an established validation procedure (i.e., 
correction for optimism via bootstrap sampling) to provide a more precise estimate of the 
model’s performance. Nevertheless, the model needs validation in an independent patient 
cohort before it can be used for clinical decision-making. Fourthly, we only included clinical 
and dosimetric parameters in this retrospective analysis, even though several biomarkers 
have been reported to be of significance as well. The acute phase response (thrombocytosis 
and anemia) and increased serum levels of specific microRNAs were found to be associated 
with AET [38,39]. Incorporating these prospectively obtained biomarkers may add to the 
predictive ability of the established model. Fifthly, it is also noted that with the use of DVH 
data spatial dosimetric information is lost. Earlier studies reporting on the influence of spatial 
dose effects (in 3D-CRT) reported ambiguous outcomes on the predictive value of spatial 
dose distribution characteristics [9,16,19,40-42]. However, the spatial dose distribution may 
be more important for IMRT than for 3D-CRT as the former technique comes with increased 
dose heterogeneity in the esophagus. The incorporation of spatial dose information in 
predictive modeling of AET is subject of further research.
In conclusion, a multivariable logistic regression NTCP model to predict Grade ≥2 AET rates in 
patients with advanced stage NSCLC undergoing intensity-modulated (chemo-)radiotherapy 
was developed. The most relevant prognostic variables are: concurrent chemoradiotherapy, 
mean dose to the esophagus, clinical tumor stage and gender. Although the model has shown 
good performance, external validation in an independent patient cohort is warranted.
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Supplemental material
Figure S1: Spearman correlation matrix (1A) for the dosimetric parameters and the model selection 
graphs (1B and 1C). 1A: the correlation matrix with the DVH parameters for the esophagus. The 
correlation coefficients (all significant) are denoted for each combination of variables, higher 
correlations are displayed in fading grey. 1B: figure shows that the optimal model order is 4. 1C: Bar-
graph shows the model that is chosen most from the bootstrap samples. 
Abbreviations: V
xxGy 
= relative volume of the esophagus receiving ≥xx Gy; D
mean
 = mean esophageal 
dose; D
max 
= maximum esophageal dose; CCR = concurrent chemoradiotherapy; VMAT = volumetric 
modulated arc therapy; IMRT = intensity-modulated radiation therapy.
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Figure S2: Calibration plot of actual outcome vs predictions for the multivariable NTCP model for 
acute esophageal toxicity. This calibration plot displays the observed frequency vs the predicted 
probabilities of Grade ≥2 acute esophageal toxicity (black solid line). The triangles indicate the average 
observed frequencies by deciles of average predicted probabilities, the open circles indicate the 
individual outcomes vs their predictions. Perfect predictions should be on the dashed 45° reference 
line. The solid line constitutes the loess fit.
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Table S1. Univariate logistic regression analysis for DVH parameters of the esophagus.
DVH parameters Grade ≥2 AET
Coefficient Odds ratio (95% CI) p-value
V5
Gy
0.033 1.033 (1.006-1.061) 0.017
V10
Gy
0.033 1.034 (1.006-1.063) 0.019
V15
Gy
0.036 1.036 (1.008-1.065) 0.011
V20
Gy
0.041 1.042 (1.014-1.070) 0.003
V25
Gy
0.039 1.040 (1.013-1.067) 0.003
V30
Gy
0.038 1.039 (1.013-1.065) 0.003
V35
Gy
0.038 1.039 (1.014-1.064) 0.002
V40
Gy
0.040 1.040 (1.016-1.065) 0.001
V45
Gy
0.041 1.042 (1.018-1.066) 0.001
V50
Gy
0.043 1.044 (1.019-1.068) <0.001
V55
Gy
0.045 1.046 (1.020-1.072) <0.001
V60
Gy
0.049 1.050 (1.023-1.078) <0.001
V65
Gy
0.049 1.050 (1.014-1.087) 0.006
V70
Gy
0.124 1.139 (0.809-1.585) 0.470
D
mean
0.078 1.081 (1.034-1.131) 0.001
D
max
0.024 1.025 (0.959-1.095) 0.473
Abbreviations: AET = acute esophageal toxicity; CI = confidence interval; VX
Gy
 = Relative volume of the 
esophagus receiving ≥X Gy; D
mean
 = mean dose; D
max
 = maximum dose.

Chapter 4
External validation of an NTCP model 
for acute esophageal toxicity 
in locally advanced NSCLC patients 
treated with intensity-modulated 
(chemo-)radiotherapy
Frank J.W.M. Dankers, Robin Wijsman, Esther G.C. Troost, Caroline J.A. 
Tissing-Tan, Margriet H. Kwint, José Belderbos, Dirk de Ruysscher, Lizza 
E. Hendriks, Lioe-Fee de Geus-Oei, Laura Rodwell, Andre Dekker, René 
Monshouwer, Aswin L. Hoffmann, Johan Bussink
Underscore indicates equal contribution 
Adapted from: Radiother Oncol. 2018 Nov;129(2):249-256
Abstract
Background and purpose
We externally validated a previously established multivariable normal-tissue complication 
probability (NTCP) model for Grade ≥2 acute esophageal toxicity (AET) after intensity-
modulated (chemo-)radiotherapy or volumetric-modulated arc therapy for locally advanced 
non-small cell lung cancer.
Materials and Methods
A total of 603 patients from five cohorts (A-E) within four different Dutch institutes were 
included. Using the NTCP model, containing predictors concurrent chemoradiotherapy, 
mean esophageal dose, gender and clinical tumor stage, the risk of Grade ≥2 AET was 
estimated per patient and model discrimination and (re)calibration performance were 
evaluated. 
Results
Four validation cohorts (A, B, D, E) experienced higher incidence of Grade ≥2 AET compared 
to the training cohort (49.3%-70.2% vs 35.6%; borderline significant for one cohort, highly 
significant for three cohorts). Cohort C experienced lower Grade ≥2 AET incidence (21.7%, 
p<0.001). For three cohorts (A-C), discriminative performance was similar to the training 
cohort (area under the curve (AUC) 0.81-0.89 vs 0.84). In the two remaining cohorts (D-E) 
the model showed poor discriminative power (AUC 0.64 and 0.63). Reasonable calibration 
performance was observed in two cohorts (A-B), and recalibration further improved 
performance in all three cohorts with good discrimination (A-C). Recalibration for the two 
poorly discriminating cohorts (D-E) did not improve performance.
Conclusions
The NTCP model for AET prediction was successfully validated in three out of five patient 
cohorts (AUC ≥0.80). The model did not perform well in two cohorts, which included 
patients receiving substantially different treatment. Before applying the model in clinical 
practice, validation of discrimination and (re)calibration performance in a local cohort is 
recommended.
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Introduction
Acute esophageal toxicity (AET) is frequently observed in locally advanced non-small cell 
lung cancer (LA-NSCLC) patients undergoing (chemo-)radiotherapy, particularly when 
patients receive concurrent chemotherapy [1, 2]. Normal-tissue complication probability 
(NTCP) models can help to estimate the risk of moderate or severe AET, which may be of 
benefit for anticipating events of hospitalization or treatment interruptions due to AET [3-
7]. These multivariable NTCP models may also be used by doctors as a tool to support their 
decision on whether or not to treat at the cost of more AET [8-10]. Furthermore, in case 
there is an increased risk of AET, patients may be selected that benefit most from other 
radiotherapy techniques such as proton therapy [11, 12].
The vast majority of the reported NTCP models for AET are based on 3-dimensional 
conformal radiotherapy (3D-CRT) techniques. Intensity-modulated radiation therapy 
(IMRT) and volumetric-modulated arc therapy (VMAT), however, produce more conformal 
dose distributions at the cost of increased volumes receiving lower dose [13-16]. These 
differences may result in a different toxicity profile and thus require new NTCP models [17-
19]. Therefore, the available NTCP models based on 3D-CRT may not be appropriate for AET 
risk prediction in patients treated with modern dose delivery techniques. We previously 
reported on an IMRT- and VMAT-based multivariable NTCP model for Grade ≥2 AET [20]. 
This model was internally validated and the area under the receiver operating curve (AUC) 
was 0.84 (0.82 after correction for optimism) indicating good discriminative power of the 
model. Nonetheless, as reproducibility (model performance on new samples from the same 
target population), and transportability (model performance on samples from different but 
related populations) of well internally validated prediction models can still be poor, external 
validation is needed to assess ‘generalizability’ of the NTCP model to external patient 
cohorts [21-24].
In this study, we used five patient cohorts from four different Dutch institutes to externally 
validate the previously reported multivariable NTCP model for Grade ≥2 AET after IMRT or 
VMAT for LA-NSCLC (TRIPOD statement Type 4 external validation  study [24]).
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Materials and Methods 
Established NTCP model for AET
The model was developed using a training cohort of 149 LA-NSCLC patients who underwent 
(chemo-)radiotherapy using IMRT or VMAT at the Radboud University Medical Center 
(Nijmegen, The Netherlands) between March 2008 and June 2013. Information on treatment 
and patient selection has been previously described in more detail [20]. In brief, all patients 
received ≥60 Gy (median 66 Gy) in 2 Gy fractions (once daily), with or without (concurrent 
or sequential) chemotherapy (Table 1). The sequential chemotherapy regimen typically 
consisted of 3 (3-weekly) courses of gemcitabine/cisplatin, whereas all patients undergoing 
concurrent chemoradiotherapy (CCR) received 2 (3-weekly) courses of etoposide/cisplatin.
AET was scored weekly during treatment by the treating radiation oncologist using the 
Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria [25]. 
Toxicity scoring was continued after treatment until acute toxicity resolved. The AET scores 
were analysed in relation to clinical risk factors and radiation treatment plan derived dose 
volume histogram (DVH) parameters.
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After multivariable logistic regression, with bootstrap sampling for model order and 
predictor selection, the following optimal NTCP model for Grade ≥2 AET (maximum at any 
timepoint) was established:
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁(𝑥𝑥) =
1
1+𝑒𝑒−𝑆𝑆(𝑥𝑥)
𝑆𝑆(𝑥𝑥) = −6.418 + 2.645 ∙ 𝑁𝑁𝑁𝑁𝐶𝐶 + 0.117 ∙ 𝑀𝑀𝑀𝑀𝑀𝑀 + 1.204 ∙ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 + 0.994 ∗ 𝑐𝑐𝑁𝑁, 
(1)
with,
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑥𝑥
𝑒𝑒 𝑆𝑆(𝑥𝑥)
𝑆𝑆 𝑥𝑥 . . ∙ 𝑁𝑁𝑁𝑁𝐶𝐶 . ∙ 𝑀𝑀𝑀𝑀𝑀𝑀 . ∙ 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 . 𝑐𝑐𝑁𝑁, (2)
and CCR = concurrent chemoradiotherapy (1 = yes, 0 = no), MED = mean esophageal dose 
(preferably first converting physical dose to linear-quadratic equivalent dose in 2 Gy fractions 
with α/β = 10 Gy using MED and its standard deviation [8, 26], or esophageal DVH or full 
dose matrix [27, 28]), gender (1 = female, 0 = male) and cT = clinical tumor stage (0 < cT3, 
1 ≥ cT3).
External validation cohorts
Five cohorts from four different Dutch institutes were available for validation of the 
abovementioned NTCP model. The patient, tumor and treatment characteristics of each 
cohort are listed in Table 1 and Supplementary Material Table S1. Except for cohort D and 
E, acute toxicity was retrieved retrospectively for these cohorts from the electronic health 
records. For all cohorts toxicity was scored weekly during radiotherapy and continued after 
radiotherapy until toxicity resolved, maximum AET score was used as outcome for model 
performance evaluation.
Cohort A (n=47) was also treated in the Department of Radiation Oncology of the Radboud 
University Medical Center [20]. This cohort consisted solely of stage III NSCLC patients that 
were treated with (chemo-)radiotherapy using VMAT between June 2013 and December 
2014. Radiotherapy and chemotherapy regimens and AET scoring were similar to those of 
the training cohort. Cohort B (n=73) consisted of stage III NSCLC patients which received 
(chemo-)radiotherapy at ‘Radiotherapiegroep’ (Arnhem, The Netherlands) between January 
2014 and March 2016 using mostly VMAT. The radiotherapy regimen and AET scoring were 
similar to the training cohort. Sequential chemotherapy was platinum based, preferentially 
cisplatin. Concurrent chemotherapy consisted of 2 courses of platinum/etoposide sometimes 
preceded by one course of a platinum doublet with either etoposide, or pemetrexed.
Cohort C consisted of 156 stage I-III NSCLC patients treated with (chemo-)radiotherapy at 
The Netherlands Cancer Institute (Amsterdam, The Netherlands) between December 1998 
and March 2003 using 3D-CRT [29]. For 27 patients, however, the predictor ‘clinical T-stage’ 
required in the NTCP-model was not available and therefore 129 patients with complete 
data were included. Varying radiotherapy schedules (total dose 49.5-94.5 Gy, 2.25-2.75 Gy 
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per fraction) were administered, and sequential and concurrent chemotherapy consisted of 
2 courses of gemcitabine/cisplatin or daily low-dose cisplatin, respectively. The incidence 
of AET in this cohort has been evaluated and reported previously; AET was scored using 
the RTOG scoring criteria [29]. Cohort D was also retrieved from The Netherlands Cancer 
Institute comprising 172 patients treated between January 2008 and November 2010, and 
their AET was scored using the Common Toxicity Criteria Adverse Effects (CTCAE) v3.0 [30]. 
See Table S2 in the Supplementary Material for a comparison between AET scoring using 
RTOG, CTCAE v3.0 and v4.0. These patients all underwent concurrent chemoradiotherapy 
(daily low-dose cisplatin) using IMRT (66 Gy in 24 fractions) [31].
The patients from cohort E (n=398) were treated at MAASTRO Clinic (Maastricht, The 
Netherlands) between April 2006 and October 2013. Of these, 216 patients had missing 
data, i.e., missing mean esophageal dose (n=201, for technical reasons), AET score (n=4; 
CTCAE v3.0 and v4.0 [32]), chemotherapy sequence (n=1) and clinical T-stage (n=10), and 
thus 182 patients were included. Patients received 1-3 courses of induction chemotherapy 
(gemcitabine or cisplatinum) typically followed by concurrent chemotherapy (n=156) or 
sequential chemotherapy (n=24) consisting of 2 courses of a platinum-based doublet. Two 
patients received no chemotherapy at all. The majority of patients (n=161) received a total 
radiation dose of 69 Gy in 1.5 Gy fractions twice daily up to 45 Gy, followed by 8 to 24 Gy in 
2 Gy once daily fractions, depending on the dose to the organs at risk (OAR) [33]. Eighteen 
patients were treated within the FDG-PET-based international multicenter Phase II dose 
escalation trial “PET-boost” [34]; they received 66 Gy in 24 once daily fractions to the gross 
tumor volume (GTV). In case dose escalation was possible (by increasing the fraction dose 
with equal number of fractions), an integrated boost was delivered to the primary tumor 
as a whole or to the volume of the primary tumor encompassed by 50% of the maximum 
standardized uptake value of FDG.
Statistical analysis
Differences between the training cohort from which the NTCP model was developed and 
the validation cohorts were tested for statistical significance using the Mann-Whitney-U or 
Fisher’s exact test, where appropriate (SPSS software, version 22.0; SPSS Inc., Chicago, USA). 
A p-value of <0.05 was considered statistically significant.
Model performance
The risk of Grade ≥2 AET was calculated for each individual patient by applying the original 
NTCP model (Formula 1 and 2). The discriminative power of the model for the validation 
cohorts was assessed by calculating the area under the curve (AUC) of the receiver operating 
characteristic (ROC). The criterion for successful external validation was AUC ≥0.80, i.e., no 
significant deterioration of model performance with respect to the training cohort (AUC 
0.84, or 0.82 after optimism correction [20]). Furthermore, the discrimination slopes were 
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calculated by the absolute difference between the mean predicted risk of the groups with 
and without Grade ≥2 AET.
Model calibration performance was assessed by calibration plots displaying grouped 
observed frequencies versus predicted outcome [35]. A loess smoother was plotted, which 
approximates the y=x identity line in case of good calibration [36]. The 95% confidence 
intervals of the binomially distributed grouped frequencies were calculated according to 
the Wilson interval [37]. Double histograms of predicted probabilities for patients with and 
without Grade ≥2 AET were also generated for the calibration plots.
To assess possible miscalibration in the cohorts, the method of logistic recalibration was 
applied [38, 39]. The linear predictors for each patient, i.e., the calculated results after 
inserting patient specific parameters into Formula 2, were used as a single predictor in a 
new logistic regression model according to:
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁(𝑥𝑥) =
1
1+𝑒𝑒−𝑆𝑆′(𝑥𝑥)
 𝑆𝑆𝑆(𝑥𝑥) = 𝑎𝑎 + 𝑏𝑏 ∙ 𝑆𝑆(𝑥𝑥). 
(3)
with updated linear predictor
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁(𝑥𝑥) =
1
1+𝑒𝑒−𝑆𝑆′(𝑥𝑥)
 𝑆𝑆𝑆(𝑥𝑥) = 𝑎𝑎 + 𝑏𝑏 ∙ 𝑆𝑆(𝑥𝑥). (4)
The resulting calibration intercept a (‘calibration-in-the-large’) compares the mean of 
the predicted risks with the mean of the observed risk and gives an indication whether 
predictions are systematically under- (a>0) or overestimated (a<0). The calibration slope b 
indicates the level of overfitting (b<1), i.e., the predictions are too extreme, or underfitting 
(b>1), the predictions are too mild. Recalibration does neither affect sensitivity nor specificity 
and thus ROC and AUC both remain the same [21, 35].
The overall performance of the recalibrated models in each cohort was additionally assessed 
by calculation of the scaled Brier score, a quadratic scoring rule corrected for dependence 
on the incidence of the outcome [21]. Additionally, Nagelkerke’s R2 was calculated, which 
is a logarithmic scoring rule to express the amount of variance in the dependent variables 
explained by the model [39, 40].
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Results
Comparison of cohorts
A comparison of training and validation cohort characteristics for the NTCP model predictors 
and AET is listed in Table 1. The incidence of Grade ≥2 AET in cohorts A, D and E was (nearly) 
twice the incidence of Grade ≥2 AET in the training cohort (70.2%, 59.3% and 68.1% vs 
35.6%, respectively; p<0.001). The patients in cohort C experienced lower rates of Grade ≥2 
AET compared to the training cohort (21.7% vs 35.6%, respectively; p=0.01). Other patient, 
tumor and treatment characteristics of the cohorts are listed as Supplementary Material in 
Table S1.
Model performance
A summary of model performance in the validation cohorts, i.e., overall performance, 
discrimination and (re)calibration, is listed in Table 2. Unsurprisingly, the best performance, 
as indicated by the highest value of the scaled Brier and Nagelkerke R2, was seen in the 
training cohort. The overall performance was high for cohorts A, B and C, but was poor for 
cohorts D and E.
The ROC curves for all cohorts are displayed in Figure 1. High discriminative performance 
of similar quality to the training cohort was obtained for cohorts A, B and C, as indicated by 
high AUCs (0.89, 0.81 and 0.84, respectively). Poor discrimination of the model was found 
in cohort D and E (AUC 0.64 and 0.63 respectively). This poor discrimination performance is 
also demonstrated by the calculated discrimination slopes (Table 2).
Model calibration performance, without recalibration, can be visually assessed from the 
calibration plots shown in Figure S1 of the Supplementary Material. Reasonable performance 
without recalibration was found by the model for cohorts A and B, demonstrated by the loess 
smoother which was relatively close to the identity line. The model generally underestimated 
the risk of Grade ≥2 AET. Increasingly poor calibration was observed for cohorts C, D and E.
Calibration plots generated after recalibration are shown in Figure 2, and the values for 
the calibration-in-the-large and calibration slope are listed in Table 2. For cohorts A and 
B, good calibration was achieved after recalibration. Similarly, for cohort C recalibration 
moderately improved the agreement between predicted and observed risk. For cohorts 
D and E, calibration did not improve after recalibration, indicated by the limited range of 
predicted probabilities (see Figure 2).
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Figure 1: ROC curves of the previously published NTCP model [20] applied on all patient cohorts 
showing good discriminating performance for 3 out of 5 validation cohorts as indicated by AUC values 
(>0.80). 
Abbreviations: ROC = receiver operating characteristic; NTCP = normal-tissue complication probability; 
AUC = area under the curve.
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Figure 2: Calibration plots of the NTCP model applied on all validation cohorts separate and combined, 
after recalibration per cohort. Recalibrated predicted probabilities are calculated by inserting the 
cohort-specific calibration-in-the-large and calibration slope values in Formulas 3 and 4. The triangles 
indicate grouped predicted probabilities of Grade ≥2 AET vs grouped observed frequencies. The 
vertical lines represent 95% confidence intervals. A loess smoother was fitted and displayed by the 
black line. Perfect predictions should be close to the dashed 45° reference line. Double histograms 
of patients with and without Grade ≥2 AET, binned according to their predicted probabilities, are 
displayed at the bottom. 
Abbreviations: NTCP = normal-tissue complication probability; AET = acute esophageal toxicity; AUC 
= area under the curve.
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Discussion
Recently, we established a multivariable NTCP model for AET in LA-NSCLC undergoing 
IMRT or VMAT and after thorough internal validation the model proved to be robust [20]. 
However, it is of paramount importance to perform external validation in order to ensure 
that the model is transportable to other patient cohorts [21, 23]. This means that the model 
produces accurate predictions in a sample that was drawn from a different but plausibly 
related population. Several components of ‘transportability’ can be distinguished, such as 
historical (e.g., a different time period), geographical (e.g., treated in a different hospital) 
and methodological (e.g., differences in toxicity scoring) transportability [41]. To account for 
all these components of transportability, we externally validated our previously established 
NTCP model for Grade ≥2 AET in cohorts of (LA-)NSCLC patients that were treated by 
(chemo-)radiotherapy in different hospitals (cohort B-E), receiving different radiation 
fractionation schedules (cohort C-E) and in a historically different period of time with less 
conformal dose delivery techniques (cohort C). Ideally, an NTCP model performs well in 
every patient cohort external to the cohort the model was developed on. However, this so-
called ‘strong calibration’ is only considered possible in utopia [35]. Therefore, applying an 
established NTCP model in different patient cohorts often needs some form of adjustments 
to account for local circumstances [42, 43].
Recalibration is a controlled form of model updating; i.e., the coefficients of the model 
are adjusted to correct for differences in for instance event rates. Initial calibration of the 
model in cohort A and B was moderate (see Figure S1 in the Supplementary Material). 
Underestimation of Grade ≥2 AET was seen, which is possibly due to a lower incidence of 
Grade ≥2 AET in the training cohort (35.6%) compared to cohort A (70.2%) and cohort B 
(49.3%). The class imbalance in the training cohort can affect the estimate of the model 
intercept and skews the predicted probabilities. After recalibration of the NTCP model for 
cohort A and B, calibration improved (see Figure 2). Discrimination of the model was good for 
the patients in cohort A and B (AUC 0.89 and 0.81, respectively). Formerly, we hypothesized 
that differences in dose delivery techniques influenced NTCP modelling since the models 
based on 3D-CRT did not perform well in head and neck cancer patients who underwent 
IMRT [18, 20, 44, 45]. Although cohort C differs substantially from the training cohort 
regarding treatment technique (3D-CRT vs IMRT/VMAT), radiation dose (49.5-94.5 Gy vs 66 
Gy), the application of concurrent chemotherapy, and the time period (1998-2003 vs 2008-
2010), the current model performed surprisingly well for this population (AUC 0.84 with a 
moderately good recalibration curve). Cohorts D and E showed poor discrimination (AUC 
0.64 and 0.63 respectively) and (re)calibration (see Figure 1 and Supplementary Material 
Figure S1). Re-estimating the regression coefficients or adding additional predictors that 
are known for their association with AET (for example, overall treatment time (OTT) and 
chemotherapy regimen; see below) are approaches to improve model predictions. Besides 
this, there may be several other reasons for the poor model performance in these cohorts. 
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Firstly, the NTCP model was developed using the RTOG grading scale for AET. However, 
toxicity for the patients in cohort D and E was scored using the CTCAE grading scales for 
AET. Differences between scoring systems were reported to be of importance in modelling of 
toxicity, for instance for modelling the risk of radiation-induced pneumonitis [46]. It is likely 
that such differences in grading scales affect AET modelling as well. This was illustrated for the 
patients of cohort B for whom both the RTOG and CTCAE v4.0 grading of AET were available. 
Applying the NTCP model using the CTCAE-based AET scores resulted in a high discrimination 
with AUC of 0.80 (compared to 0.81 for the RTOG based scores), however, model calibration 
was poor since it considerably underestimated the risk of CTCAE Grade ≥2 AET (data not 
shown). The latter can be explained by the finding that in 35.6% of the patients AET was 
scored as Grade 1 using the RTOG scale and as Grade 2 using the CTCAE scale (see Table S2 
in the Supplementary Material). Secondly, the patients from cohort D received concurrent 
chemoradiotherapy in a fundamentally different protocol compared to the patients in the 
training cohort as they received daily low-dose cisplatin and moderately hypofractionated 
radiotherapy schedules. Thirdly, the OTT is shorter for cohort D and E (5 weeks) than for 
the training cohort (6.5 weeks). Besides, the majority of patients (88.5%) from cohort E 
were treated twice-daily. Both factors are known to result in a strong increase of AET [3, 6]; 
including OTT in the NTCP model for patients receiving treatment with a shorter OTT is likely 
to improve model performance for these cohorts as reported by Dehing-Oberije et al. [3].
Despite our aim to thoroughly validate the established NTCP model for Grade ≥2 AET by 
assessing the transportability of the model using multiple different patient cohorts, some 
potential limitations should be noted. Firstly, the data of most cohorts were retrieved 
retrospectively (except cohort D and E) possibly introducing unwanted bias. Furthermore, 
for some patients of the validation cohorts the necessary NTCP model predictor values 
could not be retrieved resulting in exclusion of these patients. The number of patients 
of the separate cohorts may be considered low for model validation, however, the total 
number of patients (n=603) included in the validation cohorts is substantial. For future 
work, by making data ‘smarter’, e.g., by implementing semantic technologies [47, 48], and 
more easily accessible, by adhering to the FAIR data principles [49], distributed learning 
techniques can allow training and validation of models  in much larger cohorts of patients 
that were not treated according to any specific study protocol [50]. Finally, this study is 
an external validation of a model previously published by us and we therefore encourage 
independent external validation by other research groups. 
In conclusion, the established NTCP model for the prediction of Grade ≥2 AET in patients 
treated for locally advanced NSCLC successfully validated in 3 out of 5 patient cohorts, 
but performed poor in 2 cohorts that were significantly different for many variables. 
Before implementing the NTCP model in clinical practice, one should always check model 
discrimination and calibration performance in a local cohort representative of the patients 
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for which the model is intended to be used in the future. If good discrimination but poor 
calibration is observed a local recalibration of the model is advised. After implementation 
the model should be evaluated over time for new patients since treatments and cohorts 
change and model performance can deteriorate to the point where the model coefficients 
need to be updated or additional predictors may become relevant and complete remodelling 
is necessary.
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Figure S1: Calibration plots of the NTCP model applied on all validation cohorts separate and 
combined, without recalibration (calibration-in-the-large and calibration slope are given but not 
applied). The triangles indicate grouped predicted probabilities of Grade ≥2 AET vs grouped observed 
frequencies. The vertical lines represent 95% confidence intervals. A loess smoother is fitted and 
displayed by the black line. Perfect predictions should be close to the dashed 45° reference line. 
Double histograms of patients with and without Grade ≥2 AET, binned according to their predicted 
probabilities, are displayed at the bottom. 
Abbreviations: NTCP = normal-tissue complication probability; AUC = area under the curve; AET = 
acute esophageal toxicity.
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Abstract
In our previous work, a multivariable normal-tissue complication probability 
(NTCP) model for acute esophageal toxicity (AET) Grade ≥2 after highly conformal 
(chemo-)radiotherapy for non-small cell lung cancer (NSCLC) was developed using 
multivariable logistic regression analysis incorporating clinical parameters and mean 
esophageal dose (MED). Since the esophagus is a tubular organ, spatial information of the 
esophageal wall dose distribution may be important in predicting AET. We investigated 
whether the incorporation of esophageal wall dose-surface data with spatial information 
improves the predictive power of our established NTCP model. For 149 NSCLC patients 
treated with highly conformal radiation therapy esophageal wall dose-surface histograms 
(DSHs) and polar dose-surface maps (DSMs) were generated. DSMs were used to generate 
new DSHs and dose-length-histograms (DLHs) that incorporate spatial information of 
the dose-surface distribution. From these histograms dose parameters were derived and 
univariate logistic regression analysis showed that they correlated significantly with AET. 
Following our previous work, new multivariable NTCP models were developed using the 
most significant dose histogram parameters based on univariate analysis (19 in total). 
However, the 19 new models incorporating esophageal wall dose-surface data with spatial 
information did not show improved predictive performance (area under the curve, AUC 
range 0.79−0.84) over the established multivariable NTCP model based on conventional 
dose-volume data (AUC = 0.84). For prediction of AET, based on the proposed multivariable 
statistical approach, spatial information of the esophageal wall dose distribution is of no 
added value and it is sufficient to only consider MED as a predictive dosimetric parameter.
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Introduction
Acute esophageal toxicity (AET) is common in patients receiving (chemo-)radiotherapy for 
advanced stage non-small cell lung cancer (NSCLC), particularly when patients are treated 
with concurrent chemotherapy (Werner-Wasik et al., 2010; Auperin et al., 2010). With the 
introduction of intensity-modulated radiation therapy (IMRT) and volumetric-modulated 
arc therapy (VMAT), it has become possible to deposit highly conformal dose distributions 
in the target volume while decreasing dose to the surrounding organs at risk (Grills et 
al., 2003; Christian et al., 2007; Liao et al., 2010; Jiang et al., 2011; Monshouwer et al., 
2010). However, treatment of centrally located tumors and metastatic mediastinal lymph 
nodes, both of which are in direct proximity of the esophagus, may still lead to severe AET. 
Moreover, AET may increase when radiotherapy dose-escalation strategies and combined 
modality treatments are applied in clinical trials (Detterbeck et al., 2009). AET heavily 
influences quality of life during and shortly after treatment, and the ability to accurately 
predict AET may allow for personalized treatment strategies to reduce risk of AET. 
Many studies report a variety of clinical and dosimetric predictors for AET, however, most 
of these concern AET after three-dimensional conformal radiotherapy (3D-CRT) (Huang et 
al., 2012; Rose et al., 2009; Bradley et al., 2004; Belderbos et al., 2005; Wei et al., 2006; 
Palma et al., 2013; Dehing-Oberije et al., 2010; Werner-Wasik et al., 2010; Zhang et al., 
2014; Zhang et al., 2010; Chapet et al., 2005; Kim et al., 2005; Ahn et al., 2005; Zhu et 
al., 2010). Even though IMRT and VMAT have the ability to produce highly conformal dose 
distributions, these techniques are associated with an increase in target dose heterogeneity 
and larger proportions of healthy tissue receiving low dose (the so called ‘low-dose bath’) 
(Grills et al., 2003; Christian et al., 2007; Jiang et al., 2011). It is evident that the employed 
radiation technique has a direct effect on the dose distribution characteristics and therefore 
will influence the risk of AET. The introduction of IMRT has reduced treatment-induced 
toxicities in various tumor sites (Veldeman et al., 2008; Staffurth et al., 2010). However, this 
is not always the case, e.g. Gomez et al. (Gomez et al., 2012) found a significant increase 
in Grade ≥3 AET after IMRT compared to 3D-CRT in NSCLC (28% versus 8%, respectively), 
possibly due to the aforementioned ‘low-dose bath’.
Previously, we analyzed AET in 149 advanced stage NSCLC patients receiving IMRT or VMAT 
with or without chemotherapy and developed a multivariable normal-tissue complication 
probability (NTCP) model (Wijsman et al., 2015). The NTCP model consisted of the variables 
concurrent chemoradiotherapy (CCR), gender, tumor stage and the volumetric mean 
esophageal dose (MED). Since MED does not provide information on possible dose-volume 
effects, we additionally analyzed dose-volume histogram (DVH) parameters, but found no 
significant improvement over MED.
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We hypothesize that incorporation of esophageal wall-based dose-surface data containing 
spatial information improves the predictive power of our established multivariable NTCP 
model based on MED. This is motivated by the fact that the esophagus is a tubular organ 
comprising a lumen and a wall, and AET likely results from irradiation of the mucosal layer 
of the esophageal lumen.
The aim of this study was to extend our DVH-based NTCP model with 2D spatial dose 
information obtained from esophageal wall dose-surface maps (DSMs) and benchmark it 
against the model based on 3D DVH data.
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Materials and methods
Patients and treatment characteristics
In this retrospective study, we assessed a cohort of 149 consecutive patients that were 
treated with (chemo-)radiotherapy for advanced stage or inoperable NSCLC between March 
2008 and June 2013. The study has been carried out in accordance with the national rules 
concerning the review of research ethics committees and informed consent. As previously 
published, all patients were treated to a dose of ≥60 Gy in 2-Gy fractions with IMRT or 
VMAT (Wijsman et al., 2015). The standard sequential chemotherapy regimen consisted 
of 3 courses of chemotherapy, whereas most patients undergoing CCR received 2 courses. 
During treatment, acute toxicity (Radiation Therapy Oncology Group acute radiation 
morbidity scoring criteria) was assessed at least on a weekly basis by the treating radiation 
oncologist, and after the end of treatment follow-up continued until acute toxicity resolved. 
Maximum AET scores were retrieved from the medical files together with patient and tumor 
characteristics.
Dose mapping procedure
Because of the retrospective nature of this analysis and the importance of obtaining accurate 
DVH data of the esophagus, the outer rim of the esophageal wall, from the lower border of 
the cricoid cartilage to the gastro-esophageal junction, was re-contoured by one radiation 
oncologist (RW).
Contours were drawn on transverse computer tomography (CT) slices with an in-plane 
resolution of 1 mm and a slice thickness of 3 mm. The dose grid resolution was to 4 × 4 × 4 
mm3. For each patient the delineated contours and the 3D dose distribution were exported 
from the treatment planning system (TPS) Pinnacle3 (Version 8.0-9.2; Philips Radiation 
Oncology Systems, Fitchburg, WI). Conventional esophageal wall dose-surface histograms 
(DSHs) without spatial dose information were calculated by converting esophageal contours 
to approximate polygon meshes. To this end quad faces consisting of four edges were 
generated by connecting adjacent contour points and taking a height equal to the slice 
thickness. For all of the faces the area was calculated and the dose was evaluated at their 
centers by linear interpolation inside the 3D dose matrix (Figure 1a).
To incorporate spatial dose information in the histograms, esophageal polar dose-surface 
maps (DSMs) were generated. Multiple algorithms for generation of DSM have been 
reported in literature and a similar approach has been followed in this study (Buettner et al., 
2009). For each CT slice the esophageal contour coordinates were interpolated at angles 1 
to 360 degrees with respect to the contour centroid location and at a one-degree increment 
(Figure 1b). Dose at these new contour coordinates was evaluated by linear interpolation 
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inside the 3D dose matrix as originally calculated by the TPS. Performing this procedure for 
all contour slices generated a dose cylinder which was virtually cut at the posterior edge and 
unfolded to acquire the esophageal wall polar DSM (Figure 1c). 
From the polar DSMs four cumulative dose histograms containing spatial information were 
acquired (Figure 1c, 1d). First, a contiguous DSH (cDSH) was constructed by converting 
the DSM to binary masks for dose thresholds from 0 to 75 Gy in 0.1-Gy increments, which 
determined the largest connected surface area (CSA) for each dose level. The entire cDSH 
was normalized with respect to the total DSM area (length of the esophagus times 360 
degrees). Care was taken to recombine CSAs that were cut in two due to virtual unfolding of 
the dose map at the posterior edge.
Second, a combined contiguous DSH (ccDSH) was constructed by adding all disjoint CSAs 
receiving at least a certain dose, but scaling their areas reciprocally by their distance with 
respect to the largest CSA. The rationale behind this approach was based on the hypothesis 
that with increasing distance between CSAs enhanced repair of endothelium cells after 
radiation is possible due to cell migration from areas surrounding CSAs receiving lower 
doses. Note that when no scaling of disjoint CSAs is applied all areas are summated resulting 
in the loss of spatial information.
Next, two dose-length histograms (DLHs) were constructed by evaluation of the DSM 
along a specific direction. A circumferential DLH (cDLH) was constructed by taking the 
maximum horizontal length in the DSM receiving at least a certain dose level. Hence, the 
cDLH represents the maximum circumference of the esophagus receiving a certain dose in 
a transverse plane. Since the quantity along the horizontal axis of the DSM is given in units 
of degrees, it was normalized to one revolution along the circumference. CSAs that are cut 
into two parts by virtual unfolding of the dose cylinder at the posterior edge are detected 
and combined to obtain the correct maximum circumferences. Similarly, a longitudinal DLH 
(lDLH) was constructed by taking the maximum craniocaudal length in the DSM receiving at 
least a certain dose. The lDLH represents the maximum length of the esophagus receiving a 
certain dose in craniocaudal direction.
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(a) (b) (c) (d)
Figure 1: Derivation of the five 2D dose histograms. (a) Conversion from esophageal contours to 
approximate polygon meshes by construction of quad faces between contour coordinates. Each face 
has a height equal to the CT slice thickness. For generation of conventional DSH the area of the faces 
are calculated and dose at their centers is interpolated inside the 3D dose matrix. (b) Interpolation of 
the esophageal contour at 1 degree angle increments with respect to the centroid location. Repeating 
for all CT slices and performing virtual unfolding at the posterior edge results in a polar DSM. (c) 
An esophageal polar DSM for patient with Grade 1 AET after sequential chemoradiotherapy. L
60Gy
 in 
longitudinal and circumferential direction are represented by vertical and horizontal white arrows, 
respectively. Repeating for all dose levels results in lDLH and cDLH. (d) Binary mask of DSM for ≥60 Gy 
showing the primary and secondary largest contiguous surface areas CSA 1 and CSA 2, respectively. For 
cDSH, only CSA 1 is used, whereas for ccDSH CSA 2 is included, but reciprocally scaled by its distance 
to CSA 1.
Abbreviations: DSH = dose-surface histogram; P = posterior, R = right, A = anterior, L = left circumferential 
direction; DSM = dose-surface map; AET = acute esophageal toxicity; L
60Gy
 = circumferential or vertical 
length of dose-surface area receiving at least 60 Gy; lDLH = longitudinal dose-length histogram; cDLH 
= circumferential dose-length histogram; CSA = contiguous surface area; cDSH = contiguous dose-
surface histogram; ccDSH = combined contiguous dose-surface histogram.
For the cumulative dose-surface histograms (i.e. DSH, cDSH and ccDSH) the surface areas 
S
xxGy
, receiving a minimum dose of xx Gy, are calculated at 5-Gy intervals. Similarly, for the 
dose-length histograms (i.e. cDLH and lDLH) the lengths L
xxGy
, receiving a minimum dose of xx 
Gy, are calculated at 5-Gy intervals. Additionally, for all five histograms the mean histogram 
dose (MHD) was determined analogous to DVH mean dose calculation. All histogram and 
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parameter derivations were performed using in-house developed MATLAB-based software 
(version R2014b; The MathWorks, Natick, MA). 
To correct for spatial fractionation effects, the dose matrices were converted from physical 
dose to linear-quadratic equivalent dose in 2-Gy fractions (Wheldon et al., 1998; Bentzen 
et al., 2012), assuming α/β=10 Gy (EQD210) for acute esophageal toxicity, prior to histogram 
derivation.
Parameter robustness
It has been shown that inter- and intrafraction mobility of the esophagus can be significant 
(Dieleman et al., 2007; Cohen et al., 2010). Conversely, treatment planning is performed 
on a single pre-treatment CT scan that does not reflect organ mobility. Therefore, the 
esophageal dose reported in the treatment plan does not accurately represent the in vivo 
accumulated dose over the entire treatment course. Intuitively it seems plausible that 
2D dose parameters, derived with high spatial resolution from a treatment plan with a 
heterogeneous dose distribution, may be more susceptible to errors due to organ movement 
than conventional DVH-based parameters.
To investigate the robustness of the derived parameters under esophageal mobility we 
applied the established method of blurring the planned dose to simulate the accumulated 
dose over the entire treatment during organ motion (van Herk, 2004; Bortfeld et al., 
2004). Patient individual 3D dose distributions were blurred by convolution with Gaussian 
probability density functions over a range of standard deviations, since the actual 
esophageal motion in our patients was unknown. The standard deviation ranged from 1 to 6 
dose voxels and filter sizes were equal to two times the Gaussian full width at half maximum 
(𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 2√2ln2σ). After blurring, the 2D dose-surface parameters were calculated 
and subsequently used for multivariable logistic regression modeling. The same approach 
was used for the established NTCP model to allow a fair comparison.
Data exploration and predictive modeling
Our established NTCP-model, based on clinical variables (CCR, Gender and tumor stage) and 
a dosimetric parameter (MED), was used to test whether the newly developed NTCP models 
based on 2D dose-surface parameters were of added value in predicting AET (Wijsman et 
al., 2015). The three clinical variables in the new NTCP models were similar to those in 
the original model, such that observed differences have to originate from the change in 
esophageal wall-based dosimetric information added to the model. 
For each of the five newly created 2D dose histograms univariate logistic regression analysis 
was used to determine the parameters that were most significantly associated with Grade 
≥2 AET. Four- and five-variable predictive models were created for DSH and DSM-derived 
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parameters. The four-variable model included the three clinical parameters and the MED 
of the initial model was substituted by the most significant esophageal wall-based dose 
parameters. The five-variable model again included the three clinical variables, but this time 
instead of substituting the MED the most significant esophageal wall-based dose parameters 
were added. Additionally, neighboring cumulative dose histogram parameters are strongly 
correlated, indicating a high degree of multicollinearity. To circumvent the challenge of 
multicollinearity the MHD of the five histograms was always chosen to generate a four-
variable and five-variable model regardless of whether it achieved the highest significance 
(analogous to the approach in the reference NTCP model).
Individual predictions for AET were calculated using multivariable logistic regression 
analysis. The discriminative ability of the model was expressed by the area under the curve 
(AUC) of the receiver operator characteristic for these four- and five-variable models (AUC-4 
and AUC-5, respectively). Differences between the obtained AUCs were statistically tested 
according to DeLong et al. (DeLong et al., 1988). The statistical analyses were conducted 
using STATA (version 11.2, StataCorp LP, College Station, TX) and SPSS (version 22.0, Chicago, 
IL). P-values below 0.05 were considered to be statistically significant for all conducted 
statistical tests.
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Results
From the 149 patients evaluated (Table 1), 72 (48.4%) patients had ≥cT3 tumors and 52 
(35%) were female. Ninety-three (62.4%) and 46 (30.9%) patients received concurrent 
or sequential chemoradiotherapy, respectively. Grade ≥2 AET was scored in 53 (35.6%) 
patients. The five dose histograms (DSH, cDSH, ccDSH, cDLH and lDLH) were calculated for 
each patient and the accompanying predictive models for the selected parameters were 
generated.
Table 1. Patient, clinical and treatment characteristics.
Characteristics N = 149
Gender (%)
Male 97 (65)
Female 52 (35)
Age (y; range)
Median 63 (36-78)
Karnofsky Performance score (%)
≥ 90 95 (64)
≤ 80 54 (36)
Histology (%)
SCC 56 (37.6)
AC 59 (39.6)
NSCLC not otherwise specified 22 (14.8)
Other/Missing 6/6 (4/4)
Overall Tumor Stage (%)
IIb 2 (1.3)
IIIa 94 (63.1)
IIIb 53 (35.6)
Clinical Tumor stage (%)
0 7 (4.7)
1 24 (16.1)
2 44 (29.6)
3 36 (24.2)
4 36 (24.2)
X 2 (1.3)
Clinical Nodal stage (%)
0 12 (8.1)
1 7 (4.7)
2 92 (61.7)
3 37 (24.8)
X 1 (0.7)
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Characteristics N = 149
Chemotherapy (%)
Concurrent 93 (62.4)
Sequential 46 (30.9)
None 10 (6.7)
Radiation dose (2-Gy fractions; %)
66 Gy 145 (97.3)
60 Gy 4 (2.7)
Radiotherapy technique (%)
IMRT 99 (66.4)
VMAT 50 (33.6)
Abbreviations: SCC = squamous cell carcinoma; AC = adenocarcinoma; NSCLC = non-small cell lung 
cancer; IMRT = intensity-modulated radiation therapy; VMAT = volumetric modulated arc therapy.
Dose parameter selection
Univariate logistic regression analysis was performed to assess the association of Grade ≥2 
AET with all dosimetric variables described below (Supplemental material, Table S1). The 
conventional DSH parameters showed a significant increase in Grade ≥2 AET for S
5Gy
 to S
65Gy
 
parameters, with the most significant increase for S
40Gy
 through S
60Gy
 (p = 0.001, respectively). 
Both contiguous and connected contiguous surface histograms, cDSH and ccDSH, showed 
significance for the parameters S
5Gy
 and S
15Gy
 through S
65Gy
. Again, the DSH parameters 
related to high-dose areas (i.e. S
50Gy
 through S
60Gy
) reached the highest level of significance 
(p=0.001, for both cDSH and ccDSH, respectively). Analysis of the cDLH and lDLH dose length 
histograms revealed a significant increase in Grade ≥2 AET for the circumferential parameters 
L
55Gy
 through L
65Gy
, and for the longitudinal length parameter a significant increase in Grade 
≥2 AET was observed for L
30Gy
 through L
65Gy
. The highest level of significance was reached for 
L
60Gy 
(p = 0.004) of the lDLH and for L
60Gy
 and L
65Gy
 for cDLH (p=0.004, respectively). Except 
for cDLH, univariate logistic regression showed that regression coefficients for all MHD 
parameters were highly statistically significant (p=0.001, p=0.003, p=0.009; for DSH, for both 
cDSH and ccDSH, and for lDLH, respectively).
Selecting the parameters that were most significantly associated with Grade ≥2 AET for 
the five histograms, and always selecting the MHD, resulted in 19 parameters for further 
multivariable modeling.
Comparison of AUCs
The AUC-4 and AUC-5 for the four- and five-parameter NTCP models respectively were 
generated for each of the 19 parameters that were highly significantly associated with Grade 
≥2 AET on univariate analysis, resulting in 38 models. The calculated AUCs for these models 
Table 1. Continued. Patient, clinical and treatment characteristics.
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are shown in Figure 2 (and Supplemental material, Table S2). For the AUC-4 models 16 out of 
19 models performed less than or equal to (AUC range 0.80−0.84; p > 0.05) the established 
DVH-based model (AUC = 0.84 (Wijsman et al., 2015)), but statistical significant decline of 
performance was found only for lDLH L
60Gy
, lDLH MHD and cDLH MHD (AUC range 0.79−0.82; 
p < 0.05). The AUC-5 models showed no statistically significant changes in performance 
compared to the reference model (AUC range 0.84−0.85; p > 0.05).
Simulation of interfraction organ motion by blurring of the 3D dose matrix prior to the 
derivation of the 2D dose-surface parameters did not result in distinguishable patterns 
between models based on the esophageal wall-based dose parameters versus the reference 
model based on MED (shown in Figure 3). 
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Figure 2: Performance comparison of AUC-4 and AUC-5 models. The reference model (AUC = 0.84) 
with the previously published clinical variables CCR, gender, tumor stage and MED is shown on the left 
(Wijsman et al., 2015). AUC-4 models retain the clinical values, but MED is replaced with the listed 
dosimetric parameters. For the AUC-5 models instead of replacing MED the listed dosimetric variable 
is added, generating a five parameter model.
Abbreviations: AUC = area under the curve; DVH = dose-volume histogram; DSH = dose-surface 
histogram; cDSH = contiguous dose-surface histogram; ccDSH = combined contiguous dose-surface 
histogram; lDLH = longitudinal dose-length histogram; cDLH = circumferential dose-length histogram; 
MED = mean esophageal dose; SxxGy relative surface area receiving at least xx Gy; MHD = mean 
histogram dose; L
xxGy
 relative length receiving at least xx Gy.
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Figure 3: Influence of esophageal movement on AUC-4 models based on esophageal wall-based 
dose measures (white faces) compared with the established model (black faces). Different amounts 
of esophageal movement are approximated by 3D blurring of the patient dose distributions by 
Gaussian probability density functions with standard deviations ranging from 1 to 6 dose voxels (4 
mm dose grid). After blurring the dose parameters are calculated and, together with the three clinical 
parameters from the established model, used for multivariate logistic regression analysis to generate 
new NTCP models.
Abbreviations: AUC = area under the curve; DVH = dose-volume histogram; DSH = dose-surface 
histogram; cDSH = contiguous dose-surface histogram; ccDSH = combined contiguous dose-surface 
histogram; lDLH = longitudinal dose-length histogram; cDLH = circumferential dose-length histogram; 
MED = mean esophageal dose; MHD = mean histogram dose; LxxGy relative length receiving at least xx Gy.
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Discussion
One of the drawbacks of DVH and DSH parameters is that they do not reflect spatial 
information on the 3D dose distribution. Several studies have reported on using esophageal 
wall-based dosimetric parameters in modeling of AET based on the hypothesis that dose 
to the mucosal layer of the esophageal lumen is likely prognostic (Rodriguez et al., 2009; 
Kim et al., 2005; Rosenman et al., 2002; Werner-Wasik et al., 2000; Hirota et al., 2001). 
However, there is no consensus regarding an adequate spatial dosimetric predictor for 
AET. Furthermore, patients in these studies were treated with 3D-CRT, whereas modern 
IMRT and VMAT lead to different dose distributions, i.e. dose to the target volume is more 
conformal and more heterogeneous outside the target. It is hypothesized that prediction 
models based on 3D-CRT cannot be extrapolated to IMRT or VMAT based radiotherapy 
techniques. For instance, model performance for prediction of xerostomia in head and neck 
cancer based on 3D-CRT declined in patients treated with IMRT (Beetz et al., 2012). Similarly, 
NTCP modeling of chronic gastrointestinal toxicities following prostate cancer treatment in 
matched 3D-CRT and IMRT patients showed poor performance of 3D-CRT derived optimal 
parameters when applied to IMRT patients and vice versa (Troeller et al., 2015). Therefore, 
it is important to revisit the correlation between the shape and location of the esophageal 
wall dose distribution and clinical outcome measures for the current treatment techniques.
Previously, we have published an NTCP model for AET in NSCLC patients receiving modern 
highly conformal radiotherapy, but this model did not incorporate esophageal wall-based 
dosimetric parameters (Wijsman et al., 2015). In the current work, new methods were 
developed to analyze the dose distribution over the esophageal wall with and without taking 
spatio-dosimetric parameters into account. The esophageal wall-based dose parameters 
were used in predictive modeling of AET using the established DVH model to determine 
their added benefit in predictive performance. It was hypothesized that an NTCP model 
incorporating shape-based dosimetric parameters outperforms the NTCP model that is 
based on DVH parameters only. However, the addition of spatio-dosimetric information did 
not improve model performance.
Some drawbacks of the current study may have lead to the observed result. The esophagus 
is a tubular organ of only a few centimeters in diameter and therefore the esophageal dose 
distribution generally consists of dose to a relatively small and elongated volume. Analysis 
showed that this specific combination of organ geometry and dose distribution resulted in 
conventional DSH and DSM-derived histograms being of similar appearance to the original 
esophageal DVH. Changes in model performance after substituting MED from the original 
model with the 2D dose parameters, i.e. parameters from DSH or DSM-derived histograms, 
are therefore understandably minor. Additionally, a large majority (139 out of 149) of 
patients showed a single CSA of high dose in the dose map. Mediastinal lymph nodes were 
located close to the primary tumor and did not result in separated areas of high dose. For a 
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minority of patients (10 out of 149) the surface area of high dose was split in two CSAs, but 
only in 4 patients this led to significantly different DSM-derived histograms when compared 
to conventional DSH. The DSM-derived histograms therefore yield no additional information 
in most patients (145 out of 149).
To incorporate spatial information of the dose distribution the approach of polar DSM 
generation has been chosen. This methodology is straightforward in its application, has 
an easy interpretation and has previously been shown to be successful, mainly in prostate 
cancer treatment. For instance, rectal DSM-derived parameters have been shown to be 
prognostic for predicting gastrointestinal toxicities (Buettner et al., 2009, 2011; Wortel et al., 
2015) and bladder DSMs are correlated with urinary toxicity (Improta et al., 2016) following 
prostate cancer radiotherapy. Analysis of rectal wall DSM data has shown a high degree of 
spatial similarity and therefore interpretation and post-processing of the DSMs can be more 
standardized than for esophageal wall DSMs. For example, Buettner et al. demonstrated that 
NTCP model performance increased through spatial parameterization of the rectal wall dose 
distribution (Buettner et al., 2011). Esophageal wall DSMs are much more heterogeneous 
due to the large variety in tumor volumes and location in NSCLC radiotherapy resulting in 
a diversity of dose distributions, ultimately making parameterization and modeling more 
difficult than for prostate radiotherapy. 
Another aspect that introduces uncertainties is the rectangular form of the polar DSMs. The 
circumference of the esophagus can change abruptly along the longitudinal coordinate, i.e. 
between adjacent CT slices, due to folding or the presence of air. Converting the contours 
to a polar DSM stretches the circumferences to a normalized length which can result in a 
jagged appearance of the isodoses in the DSM. This may have a detrimental effect on the 
prognostic value of the parameters that are derived from these maps.
Dose distributions in the esophagus often contain steep dose gradients due to rapid dose 
fall-off outside of tumor volumes when using modern treatment techniques such as 
IMRT and VMAT. This is important, as the esophagus can move up to a few centimeters 
between fractions (Lever et al., 2014; Dieleman et al., 2007). The CT scan that is used for 
treatment planning is merely a ‘snapshot’ and the impact of movement on the esophageal 
dose distributions is not taken into account. However, these organ movements can have 
significant impact on the dose distribution that is accumulated in vivo, especially when 
the esophagus is located near high-dose regions with steep dose fall-off. Steep dose 
gradients are often present in dose distributions for patients with advanced stage (non-)
small cell lung cancer, frequently presenting with multi-level metastatic mediastinal lymph 
nodes. 2D dose parameters derived at the esophageal wall may be more susceptible to 
organ motion than conventional MED which is calculated over the entire volume. The 
robustness of these parameters, i.e. the amount of change in their values for a given 
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movement of the esophagus may be larger than conventional volumetric parameters. To 
simulate motion of the esophagus we applied blurring of the 3D dose matrix with Gaussian 
probability density functions having different standard deviations. After blurring, the 2D 
dose-surface parameters were calculated and subsequently used in predictive modeling. 
No clear difference in model performance was observed between the 2D dose parameters 
and the original MED parameter for the blurred dose distributions. Therefore, it cannot 
be concluded that the 2D spatio-dosimetric parameters are less robust than the original 
volumetric MED parameter.
Finally, precise determination of the mucosal dose is not possible due to the usually 
collapsed lumen of the esophagus. The inner wall of the esophagus may be folded, but 
contrast resolution of the planning CT scan is inadequate to observe this. As a first order 
approximation the outer esophageal wall was delineated. However, this may have introduced 
errors during virtually unfolding for DSM generation since the delineated contour of the wall 
was unfolded and not the actual wall contour.
Conclusion
In this work new methods were developed to derive esophageal wall-based dose-surface 
measures that include spatial information of the dose distribution. We tested if these shape-
based dose measures improved the predictive performance of an established multivariable 
NTCP model for Grade ≥2 AET in patients with advanced stage NSCLC undergoing intensity-
modulated (chemo)radiotherapy. We found that incorporation of the esophageal wall dose-
surface measures with spatial information did not improve the predictive performance of 
the existing model.
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Machine learning algorithms for 
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Abstract
Purpose
Machine learning classification algorithms (classifiers) for prediction of treatment response 
are becoming more popular in radiotherapy literature. General machine learning literature 
provides evidence in favor of some classifier families (random forest, support vector machine, 
gradient boosting) in terms of classification performance. The purpose of this study is to 
compare such classifiers specifically for (chemo)radiotherapy datasets and to estimate their 
average discriminative performance for radiation treatment outcome prediction.
Methods
We collected 12 datasets (3484 patients) from prior studies on post-(chemo)radiotherapy 
toxicity, survival, or tumor control with clinical, dosimetric, or blood biomarker features from 
multiple institutions and for different tumor sites, i.e. (non-)small cell lung cancer, head and 
neck cancer, and meningioma. Six common classification algorithms with built-in feature 
selection (decision tree, random forest, neural network, support vector machine, elastic 
net logistic regression, LogitBoost) were applied on each dataset using the popular open-
source R package caret. The R code and documentation for the analysis are available online1. 
All classifiers were run on each dataset in a 100-repeated nested 5-fold cross-validation 
with hyperparameter tuning. Performance metrics (AUC, calibration slope and intercept, 
accuracy, Cohen’s kappa, and Brier score) were computed. We ranked classifiers by AUC 
to determine which classifier is likely to also perform well in future studies. We simulated 
the benefit for potential investigators to select a certain classifier for a new dataset based 
on our study (pre-selection based on other datasets) or estimating the best classifier for a 
dataset (set-specific selection based on information from the new dataset) compared to 
uninformed classifier selection (random selection).
Results 
Random forest (best in 6/12 datasets) and elastic net logistic regression (best in 4/12 
datasets) showed the overall best discrimination but there was no single best classifier 
across datasets. Both classifiers had a median AUC rank of 2. Pre-selection and set-specific 
selection yielded a significant average AUC improvement of 0.02 and 0.02 over random 
selection with an average AUC rank improvement of 0.52 and 0.65, respectively.
Conclusion 
Random forest and elastic net logistic regression yield higher discriminative performance 
in (chemo)radiotherapy outcome and toxicity prediction than other studied classifiers. 
Thus, one of these two classifiers should be the first choice for investigators when building 
classification models or to benchmark one’s own modelling results against. Our results also 
show that an informed pre-selection of classifiers based on existing datasets can improve 
discrimination over random selection.
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Introduction
Machine learning algorithms for predicting (chemo)radiotherapy outcomes (e.g., survival, 
treatment failure, toxicity) are receiving much attention in literature, for example in 
decision support systems for precision medicine2,3. Currently, there is no consensus on an 
optimal classification algorithm. Investigators select algorithms for various reasons: the 
investigator’s experience, usage in literature, data characteristics and quality, hypothesized 
feature dependencies, availability of simple implementations, and model interpretability. 
One objective criterion for selecting a classifier is to maximize a chosen performance metric, 
e.g., discrimination (expressed by the area under the receiver operating characteristic 
curve, AUC). Here, we discuss the performance of binary classifiers in (chemo)radiotherapy 
outcome prediction, i.e. algorithms that predict whether or not a patient has a certain 
outcome. We empirically study the behaviour of existing simple implementations of 
classifiers on a range of (chemo)radiotherapy outcome datasets to possibly identify a 
classifier with overall maximal discriminative performance. This is a relevant question for 
investigators who search for a rational basis to support their choice of a classifier or who 
would like to compare their own modelling results to established algorithms.
We employ various open-source R packages interfaced with the R package caret4 (version 
6.0-73) that is readily available for investigators and has shown to produce competitive 
results5. With our results, we also wish to provide guidance in the current trend to delegate 
modelling decisions to machine learning algorithms.
Large scale studies in the general machine learning literature5–7 provide evidence in favor of 
some classifier families (random forest (rf), support vector machine (svm), gradient boosting 
machine (gbm)) in terms of classification performance. In our study, we investigate how 
these results translate to (chemo)radiotherapy datasets for treatment outcome prediction/
prognosis. To the best of our knowledge, this is the first study to investigate classifier 
performance on a wide range of such datasets. The studied features are clinical, dosimetric, 
and blood biomarkers.
Within the framework of existing classifier implementations, we attempt to answer three 
research questions:
(1) Is there a superior classifier for predictive modelling in (chemo)radiotherapy?
(2) How dataset-dependent is the choice of a classifier?
(3) Is there a benefit of choosing a classifier based on empirical evidence from similar 
datasets (pre-selection)? 
Parmar et al. (2015)8 compared multiple classifiers and feature selection methods (i.e. filter-
based feature selection) on radiomics data using the caret package. We build upon this 
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work and extend the analysis to 12 datasets outside the radiomics domain. We omit filter 
methods because all classifiers in our study comprise built-in feature selection methods 
(i.e. embedded feature selection) and the main advantage of filter methods, i.e. low 
computational cost per feature, is not relevant for our datasets with only modest numbers 
of features.
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Material and Methods
Data collection
Twelve datasets (3484 patients) with treatment outcomes described in previous studies 
were collected from public repositories (www.cancerdata.org) or provided by collaborators. 
Table 1 characterizes these datasets. Given availability, some datasets consist of subsamples 
of or contain fewer/more patients and/or features than the cohorts described in the original 
studies. Two datasets were excluded after a preliminary analysis (these datasets are also 
not mentioned in table 1) where none of the studied classifiers resulted in an average AUC 
above 0.51, which is evidence that they contain no discriminative power. Datasets without 
discriminative power are not suitable for this analysis as we would be unable to determine 
differences in discriminative performance across classifiers. The patient cohorts of 2 
datasets, Wijsman et al. (2015 and 2017), partially overlap but each dataset lists a different 
outcome (esophagitis and pneumonitis). Datasets were anonymized in the analysis because 
their identity is not relevant for interpreting the results and to encourage investigators to 
share their datasets. 
Non-binary outcomes were dichotomized, e.g., overall survival was translated into 2-year 
overall survival in the dataset of Carvalho et al. (2016). Missing data was imputed for training 
and test sets (the splitting of datasets into training and test sets is described in section 
Experimental Design) by medians for continuous features and modes for categorical features 
based on the training set. Basing the imputation on the training set avoids information 
leakage from test to training sets. Categorical features in training and test sets were dummy 
coded, i.e. representing categorical features as a combination of binary features, based 
on the combined set for classifiers that cannot handle categorical features (see table 2). 
Dummy coding on the combined set ensures that the coding represents all values observed 
in a dataset. Features with zero variance in training sets were deleted in the training set 
and in the corresponding test set. Additionally, we removed near-zero variance features 
for glmnet to avoid the classifier implementation from crashing during the fitting process. 
Features in training sets were rescaled to the interval [0,1] and the same transformation 
was applied to the corresponding test sets. Rescaling is needed for certain classifiers, e.g., 
svmRadial. All these operations (imputation, dummy coding, deleting (near-)zero variance 
features, rescaling) were performed independently for each pair of training and test sets 
(step 2 in figure 1).
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Classifiers
Six common classifiers were selected and their implementations were used via their 
interfacing with the open-source R package caret. The selection includes classifiers 
frequently used in medical data analysis and advanced classifiers such as random forests or 
neural networks. 
• Elastic net logistic regression is a regularized form of logistic regression, which 
models additive linear effects. The added shrinkage regularization (i.e. feature 
selection) makes it is suitable for datasets with many features while maintaining 
the interpretability of a standard logistic regression.
• Random forests generate a large number of decision trees based on random 
subsamples of the training set while also randomly varying the features used in the 
trees. Random forests allow modelling non-linear effects. A random forest model 
is an ensemble of many decision tree models and is therefore difficult to interpret.
• Single-hidden-layer neural networks are simple versions of multi-layer perceptron 
neural network models, which are currently popularized by deep neural network 
applications in machine learning. In the hidden layer, auxiliary features are 
generated from the input features which are then used for classification. The 
weights used to generate auxiliary features are derived from the training set. The 
high number of weights require more training data than other simpler algorithms 
and reduce interpretability. However, if sufficient data is available, complex 
relationships between features can be modelled.
• Support vector machines with a radial basis function (RBF) kernel transform 
the original feature space to attain a better separation between classes. This 
transformation, however, is less intuitive than linear SVMs where a separating 
hyperplane is in the original feature space.
• LogitBoost (if used with decision stumps as in this paper) learns a linear combination 
of multiple single feature classifiers. Training samples that are misclassified in early 
iterations of the algorithm are given a higher weight when determining further 
classifiers. The final model is a weighted sum of single feature classifiers. Similar 
to random forests, it builds an ensemble of models which is difficult to interpret.
• A decision tree iteratively subdivides the training set by selecting feature cutoffs. 
Decision trees can model non-linear effects and are easily interpretable as long as 
the tree depth is low.
Classifier details can be found in general machine learning textbooks23,24. Table 2 further 
characterizes these classifiers. We use the option in caret to return class probabilities for all 
classifiers, including non-probabilistic classifiers like svmRadial. Classifier hyperparameters, 
i.e. model-intrinsic parameters that need to be adjusted to the studied data prior to 
modelling, were tuned for each classifier using a random search: 25 randomly chosen points 
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in the hyperparameter space are evaluated and the point with the best performance metric 
(we chose the AUC in this study) is selected. The boundaries of the hyperparameter space 
are given in caret. 
Table 2. Classifier characteristics.
Classifier caret4 label  R package Requires dummy coding
Tuned hyper-
parameters
Elastic net logistic regression glmnet glmnet25 Yes 𝛼𝛼, 𝜆𝜆 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠, 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑚𝑚 
𝜎𝜎, 𝐶𝐶 
𝑛𝑛𝑛𝑛𝑚𝑚𝑠𝑠𝑚𝑚 
𝑑𝑑𝑐𝑐 
Random forest rf randomForest26 No
𝛼𝛼, 𝜆𝜆 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠, 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑚𝑚 
𝜎𝜎, 𝐶𝐶 
𝑛𝑛𝑛𝑛𝑚𝑚𝑠𝑠𝑚𝑚 
𝑑𝑑𝑐𝑐 
Single-hidden-layer neural 
network
nnet nnet27 No
𝛼𝛼, 𝜆𝜆 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠, 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑚𝑚 
𝜎𝜎, 𝐶𝐶 
𝑛𝑛𝑛𝑛𝑚𝑚𝑠𝑠𝑚𝑚 
𝑑𝑑𝑐𝑐 
 
Support vector machine with 
radial basis function (RBF) 
kernel
svmRadial kernlab28 Yes
𝛼𝛼, 𝜆𝜆 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠, 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑚𝑚 
𝜎𝜎, 𝐶𝐶 
𝑛𝑛𝑛𝑛𝑚𝑚𝑠𝑠𝑚𝑚 
𝑑𝑑𝑐𝑐 
 
LogitBoost LogitBoost caTools29 Yes
𝛼𝛼, 𝜆𝜆 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠, 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑚𝑚 
𝜎𝜎, 𝐶𝐶 
𝑛𝑛𝑛𝑛𝑚𝑚𝑠𝑠𝑚𝑚 
𝑑𝑑𝑐𝑐 Decision tree rpart rpart30 No
𝛼𝛼, 𝜆𝜆 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠, 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑚𝑚 
𝜎𝜎, 𝐶𝐶 
𝑛𝑛𝑛𝑛𝑚𝑚𝑠𝑠𝑚𝑚 
𝑑𝑑𝑐𝑐 
Experimental Design
For each classifier, test set (or out-of-sample) performance metrics (AUC, Brier score, 
accuracy, and Cohen’s kappa) were estimated for each of the 12 datasets. The performance 
metric estimator was the average performance metric computed from the outer test folds 
in a nested and stratified 5-fold cross-validation (CV). The experiment was repeated 100 
times. The 100 times repeated nested cross-validation yields a better estimate of the true 
test set performance by randomly simulating many scenarios with varying training and test 
set compositions.
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6Figure 1: Experimental design: each dataset is split into 5 stratified outer folds (step 1). For each of the 
folds, the data is pre-processed (imputation, dummy coding, deleting zero variance features, rescaling) 
(step 2). The hyperparameters are tuned in the training set via a 5-fold inner CV (steps 3-5). Based on 
the selected hyperparameters, a model is learned on the training set (step 6) and applied on the test 
set (step 7). Performance metrics are calculated on the test set (step 8) and stored for all outer folds. 
This process is repeated 100 times for each classifier. Randomization seeds are stable across classifiers 
within a repetition to allow pairwise comparison.
The experimental design is depicted in figure 1: Each dataset was split into 5 random 
subsamples stratified for outcome classes (step 1 in figure 1), each of them acting once as a 
test set and 4 times as a part of a training set. The number of inner and outer folds was set to 
5 following standard practice24(p242). Data pre-processing is done per pair of training and test 
sets (step 2; see details in section Datasets). The models were trained on the training set 
(step 6) and applied on the test set (step 7) to compute the performance metrics for the test 
set (step 8) resulting in 5 estimates per performance metric (i.e. 1 per outer fold). During 
the training in each outer fold, the best tuning parameters were selected from the random 
search (see section Classifiers) according to the maximum AUC of an inner 5-fold CV. In the 
inner CV, the training set was again split into 5 subsamples and models with different tuning 
parameters were compared (steps 3-5). The nested 5-fold CV was repeated 100 times with 
different randomization seeds which are used, e.g., for generating the outer folds in step 1. 
Note that the performance metrics computed on the outer test folds of any two classifiers 
can be analysed by pairwise comparison because the classifiers were trained (step 6) and 
tested (step 7) on the same training and test sets for a specific dataset within each of the 
100 repetitions. 
The mean AUC, Brier score, accuracy, and Cohen’s kappa were computed from the 5 
estimates of the 5 folds in the outer CV. Calibration intercept and slope were computed from 
a linear regression of outcomes and predicted outcome probabilities for each of the 5 outer 
folds. To attain aggregated calibration metrics over the 5 outer folds of the CV, the mean 
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absolute differences from 0 and 1 were computed for the calibration intercept and slope, 
respectively. Classifier rankings were computed per dataset and repetition by ordering the 
classifiers’ CV-mean AUC (i.e. the average AUC for 5 test sets) in descending order and then 
assigning the ranks from 1 to 6. Using CV-mean AUCs and CV-mean AUC ranks, we answer 
research questions 1 & 2. We chose AUC for the analysis following Steyerberg et al. (2010)31. 
They emphasize the importance of discrimination and calibration metrics when assessing 
prediction models. For the simplicity, we restricted the extended analysis to discrimination 
(AUC) but also report results for calibration and other metrics in appendix A. 
To address the question of pre-selection (research question 3), we assess the advantage 
of choosing a classifier based on performance metrics from similar datasets, which we call 
pre-selection below. To estimate the benefit of our classifier pre-selection for a new dataset 
and to compare it to alternative strategies, the results of the experiment above were used 
as input for a simulation. For each outer fold of the 1200 5-fold CVs (12 datasets * 100 
repetitions * 5 folds = 6000 folds), 3 classifier selections were made and tested on the test 
set that belongs to the specific outer fold: 
• pre-selecting the classifier according to the average AUC rank in all other datasets 
(excluding all folds from the current dataset),
• selecting the classifier that performed best in the inner CV on the training set,
• randomly selecting a classifier.
Pre-selecting the classifier for one dataset that had the best average AUC rank in the 
other datasets simulates the scenario in which an investigator bases their classifier choice 
on empirical evidence as is reported in this manuscript. Randomly selecting a classifier 
represents the case where an investigator chooses a classifier without any prior knowledge 
about the dataset that (s)he is about to analyze. Selecting the tuned classifier with best 
inner CV performance corresponds to evaluating multiple classifiers on the training dataset 
and thus including dataset-specific information in the classifier selection. The performance 
metrics are averaged over all 500 outer folds (5 folds * 100 repetitions) for each of the 12 
datasets.
The documented R code used for the analysis is available online1.
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Results
Running 1 nested 5-fold cross-validation and computing the metrics on 1 dataset for all 6 
classifiers allows 1 comparison of classifiers. This was applied on 12 different datasets, with 
each run repeated 100 times for a total of 1200 comparisons. The total computation time 
was approximately 6 days on an Intel Core i5-6200U CPU (or 15 seconds per classifier per 
dataset per outer fold, on average).
The results are presented and discussed threefold:
(1) results aggregated over all datasets and repetitions to determine the presence of a 
superior classifier,
(2) separate results for each dataset but aggregated over repetitions to determine 
dataset dependency,
(3) a simulation of classifier selection methods in new datasets to estimate the relative 
effect of classifier pre-selection.
The detailed analysis is restricted to the classifiers’ discriminative performance according 
to the AUC. Results for the remaining metrics (Brier score, calibration intercept/slope, 
accuracy, and Cohen’s kappa) are reported in appendix A.
Results aggregated over all datasets
Figure 2 shows the distribution of classifier rankings based on the average AUC (12 datasets 
* 100 repetitions = 1200 data points per classifier). Figure 3 depicts pairwise comparisons 
for each classifier pair (1200 comparisons per pair). The numbers in the plot indicate how 
often classifier A (y-axis) achieved an AUC greater than classifier B (x-axis). Coloring indicates 
whether the increased AUCs of classifier A are statistically significant (violet) or not (light 
violet). Untested pairs are colored grey. The significance cutoff was set to the 0.05-level 
(one-sided Wilcoxon signed-rank test, Holm-Bonferroni correction for 15 tests).
rf and glmnet showed the best median AUC rank, followed by nnet, svmRadial, LogitBoost, 
and rpart (figure 2). At the low end of the ranking, rpart showed poor discriminative 
performance. Manual inspection of the rpart models showed that rpart frequently returns 
empty decision trees for particular sets (for 34%, 67%, 35%, 58% of all outer folds for sets D, 
F, K, L, respectively). In pairwise comparisons, rf and glmnet significantly outperformed all 
other classifiers (figure 3). rf exhibited a small but statistically insignificant better AUC rank 
than glmnet. 
The results in figures 2 and 3 indicate the existence of a significant classifier ranking for these 
datasets. However, the considerable spread per classifier in figure 2 and the low pairwise 
comparison percentages (between 57% and 88% in figure 3) also suggest a yet unobserved 
126 CHAPTER 6
dependency for classifier performance. To this end, the relationship between datasets and 
varying classifier performance is investigated.
Figure 2: Box- and scatterplot of the AUC rank (lower being better) per outer 5-fold CV aggregated 
over all datasets and repetitions (12 datasets * 100 repetitions = 1200 data points per classifier).
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Figure 3: Pairwise comparisons of each classifier pair (12 datasets * 100 repetitions = 1200 
comparisons per pair). The numbers in the plot indicate how often classifier A (y-axis) achieved an 
AUC greater than classifier B (x-axis). The color indicates whether the increased AUCs by classifier 
A are statistically significant (violet), insignificant (light violet), or have not been tested (grey). The 
significance cutoff was set to the 0.05-level (one-sided Wilcoxon signed-rank test, Holm-Bonferroni 
correction for 15 tests).
Results separate for each dataset 
Figure 4 shows the average AUC for each pair of classifier and dataset (100 repetitions = 
100 data points per pair). Figure 5 depicts the average rank derived from the AUC (100 data 
points per pair). 
rf and glmnet generally yielded higher AUC values and AUC ranks per dataset (figures 4 & 
5). However, this observation is not consistent over all datasets: e.g., nnet outperforms rf in 
sets G, J, and K, and svmRadial outperformed glmnet in sets A and C.
The results in the figures 4 and 5 indicate that dataset-specific properties impact the 
discriminative performance of classifiers. These results challenge our proposition that 
one can pre-select classifiers for predictive modelling in (chemo)radiotherapy based on 
representative datasets from the same field.
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Figure 4: The mean AUC for each pair of classifier and dataset (100 repetitions = 100 data points 
per pair).
Figure 5: The mean rank derived from the AUC (100 repetitions = 100 data points per pair).
Effects of empirical classifier pre-selection on discriminative performance
Table 3 lists, for each dataset, the name and average AUCs, i.e. averaged over all 100 
repetitions, for random classifier selection, classifier pre-selection, and set-specific classifier 
selection.
The pre-selection procedure always results in rf or glmnet. The mean benefit of empirically 
pre-selecting a classifier is small: the AUC improvement ranges between -0.01 and 0.07 with 
a mean of 0.02. In a pairwise comparison over all datasets (p < 0.05, one-sided Wilcoxon 
signed-rank test), the AUC values by pre-selection were significantly larger than the AUC 
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values by random selection. The AUC rank improves by 0.52 on average. Including dataset-
specific information by inner CV yields a mean AUC improvement of 0.02 and improves the 
rank, on average, by 0.65. In a pairwise comparison of set-specific and random classifier 
selection over all datasets (p < 0.05, one-sided Wilcoxon signed-rank test), the AUC increase 
was also statistically significant.
Given this simulation, the expected benefit of pre-selecting a classifier for a new dataset 
based on results from (chemo)radiotherapy-specific numerical studies is limited with an 
average increase in AUC of 0.02.
Table 3: For each dataset, the AUC rank averaged over all repetitions when (a) randomly selecting a 
classifier (Random classifier), (b) pre-selecting the classifier with the average best AUC rank in all other 
datasets, i.e. without any information about the current dataset (Pre-selected classifier), (c) selecting 
the classifier that yielded the highest AUC in the inner CV (Set-specific classifier). Improvements in 
average AUC and average AUC rank compared to (a) are reported. The average AUC improvements 
by pre-selection and set-specific selection were tested for statistical significance (p < 0.05, one-sided 
Wilcoxon signed-rank test) and found to be statistically significant (*). No other statistical tests besides 
the two aforementioned tests were conducted.
Dataset
Random 
classifier Pre-selected classifier Set-specific classifier
Rank
Name
Rank AUC Rank AUC
Mean Mean Increase Increase Mean Increase Increase
Set A 3.43 glmnet 3.64 -0.21 0.00 3.10 0.33 0.02
Set B 3.44 rf 2.92 0.52 0.02 3.31 0.13 0.00
Set C 3.49 rf 1.94 1.55 0.05 2.78 0.71 0.03
Set D 3.59 rf 2.60 0.99 0.05 3.31 0.28 0.02
Set E 3.53 rf 1.89 1.63 0.05 2.58 0.94 0.03
Set F 3.57 rf 2.99 0.58 0.04 3.52 0.05 0.01
Set G 3.43 rf 3.81 -0.39 0.00 1.70 1.73 0.05
Set H 3.65 rf 1.59 2.06 0.07 1.71 1.93 0.06
Set I 3.49 glmnet 3.50 0.00 0.00 2.08 1.42 0.03
Set J 3.52 rf 4.18 -0.67 -0.01 3.41 0.11 0.01
Set K 3.59 rf 3.33 0.26 0.02 3.20 0.39 0.02
Set L 3.44 rf 3.50 -0.06 0.00 3.66 -0.22 -0.01
Mean 3.51  2.99 0.52 0.02* 2.86 0.65 0.02*
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Discussion
Our results suggest that there is indeed an overall ranking of classifiers in (chemo)
radiotherapy datasets, with rf and glmnet leading the ranking. However, we also observe 
that the performance of a classifier depends on the specific dataset. Pre-selecting 
classifiers based on evidence from related datasets would, on average, provide a benefit 
for investigators because it increases discriminative performance. An increase in average 
discriminative performance is desirable in that an investigator would be less likely to discard 
their data because of a perceived absence of predictive or prognostic value. The estimated 
0.02 mean AUC improvement might appear small but it comes ‘for free’ with classifier 
selection based on empirical evidence from multiple radiotherapy datasets. Furthermore, 
the 0.02 AUC improvement is relative to random classifier selection. If an investigator had 
initially chosen rpart, which is the overall worst performing classifier in our study, switching 
to the preselected classifier would result in an average AUC increase of 0.07. Switching from 
LogitBoost, which is the second worst performing classifier in our study, to the preselected 
classifier would result in an average AUC increase of 0.04.
The results in table 3 show that classifier pre-selection and set-specific classifier selection, on 
average, yield the same AUC increase. We think that the usefulness of set-specific classifier 
selection is dependent on the size of the training set: classifier pre-selection is preferable 
for small datasets, set-specific classifier selection is better for larger datasets. Classifier pre-
selection represents choosing classifiers using evidence from a large collection of similar 
datasets from the general radiotherapy outcome domain. Set-specific classifier selection 
represents choosing classifiers based on the training set, which is a considerably smaller 
evidence base but comes from the patient group under investigation. If the training dataset 
is too small, selecting classifiers based on results from other datasets might be less-error 
prone. On the contrary, if an investigator has collected a large dataset, they have the option 
to conduct set-specific classifier selection (with all 6 classifiers) for their training data using 
our documented R code1.
In table 3, one can observe that the pre-selected classifier is mostly rf and sometimes 
glmnet. To understand this behaviour, consider dataset A: glmnet was pre-selected for set 
A by selecting the classifier with the best average AUC rank in all other sets (excluding set 
A). Note that, for all 12 datasets together, the average AUC rank for rf is only slightly better 
than for glmnet (2.29 for rf and 2.45 for glmnet; the average of the rows in figure 5). Since 
glmnet performs badly while rf performs best in set A, excluding this information leads to a 
better average AUC rank for glmnet and a worse average AUC rank for rf in the remaining 11 
datasets. As a consequence, glmnet becomes the pre-selected classifier for this dataset. A 
similar behaviour is observed for set I but not in sets C, D, E, H, where glmnet also performs 
worse than rf but the difference between both classifiers is smaller and does not induce a 
switch in the pre-selected classifier. 
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The result that classifier pre-selection is as good as set-specific selection in the studied 
datasets does not imply that one cannot determine a better classifier for a new dataset. 
Our implementation of set-specific classifier selection only evaluates the performance of 
various classifiers but does not directly take into account properties of the dataset itself. 
For example, if an investigator collected a dataset in which the outcome has a quadratic 
dependency on a feature, glmnet would not be able to capture this relation (since it models 
only linear effects) but rf would. However, pre-selecting a classifier based on results from 
other (chemo)radiotherapy datasets works well on average. Furthermore, including set-
specific classifier selection complicates the modelling process and therefore might not be 
desirable.
In this study, we collected 12 datasets for different treatment sites, i.e. (non-)small cell 
lung cancer, head and neck cancer, meningioma with different outcomes, i.e. survival, 
pneumonitis, esophagitis, odynophagia, regional control. However, this collection is 
certainly not a complete representation of treatment outcome datasets analyzed in the 
field of radiotherapy. Furthermore, we only studied one implementation of classifiers 
while classifier performance may vary between implementations. Past studies, however, 
indicate that classifier implementations in R interfaced with caret are competitive5. Given 
the apparent lack of comparative classifier studies in radiotherapy, our intention has been to 
provide numerical evidence for classifier selection to investigators even though our analysis 
is not exhaustive.
We intentionally limited the analysis to classifier selection while ignoring factors such as the 
investigator’s experience, usage in literature, hypothetical feature dependencies, and model 
interpretability. This restriction imitates the current trend to delegate modelling decisions 
to machine learning algorithms and/or non-domain experts. Nonetheless, we feel the need 
to emphasize that including these factors has merit. Furthermore, expertise on a specific 
classifier could warrant its selection: Lavesson and Davidsson (2006)32 observed in a study 
on 8 datasets from different research domains that the impact of hyperparameter tuning 
exceeds that of classifier selection. Therefore, the investigator could tune a classifier for better 
performance by also tuning the hyperparameters outside the subset of hyperparameters 
tuneable inside caret. Even in those cases, however, we suggest comparing these results 
to simpler implementations of rf and glmnet as these classifiers on average have the best 
discriminative performance according to this study. 
Finally, for the clinical implementation of classifiers, model interpretability is arguably a major 
requirement33: this view is also convincingly motivated by Caruana et al.34. Fortunately, our 
study shows that glmnet, which is an intuitive classifier, is also one of the best performing 
classifiers.
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Conclusion
We have modelled treatment outcomes in 12 datasets using 6 different classifier 
implementations in the popular open-source software R interfaced with the package caret. 
Our results provide evidence that the easily interpretable elastic net logistic regression and 
the complex random forest classifiers generally yield higher discriminative performance in 
(chemo)radiotherapy outcome and toxicity prediction than the other classifiers. Thus, one 
of these two classifiers should be the first choice for investigators to build classification 
models or to compare one’s own modelling results. Our results also show that an informed 
pre-selection of classifiers based on existing datasets improves discrimination over random 
selection.
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Appendix A
Table A1 lists performance metrics per classifier. These values are averaged over all 
repetitions and datasets (100 repetitions * 12 datasets = 1200 data points each). Accuracy 
and Cohen’s kappa were computed at the 0.5-cutoff. Calibration fails in some outer folds for 
every classifier resulting in either large or undefined values for intercept and/or slope. This 
failure occurs frequently with nnet and rpart. Undefined (NaN) values are excluded when 
calculating the median.
Table A1: Median performance metrics per classifier aggregated over repetitions and datasets (1200 
data points each). Undefined (NaN) values are excluded when calculating the median.
Classifier AUC Brier score Accuracy Cohen's kappa
Calibration 
intercept error
Calibration 
slope error
rf 0.71 0.19 0.70 0.14 0.12 0.38
glmnet 0.71 0.20 0.70 0.14 0.26 0.66
nnet 0.69 0.22 0.67 0.11 0.31 0.87
svmRadial 0.69 0.19 0.70 0.06 0.32 0.82
LogitBoost 0.66 0.24 0.66 0.18 0.24 0.60
rpart 0.62 0.23 0.67 0.17 0.22 0.55
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Abstract
Access to healthcare data is indispensable for scientific progress and technological 
innovation. Sharing healthcare data is time-consuming and notoriously difficult due to 
privacy and regulatory concerns. The Personal Health Train provides a privacy-by-design 
infrastructure connecting FAIR (Findable, Accessible, Interoperable, Reusable) data sources 
and allows distributed data analysis and machine learning. Patient-specific data never leaves 
a healthcare provider. We present results of the Personal Health Train’s application across 
eight international healthcare institutes (Amsterdam, Cardiff, Maastricht, Manchester, 
Nijmegen, Rome, Rotterdam, Shanghai): a study executed and analyzed in only 4 months. 
We trained and validated a distributed logistic regression model predicting post-treatment 
two-year survival in 23 203 non-small cell lung cancer patients treated between 1978-2015 
based on tumor staging definitions established by the American Joint Committee on Cancer. 
The Personal Health Train infrastructure demonstrably overcomes patient-privacy barriers 
to healthcare data sharing and promotes global evidence-based medicine. 
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Introduction
Many current innovations in medicine, including personalized medicine, artificial intelligence, 
(big) data-driven medicine, learning healthcare systems, value-based healthcare and decision 
support systems, rely on the sharing of data across healthcare providers. Conventional data 
analysis requires sharing and centralization of data to answer research questions. However, 
data sharing is hampered by administrative, political, ethical, and technical barriers1. This 
limits the amount of healthcare data available for life sciences in general as well as for other 
secondary uses such as healthcare quality assurance. 
Distributed (machine) learning reformulates conventional data analysis algorithms so 
that data centralization becomes unnecessary. Distributed algorithms iteratively analyze 
separate databases and return the same solution as if data were centralized: essentially 
sharing research questions and answers between databases instead of data.
We are convinced that only sharing research questions (and answers) between healthcare 
providers is a better, sustainable approach to medical data analysis, and can unlock orders 
of magnitude more data without violating privacy. To this end, we have developed an 
infrastructure called the Personal Health Train2 (PHT) consisting of 
- sites (“stations”) containing FAIR3 (Findable, Accessible, Interoperable, Reusable) data,
- technical network connections and legal frameworks (“tracks”),
- statistical learning applications (“trains”).
A global community of likeminded healthcare providers and academic partners called CORAL 
(Community in Oncology for RApid Learning) was initiated at the 2016 European Society 
for Radiotherapy and Oncology (ESTRO) conference. In various research projects across the 
globe, CORAL members have worked on the realization of the PHT.
An infrastructure to bring research questions to the data has been demonstrated to work 
recently in projects such as euroCAT4,5, DataSHIELD6 and OHDSI7. However, challenges remain 
in terms of the number of data subjects, number of data providers, and global coverage.
The aim of this study is to show that the PHT distributed learning infrastructure can be 
scaled to many thousands of patients, approaching the size of national healthcare registries. 
Specifically, we set the goal (as registered on clinicaltrials.gov8) to machine learn a predictive 
model for post-treatment two-year survival on more than 20 000 non-small cell lung cancer 
(NSCLC) patients, in at least five healthcare providers from more than five countries—
without any patient data leaving a healthcare provider.
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Results
In total, eight healthcare providers (“stations”) were contacted on 18-06-2018 and two 
additional sites were contacted later. At the deadline of 01-09-2018 (71 days after the 
first formal project invitation), eight sites (in Amsterdam, Cardiff, Maastricht, Manchester, 
Nijmegen, Rome, Rotterdam, Shanghai) made NSCLC patient data available in their local 
database endpoints and two sites did not participate for logistical reasons: delayed response 
to first formal invitation in one case and too little time to participate after a second round 
of invitations in another case. NSCLC patient data consists of two-year survival information
- diagnosis,
- diagnosis date,
- survival follow-up status, 
- survival follow-up status date, 
and cancer staging as defined by the American Joint Committee on Cancer (AJCC, see 
Methods for details)
- tumor (T) stage, 
- lymph node (N) stage, 
- metastasis (M) stage,
- overall disease stage.
Data availability
A summary statistics application (“train”) was sent via the Varian Learning Portal (“track”). It 
computed patient counts for each variable category, displayed in Table 1. Each site confirmed 
the validity of the summary statistics, a quality control step to ensure that correct data was 
used for modelling. A total number of 37 090 patients became available in the system. When 
restricting the search to patients
- diagnosed or treated from 01-01-1978 (effective date of the AJCC TNM cancer 
staging edition 1) and before 01-01-2016 (allowing at least two years survival 
follow-up), 
- with complete diagnosis date, follow-up date, and follow-up status (to calculate 
two-year survival),
the number of available patients decreased to 28 178, which forms the modelling cohort. 
Data of patients diagnosed before 2005 were mainly collected by two sites (with minor 
contributions from two other sites). Data of patients diagnosed after 2005 were made 
available by all sites. Overall, recent data was more abundant. More than half of the 
modelling data was provided by two sites: site G (43.0%) and site E (17.0%). Less than 
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6% of the modelling data was sourced from three sites: site D (2.4%), site C (2.3%), and 
site B (1.0%).
Modelling cohort distribution
Histograms for T, N, M, and overall stage categories after binning into supercategories 
(Table 6) but before imputation are shown in Figure 1. Patients with missing or right-censored 
two-year survival are excluded. The histograms are separate per site (x-axis) and split for 
patients alive and dead at two years after diagnosis (above and below x-axis). Patient counts 
are normalized per site. Sites are ordered by the percentage of patients alive at two years.
The percentage of patients alive at two years differed greatly in the provided data across 
sites (Figure 1): from 89.1% in site A to 18.8% in site H. The distribution of T, N, M, and 
overall stage categories also varied across sites. Notably, T1 clearly dominated in sites A and 
C but other sites display a more balanced distribution of T categories (Figure 1a). In sites 
A-E, N0 is the modal lymph node category but N2 is most frequent in sites F-H (Figure 1b). 
All sites report most patients in the M0 category but the decrease in M0 patients correlates 
loosely with the percentage of patients alive at two years per site, e.g., site H reports 41.4% 
M1 compared to 8.8% in site A (Figure 1c). As a direct consequence of the differences in T, 
N, and M category distributions, the overall stage distribution varies across sites (Figure 1d).
In general, data completeness is not consistent in the network (Table 1). Sufficient follow-
up information to compute two-year survival ranges from 92.1% (site D) to 44.1% (site B). 
Note that patients with incomplete follow-up (right-censored) have not been included in 
the modelling cohort displayed in Figure 1 and Figure 2. T, N, M, or overall stage information 
is frequently missing in half of the sites (sites E-H). Overall stage categories are not always 
reported: sites E and H do not provide overall stage information. Sites G, F, and A miss it for 
39.8%, 31.8%, and 2.2% of their patients, respectively.
Distributed machine learning
Based on the temporal distribution of patients in the modelling cohort, we selected patients 
from 01-01-1978 until and including 31-12-2011 for training and patients from 01-01-2012 
until and including 31-12-2015 for validation so that we achieved a split of approximately 2/3 
to 1/3. We selected a temporal split for training and validation (TRIPOD type 2b validation9) 
to simulate the development of the model on historical patient data and subsequent 
application in future patients.
Only 14 660 patients of 28 178 patients were complete cases (T, N, M, overall stage, and 
two-year survival) in the modelling cohort (Table 3). Missing T, N, M and overall stage were 
imputed using logical rules according to the AJCC TNM cancer staging editions and observed 
patient frequencies in the respective site. Imputation did not result in complete cases for 
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a subset of patients (see methods section for details) yielding 14 810 (63.8%) patients for 
training and 8 393 (36.2%) patients for validation, a total of 23 203 patients.
The logistic regression application trained a model from the training data (years 1978-2011) 
with coefficients as displayed in Table 2. The convergence criteria of the algorithm are met 
after 81 iterations (25 minutes). The convergence of the algorithm is displayed in Figure 2b: 
the root mean square error (RMSE) for predicting the probability of two-year survival (left 
y-axis) in the training cohort decreases per iteration and approaches 0.42. Although the 
RMSE has stabilized, not all regression coefficients (right y-axis) have converged.
The validation application assessed the model’s performance on the validation cohort (years 
2012-2015). The validation performance is described by the combined RMSE for patients 
from all sites (Figure 2b), the receiver operating characteristic (ROC) curve per site and their 
corresponding areas under the curve (AUCs) (Figure 2c), and by an exemplary calibration 
plot of the site with most patient data provided for training and validation (site G, Figure 2d). 
Calibration plots for all other sites are displayed in Figure S1 (Supplementary Information). 
Table 3 summarizes patient counts (available in the system and in the modelling cohort 
before and after imputation) and model performance per site. The validation RMSE 
almost-monotonically decreases during optimization on the training cohort. Discriminative 
performance of the model (as measured by the AUC), varies across sites from 0.85 (site A) 
to 0.58 (site D). Model calibration in site G is good with a calibration-in-the-large of 0.02 
and calibration-slope of 0.75 but calibration varies strongly across sites. For example, site 
A (Supplementary Information, Figure S1) displays a calibration-in-the-large of 2.39 and a 
calibration slope of 1.09. 
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Table 2: Logistic regression coefficients per supercategory. T1N0M0 and overall stage category I is the 
reference case.
Intercept T N M Overall stage
0.93 0 0.96 0 ref. 0 ref. 0 1.05
 1 ref. 1 -0.01 1 -1.09 I ref.
 2 -0.69 2 -0.19 X 0.00 II -0.19
 3 -1.08 3 -0.67   III -0.76
 4 -0.87 X -0.54   IV -0.82
 X -1.22     Occult 0.37
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Discussion
We trained a distributed logistic regression model on 14 810 NSCLC patients and validated 
it on 8 393 patients from eight sites worldwide, yielding a total of 23 203 patients. While we 
thus easily exceeded the goal of 20 000 by 16.0%, the eight participating sites originate from 
only five countries which is one country short of the intended goal.
Applying FAIR principles in this project highlighted the challenges in introducing modern 
data storage and processing approaches in a clinical research context. Semantic web 
technology allows concepts and relationships between concepts to be coded which makes 
data more interpretable – an important FAIR principle. The use of semantic web technology 
requires expertise that is often not present at healthcare institutes. In this project, we 
worked closely with all partners to support installations. Future projects would benefit from 
user-friendly software assisting healthcare institutes in transforming their data according 
to FAIR principles. Creating such software is the goal of an ongoing research project in the 
CORAL community.
We observed heterogeneity in modelled variables (T, N, M, and overall stage) and outcome 
(two-year survival) between sites. Sites provided different cohort types, either (complete) 
clinical records of heterogeneous NSCLC cases or study cohorts with narrower inclusion 
criteria which can explain much of this heterogeneity (Table 4). Specifically, site A had a 
biased inclusion towards surviving patients (89.1% two-year survival, Figure 1) and site 
C provided study cohorts. For both sites, these biases skewed T, N, M, and overall stage 
distributions towards lower stages. Even for sites providing data based on their full clinical 
records, different model variable distributions are not surprising since healthcare providers 
treat different patient subgroups. For example, data in site F originates from a radiotherapy 
clinic while the data in site G is provided by a comprehensive cancer care center offering 
different treatments (surgery, (chemo-)radiotherapy, etc.).
For differences in model outcome (two-year survival), there are multiple (possible) causes. 
For example, site A experienced a biased collection of survival information due to its 
unavailability in the healthcare provider’s Electronic Medical Records (EMR) and the difficulty 
of retrospectively gathering this missing information when there is no access to survival 
registries. Furthermore, some sites contributed historical data dating back to 1978 where 
treatment outcomes were generally worse. Additionally, treatment choices for patient 
subgroups differ due to national and local treatment guidelines. Another explanation is the 
difference in patient subgroups admitted for treatment with possibly worse prognosis, e.g., 
patients with metastasized NSCLC. 
Heterogeneity throughout the network is generally advantageous for prediction modelling 
as it allows models to be trained that are generalizable to a wider range of patients. On the 
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other hand, if the difference in cohorts is caused by characteristics not considered by the 
model, e.g., difference in treatments or data collection biases, then these differences can 
have a negative effect on model performance. In our study, site A suffered from a biased 
inclusion of surviving patients. The effect on the trained model should be low as site A 
only contributed 7.3% of the training cohort (Figure 2a). However, the usefulness of this 
dataset for model validation is limited because the performance of this model has not been 
evaluated for the entire patient population of the site but only for the subgroup following 
the biased collection (long survivors or recent patients, Table 4). A further inclusion bias is 
present in site C which provided two study cohorts (predominantly overall stage I and III) for 
training and validation. Care has to be taken when interpreting validation results: one can 
only draw conclusions for the patient subpopulation from which the validation dataset has 
been sampled.
Inter-comparison of summary statistics between sites highlights significant differences in 
variable distributions that can then be investigated to assure data quality. For example, 
earlier in this study, the N stage statistics showed one site to have an excess of N3 incidence 
as compared to other sites. This was subsequently investigated and uncovered a processing 
error at that site. This role will become increasingly important as outcome modelling studies 
move away from curated clinical trial datasets and towards routinely collected data and 
structured information retrospectively extracted from clinical notes.
We also observed varying model performance between sites: the validation cohort AUCs 
ranged from 0.58 (site D) to 0.85 (site A) and calibration plots (Supplementary Information, 
Figure S1) display obvious differences. Multiple factors might influence stable performance 
across sites: e.g., the aforementioned heterogeneity due to unobserved but important 
variables, or different staging practices across sites. Methods to detect and analyze these 
discrepancies are yet to be developed. Future work can take advantage of the large patient 
numbers in the network to analyze subgroups of similar patients to generate better 
performing models. The Personal Health Train infrastructure provides the means to conduct 
such analyses.
We observe that our results are qualitatively in accordance with the AJCC TNM cancer staging 
system: the regression coefficients of the presented model (Table 2) indicate decreased 
survival probabilities for increases in T, N, M, and overall stage supercategories (with 
exception of T4). For example, the regression coefficients for overall stage supercategories 
decrease from 1.05 for overall stage category 0 to -0.82 for overall stage category IV. 
Additionally, we quantitatively compared the presented model to the AJCC TNM cancer 
staging system: we retrieved two-year survival probabilities for the overall stages IA, IB, IIA, 
IIB, IIIA, IIIB, IV of the AJCC TNM cancer staging edition 710 (which is the effective edition 
of the validation cohort) and predicted two-year survival in the validation cohort. Patients 
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with overall stages other than IA, IB, IIA, IIB, IIIA, IIIB, IV were excluded because these stages 
are either not defined or survival probabilities are not reported in TNM edition 7. AUCs of 
the presented model and the AJCC TNM cancer staging edition 7 coincided (Supplementary 
Information, Table S1).
Published NSCLC two-year survival prediction models report AUCs of, for example, 
0.68-0.7711,12. Comparing the presented model’s performance with published models is 
difficult for multiple reasons:
- inclusion criteria: patient inclusion is restricted to treatment with curative intent12 
or different treatment techniques13,
- methodology: Cox regression models14–16 or early mortality17 predictions are not 
directly comparable to two-year survival predictions,
- performance estimates: sizes of validation cohorts vary across studies, causing 
different degrees of variability in the performance estimates, therefore rendering 
comparison unreliable.
The presented model is trained and validated on patients exhibiting all NSCLC stages, 
including stage IV patients who are generally not treated with curative intent, have the 
worst prognosis, and are least likely to survive two years after diagnosis (the two-year 
survival probability is approximately 10% according to the seventh edition AJCC TNM cancer 
staging manual10). Their bad prognosis is easily predicted but published studies mostly do 
not include stage IV NSCLC patients. Therefore, the presented model’s estimated two-year 
survival prediction performance is expected to be higher than for published models.
For this project, we have implemented logistic regression, a tool popular in statistical analysis 
and machine learning for its simplicity and interpretability. Despite logistic regression being 
a simple method, penalized logistic regression ranked second in discriminative performance 
after random forest (which is a much less interpretable classifier) in a recent empirical analysis 
of six classification algorithms for radiotherapy outcome prediction18. The presented model 
is unpenalized. Penalization might help the individual regression coefficients to converge as 
it alleviates the multicollinearity problem (Figure 2b) and will be explored in future studies. 
With this study, we extend the list of distributed methods that are already implemented 
in the PHT: Bayesian networks19 and linear support vector machines4. Distributed learning 
approaches for other machine learning methods are available for future implementation, 
e.g., (convolutional) neural networks20.
An alternative to the PHT is DataSHIELD21, a mature open-source distributed data analysis 
and machine learning platform with multiple applications. It is based on the open-source 
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software R and Opal data warehouses. The PHT infrastructure differentiates itself from 
DataSHIELD in multiple aspects:
- it is not limited to R but is compatible with multiple languages (e.g., Java, 
MATLAB, C#, Python, R),
- it offers analytical flexibility by not limiting the researcher to a fixed function 
library (DataSHIELD v4.0 comprises 140 R functions21),
- it uses Semantic Web technology to store and query data at sites but also allows 
relational databases and SQL queries,
- the long-term aim of the PHT infrastructure is to connect databases with routine 
clinical care data.
The presented PHT study only considers a very limited number of clinical data elements 
(T, N, M, overall stage, diagnosis year, survival follow-up). Arguably, individual predictions 
need many more data elements. Additional clinical (e.g., age, comorbidities), biological 
(e.g., genomics, proteomics), imaging (e.g., screening, radiomics22) and treatment sources 
(e.g., radiotherapy treatment planning) are likely to contain relevant data elements for 
the prediction of a survival outcome. Furthermore, the two-year survival outcome is not 
sufficient for clinical decision support, quality-of-life, toxicity and cost are also relevant for 
a balanced decision to be taken. However, due to the limited number of data elements 
required for inclusion, we could reach very high inclusion numbers and could show that the 
methodology of distributed learning scales to these numbers. Although the data quality 
is improving in routine care, the more data elements a study requires, the less complete 
datasets will be available. As quality improves, future studies are possible where additional 
data elements (not only prognostic but also predictive for treatment outcomes) can be 
included and thus better and more clinically relevant models can be developed using the 
proposed infrastructure.
This project shows distributed learning infrastructures are capable of delivering cohort 
sizes to rival those available to researchers from national registries. However, distributed 
approaches such as the PHT, where each institute must only satisfy its local information 
and research governance requirements, ease the bureaucratic burden of learning from 
internationally separated pools of patients, particularly between countries with differing 
information governance regimes. Furthermore, the system is much more flexible and makes 
including additional data elements into analyses a simple process. If an item is not present in 
a registry dataset, retrospectively adding this information to previous years is very difficult 
if not logistically impossible. Lastly, the infrastructure provides a mechanism to expedite the 
external validation of prognostic and predictive models in cohorts from different countries 
with different patient demographics, organizational cultures, and treatment regimens.
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Changes in the AJCC TNM cancer staging edition were not considered in this study nor was 
the more granular classification (e.g., T1a, T1b). The staging edition which was used by the 
physician is not often noted explicitly but future analyses may use the diagnosis year (or 
institutional information on when they ‘switched’ editions) as a predictor in the logistic 
regression model. Knowing the staging edition on a per patient level would make it possible 
to validate if more recent staging editions are indeed more prognostic and could generally 
improve the predictive performance of the trained models.
This study has shown that distributed machine learning using Semantic Web technology can 
be implemented in a short time frame to answer specific research questions. In future work, 
we will extend the CORAL community with more cancer centers and include more data 
elements noted in routine care. We expect therefore that, the PHT will enable researchers 
to rapidly train new prediction models as new patients and data elements become available: 
accelerating the speed at which clinical observations are turned into actionable knowledge.
The Personal Health Train infrastructure was deployed across eight healthcare institutes in 
five countries in four months. A two-year survival prediction model was trained and validated 
in more than 20 000 non-small cell lung cancer patients. This infrastructure demonstrably 
overcomes patient-privacy barriers to healthcare data sharing and implements distributed 
data analysis and machine learning across healthcare providers worldwide.
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Methods
This study was registered on clinicaltrials.gov8 (https://www.clinicaltrials.gov/ct2/show/
NCT03564457) on 11-06-2018 (first posted date: 20-06-2018, actual study start date: 01-
07-2018). In all sites, the project was approved by their institutional review boards (IRBs) or 
was conform to national information and research governance regulations. Official project 
invitations were sent to eight sites on 18-06-2018 and two additional sites were contacted 
later but before the deadline of September 1. Figure 3 shows the project timeline.
Figure 3: Project timeline. ESTRO: European Society for Radiotherapy and Oncology.
Given that the PHT is a privacy-by-design infrastructure where no individual patient data 
leaves the individual healthcare provider, no researcher has access to the data, data is 
anonymized or pseudonymized, and given the number of patients involved, internal privacy 
officers often felt informed consent was neither feasible nor necessary.
Patients
Exports of routine clinical care databases (sites A-B and D-H) or study cohorts (site C) 
identified as non-small cell lung cancer patients were included in this study (Table 4). Data 
elements retrieved were the diagnosis, diagnosis date, T, N, and M stages, overall stage, 
date of last follow-up after the diagnosis date and vital status at last follow-up (alive or 
dead). If the diagnosis date was not available, date of first treatment, date of histology or 
date of intake were allowed as a surrogate for the date of diagnosis. Various staging editions 
(AJCC TNM cancer staging editions 1-8) were published and implemented during the period 
of treatment. Two-year survival was defined as a reported time interval between date of 
diagnosis and date of last follow-up of more than 2 * 365.24 days with a vital status ‘alive’ 
at last follow-up or a reported time interval between date of diagnosis and date of death of 
more than 2 * 365.24 days. Two-year death was defined as date of death less than 730.48 
days after the date of diagnosis. Two-year survival was labelled missing if date of diagnosis, 
date of last follow-up, or vital status at last follow-up were missing. Two-year survival was 
also defined as missing if the date of last follow-up was earlier than two years after the date 
of diagnosis and the vital status at last follow-up was ‘alive’ (right-censored). 
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Table 4: Cohort information. NSCLC: non-small cell lung cancer. SBRT: stereotactic body radiotherapy. 
RT: radiotherapy. CHART: continuous, hyperfractionated, accelerated radiotherapy. 
 Disease Interval Treatment
Site A NSCLC Stage I-IV 
(histologically confirmed) 
January 
2008-August 
2016
(Chemo-)radiotherapy, surgery, 
chemotherapy. 
Filtered for having last follow-up records in 
2018 or documented vital status.
Site B NSCLC, Stage I-IV, histo-
cytologically confirmed
October 2004-
May 2018
(Chemo-)radiotherapy, chemotherapy, 
surgery, multimodality treatment.
Site C NSCLC, 1) Peripheral  
stage I, 2) stage III
1) 2005-2016,  
2) 2008-2013
1) SBRT only, 2) concurrent (chemo-)
radiotherapy, surgery.
Site D
NSCLC Stage I-IV (either 
clinical diagnosis or 
histologically confirmed) 
2004-2017
Definitive radiotherapy (55Gy in 20 
fractions, CHART, concurrent or sequential 
chemo-radiotherapy or other standard/
accepted radical radiotherapy schedules) 
excluding SBRT or post-surgery adjuvant RT.
Site E
NSCLC, Stage I-IV (either 
clinical diagnosis or 
histologically confirmed)
1997-2018
First available T, N, and M staging 
information of lung cancer patients 
treated with curative and palliative 
RT. Includes post-surgery RT, (chemo-)
radiotherapy, recurrences.
Site F NSCLC, Stage I-IV 1982-2018
First available T, N, M, and overall staging 
information of lung cancer patients 
treated with curative and palliative 
RT. Includes post-surgery RT, (chemo-)
radiotherapy, recurrences.
Site G NSCLC, Stage I-IV 1955-2018
First available T, N, M, and overall staging 
information of lung cancer patients. 
Includes surgery, (chemo-)radiotherapy.
Site H NSCLC, Stage I-IV 1971-2018
First available T, N, M, and overall staging 
information of all lung cancer patients  
treated with curative and palliative 
RT. Includes post-surgery RT, (chemo-)
radiotherapy, recurrences, SBRT.
FAIR data model
To make data FAIR, a data model has to be agreed upon between parties. As per prior 
work23 we have implemented this model using Semantic Web technology. In Figure S2, 
a graphical representation of the model is shown and on github24 (https://github.com/
RadiationOncologyOntology/20kChallenge/wiki/Data-model) the full data model including 
used classes and properties can be found.
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FAIR data stations
Creating FAIR data out of clinical information systems generally involved the following tools
• Source systems: these are the clinical systems in which the data elements required 
for this study were stored
• ETL: software to extract data from source systems, transform data, and load it into 
a data warehouse
• Data warehouse: a database where data from multiple source systems are 
combined
• Mapping: transformation from the data warehouse schema to medical ontologies, 
e.g., the Radiation Oncology Ontology23 (ROO) or the National Cancer Institute 
thesaurus25 (NCIt)
• Graph database: RDF database where data elements are FAIR. 
Table 5 shows an overview of the tools used at the various care providers. To support the 
setup of mapping and graph database software, installation manuals were distributed and 
remote support was provided.
Table 5: Overview of tools used to make data FAIR. EMR: electronic medical records.
Provider Amsterdam 
(NL)
Cardiff  
(WAL)
Maastricht  
(NL)
Manchester  
(ENG)
Nijmegen  
(NL)
Rome  
(IT)
Rotterdam 
(NL)
Shanghai 
(CN)
Source 
systems
NKI-AVL 
Tumour 
registry
Canisc (Cancer 
Network 
Information 
System 
Cymru, 
NHS Wales 
Information 
Services)
HiX (Chipsoft, 
Netherlands), 
municipality 
population 
registry  
(survival data)
Clinical Web 
Portal (in house 
e-records 
system). Mosaiq 
radiotherapy 
oncology 
information 
system. Medway 
Sigma BI patient 
administration 
system.
Radiotherapieweb 
(in-house EMR), 
municipality 
population  
registry  
(survival data)
BOA26 and 
Speed RO
OpenClinica, 
Microsoft 
Access
Chinese  
EMR
ETL tools MS SSIS MATLAB
SAP Business 
Objects, 
MATLAB
Pentaho data 
integration, SQL, 
Java, Python, R
PHP, SQL, MATLAB SQL MATLAB
In-house 
software
Data 
warehouse
MS SQL 
Server MS SQL Server
SAP Business 
Objects
PostgreSQL SQL Server SQL Server None
Mapping D2RQ
Graph   
database Blazegraph
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Network for secure application distribution, execution, and communication
For the secure distribution of and messaging between applications, a solution called the 
Varian Learning Portal (VLP, Varian Medical Systems, Palo Alto, CA) was used. The VLP is a 
cloud-based system which has implemented user, site, and project management so that a 
research project consisting of multiple data providers and researchers can securely share 
applications and communication between applications. To connect the VLP to a local data 
station, a learning connector is installed at each data provider. The learning connector is 
a gateway through which applications and communication are handled. The iterative 
execution of applications and communication between them is called a learning run and 
each data provider can accept or deny each learning run. All communication and other 
actions are logged and auditable by members of a given project. 
Applications for distributed cohort discovery, and learning
The VLP allows a certificate-based upload of applications. Each application group has two 
parts. One that runs at the VLP in the cloud (master application) and one at each of the sites 
(site application). Multiple application groups were developed in this project.
• The first application group’s aim is cohort discovery. An application is sent to each 
site to determine and communicate generic statistics (counts) of the available 
data in the FAIR data station. This cohort discovery application includes a SPARQL 
Protocol and RDF Query Language (SPARQL) query. Each site application reports its 
site statistics to a master application running at the VLP which are then reported 
back to the researcher who initiated the application. Multiple variations of this 
application group were employed to generate summary statistics for patient 
subgroups.
• The second application group aims to train a logistic regression (LR) model. Each LR 
site application can, given a SPARQL query, train a LR model from the local dataset. 
The regression coefficients of each site LR model and patient counts are then sent 
to the master application that reaches consensus in an iterative manner. Figure 4 
illustrates the process followed in the LR application group.
• The third application group validates a given LR model on the sites. An application 
is sent to each site to compute model performance metrics (RMSE, ROC curve, 
AUC, calibration plots) and transfers these back to the master application which 
combines and passes them on to the researcher. Calibration plots reporting 
calibration-in-the-large and calibration slope are generated following Steyerberg27 
and include Wilson confidence intervals implemented by Winkler and Nichols28.
The LR model is trained on patients treated between 1978 and 2012 and validated on all 
patients treated between 2012 and 2015. Only patients with complete diagnosis date, 
follow-up date, follow-up status, and complete T, N, M, and overall stage after imputation 
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are included. This approach simulates the development of an LR model and sequential 
validation on new data becoming available over time. This is a TRIPOD type 2b validation9.
The application used to train the LR coefficients in a distributed manner is based on the 
Alternating Direction Method of Multipliers (ADMM) and exemplary implementations by 
Boyd et al.29,30. ADMM decomposes the optimization problem underlying logistic regression 
(finding regression coefficients that maximize the log-likelihood of all training data) into an 
iterative optimization: each site computes regression coefficients that optimize a trade-off 
between maximizing the log-likelihood for the site’s local data and a degree of agreement 
with the network consensus (a combination of the regression coefficients determined 
at all sites). This trade-off includes a penalty for disagreeing with this consensus. At the 
master, the sets of site-specific regression coefficients are combined to a new consensus 
and a new disagreement penalty value is determined. This consensus and the new penalty 
are then returned to each site to again optimize site-specific coefficients (the trade-off 
between maximizing log-likelihood and agreement with consensus changes because of the 
new consensus and disagreement penalty). This iterative procedure is repeated until the 
discrepancy between the sites’ local coefficients and the consensus, as well as the change 
in the consensus solutions over iterations is sufficiently small. For an excellent technical 
description of ADMM, we suggest Boyd et al.29. All application groups are implemented 
in MATLAB R2018a (Mathworks, Natick, MA). Code and accompanying documentation are 
available open-source31 (https://github.com/RadiationOncologyOntology/20kChallenge). 
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Data processing before LR training
The levels for each variable (T, N, M, and overall stage) are grouped in supercategories 
(Table 6) to allow regression on data of different AJCC TNM cancer staging editions and to 
bundle similar categories.
Table 6: Supercategories for T, N, M, and overall stages grouping AJCC TNM cancer staging editions 1-8.
T N M Overall stage
0 T0 0 N0 0 M0 0 0
1 T1, T1a, T1b, T1c, T1mi, Tis 1 N1 1 M1, M1a, M1b, M1c I IA, IA1, IA2, IA3, IB
2 T2, T2a, T2b 2 N2 X MX II IIA, IIB
3 T3 3 N3 III III, IIIA, IIIB, IIIC
4 T4 X NX IV IV, IVA, IVB
X TX Occult Occult
T, N, M, and overall stages were dummy-coded to estimate the individual effect of each 
stage on two-year survival. T1, N0, M0 and overall stage I categories were used as the 
reference categories to avoid multicollinearity issues in the regression model. For example, 
the ordinal variable T stage, which takes six values (0 to 4, X), is converted to five binary 
variables representing T0, T2, T3, T4, TX.
Imputation
If a patient misses entries for one or more of the variables T, N, M, and/or overall staging 
(but not all of them), imputation of the missing values is attempted. A detailed imputation 
process description is presented in Figure S3 (Supplementary Information) and an outline 
is given below. 
First, the missing values are logically induced from the permitted combinations of T, N, M, 
and overall stages. For example, a patient diagnosed in 2011 with N0M0 and overall stage 
IIA but missing T can only have T2b according to TNM edition 7. 
If the logical imputation is ambiguous because multiple imputation results are possible, the 
missing values are imputed probabilistically based on a subset of patients treated at the 
same site. This subset contains patients treated at the same site, within the time interval 
corresponding to the selected AJCC TNM edition, and matching the available variables of the 
patient. This subset also contains patients for which missing values are logically imputed so 
that probabilistic imputation is also feasible for sites E and H which miss some variable for all 
patients. The empirical probability of each T, N, M, and overall stage combination observed 
in this patient subset is computed and one of these combinations is randomly sampled 
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according to the computed empirical probabilities. For example, a patient diagnosed in 2013 
with T1aN0 and overall stage IV but missing M can be imputed with M1a or M1b according 
to TNM edition 7. If there are 30 patients with T1aN0M1a & overall stage IV and 70 patients 
with T1aN0M1b & overall stage IV diagnosed starting 2010 and before 2018, the missing M 
value is imputed by 1a with probability 0.3 and by 1b with probability 0.7. This probabilistic 
imputation procedure assumes variables to be missing at random which is a simplifying 
assumption in routine clinical care data.
This imputation procedure is repeated for all available TNM editions (1-8). To decide on a 
single imputation for a given patient, the most recent TNM edition meeting two criteria is 
selected: 
- it was effective before or in the patient’s year of diagnosis,
- it yields a complete imputation. 
The modelling choice to also use preceding editions takes into account the possibility that 
the treating physician has not yet adopted the newest AJCC TNM cancer staging edition.
The following official effective dates for AJCC TNM cancer staging editions are used32:
• Edition 1: 1978 – 1983
• Edition 2: 1984 – 1988
• Edition 3: 1989 – 1992 
• Edition 4: 1993 – 1997
• Edition 5: 1998 – 2002
• Edition 6: 2003 – 2009 
• Edition 7: 2010 – 2017
• Edition 8: 2018 – present
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Figure 4: A simplified process description of the distributed logistic regression application group. 
VLP: Varian Learning Portal. ADMM: Alternating Direction Method of Multipliers.
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Supplementary Information
(a) (c)
(b) (d)
Figure S1: Calibration plots of the validation data for all sites excluding site G (Figure 2d). AUC: area 
under the receiver operating characteristic curve.
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(e) (g)
(f)
Figure S1: Continued. Calibration plots of the validation data for all sites excluding site G (Figure 2d). 
AUC: area under the receiver operating characteristic curve.
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Table S1: Patient counts with stages IA, IB, IIA, IIB, IIIA, IIIB, IV in the validation cohort and 
corresponding model performance per site for the presented model and the AJCC TNM cancer staging 
edition 7 survival probabilities10. Survival probabilities for stage 0 and Occult are not available in the 
reference. The corresponding patients were thus excluded. Patients not staged according to edition 
7 in the validation cohort were also excluded. AUC: area under the receiver operating characteristic 
curve. CI: confidence interval. 
Site Validation cohort patient counts (stage IA, IB, IIA, IIB, IIIA, IIIB, IV)
Model performance
Logistic regression AJCC edition 7
AUC 95%-CI AUC 95%-CI Δ AUC
Site A 2803 0.87 [0.84, 0.89] 0.86 [0.84, 0.89] 0.00
Site B 87 0.67 [0.54, 0.78] 0.69 [0.56, 0.80] -0.02
Site C 131 0.54 [0.43, 0.64] 0.52 [0.42, 0.61] 0.02
Site D 273 0.59 [0.52, 0.66] 0.59 [0.53, 0.65] 0.00
Site E 2455 0.73 [0.70, 0.74] 0.71 [0.69, 0.73] 0.01
Site F 939 0.73 [0.69, 0.76] 0.72 [0.68, 0.75] 0.01
Site G 878 0.71 [0.67, 0.75] 0.71 [0.66, 0.74] 0.01
Site H 341 0.76 [0.69, 0.82] 0.77 [0.69, 0.81] -0.01
Total 7907
 
Figure S2: A graphical representation of the data model employed in the distributed learning network.
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Figure S3: Imputation process. The TNM imputation wrapper function (a) is the outermost function 
which uses the TNM imputation function (b) and the Filter cell by row function (c) as subfunctions. 
The wrapper function has two input groups: data for the patients that are to be imputed and data for 
patients that act as the reference for probabilistic imputation. For both input groups, T, N, M, overall 
stage, and diagnosis year per patient are needed. TNM: cancer staging system based on tumor size 
(T), lymph node involvement (N) and metastasis (M). TNM edition: one of eight released TNM cancer 
staging system editions effective since 1978 and in non-overlapping time periods. TNMS: combination 
of TNM and cancer stage (S) for a patient (can contain missing values) or in the TNMS library (complete 
cases). Years: year of diagnosis corresponding with time of TNM staging, and used to determine the 
currently effective TNM edition. TNMS ref: reference patient TNMS combinations to be used for logic 
probabilistic imputation. TNMS library: library of valid combinations of TNM and cancer stages according 
to a specific TNM edition. Logic imputation: imputation of a missing TNMS value according to a single 
conclusive combination in the TNMS library. Logic probabilistic imputation: imputation of a missing 
TNMS value according to multiple inconclusive combinations in the TNMS library and their respective 
probabilities of occurrence in the TNMS reference cell. Imputation code: patient specific codes to 
indicate if the TNMS entries follow the TNM edition logic and the type of imputation performed (if any).
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Abstract
Background and purpose
The goal of this study is to retrain a previously published and externally validated model for 
the prediction of Grade ≥2 acute esophageal toxicity (AET) on a larger cohort of patients 
from four institutes using The Personal Health Train (PHT); a privacy-preserving distributed 
learning infrastructure. 
Materials and methods
Locally advanced NSCLC patients undergoing (chemo-)radiotherapy were collected from 
four routine clinical care systems. Patient data was stored at each institute according to 
FAIR principles using Semantic Web technology and public ontologies. Logistic regression 
coefficients for the model parameters were fitted on Grade ≥2 AET on a total of 787 patients. 
The improvement in root mean square error (RMSE) of the retrained model over to the 
existing model was tested for significance in a pairwise comparison using a 1000-times 
repeated Monte Carlo cross-validation (MCCV). Secondary metrics were: mean absolute 
error (MAE), mean log-likelihood, area under the curve (AUC) of the receiver operating 
characteristic and calibration plots.
Results
The RMSE in the retrained models improved significantly: on average by 5.4% in the MCCV. 
All secondary objectives improved significantly except for MAE and the AUC of one institute.
Conclusion
An existing model for Grade ≥2 AET was retrained with more than four times the training 
data from four institutes. As this model is now based on multi-institutional data and the 
RMSE improved significantly, we recommend the retrained model over the existing model 
for independent validation. Given that the improvement of RMSE is small, we conclude 
that this model cannot be improved much further and propose future studies to consider 
additional variables. This multi-institutional machine learning study has been conducted 
without patient data leaving the institutes by using the Personal Health Train infrastructure.
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Introduction
Over the past decades, major advances in medical and computer technology have spurred 
the collection of large bulks of patient-level clinical care data in healthcare [1,2]. In the field 
of radiation oncology, we now routinely collect a multitude of clinical, imaging, genomic 
and treatment data. This increase in healthcare data presents us with great opportunities 
for gaining new insights that will aid physicians and patients in personalizing treatments [3].
On the other hand, the rapid improvement and introduction of new treatment technologies 
(e.g., volumetric-modulated arc therapy (VMAT) or MR-Linac) presents challenges for 
establishing evidence to support these innovations in a short timeframe. For example, 
single institute cohort sizes for a given radiation treatment typically remain small and lack 
variability from the viewpoint of the employed statistical learning methodologies. This 
makes prediction models susceptible to overfitting and hampers their generalizability and 
implementation [4].
The obvious solution is to achieve larger cohorts by combining data from multiple institutes. 
Centralizing medical data raises privacy concerns and regulatory frameworks are in place 
to protect individuals and their personal data (e.g., GDPR and HIPAA [5]). To preclude these 
concerns, we have published proof of concept solutions for distributed learning [6,7], 
negating the need for centralization of patient-level data. Recently we have shown, through 
our introduction of the Personal Health Train (PHT) infrastructure [8], that the technology 
scales to large patient numbers and can be readily implemented.
The PHT is a privacy-by-design system for distributed learning, and is well suited for model 
validation, retraining and development. The infrastructure consists of stations, tracks 
and trains. Participating institutes form the stations and host their data according to FAIR 
guiding principles (Findable, Accessible, Interoperable and Reusable [9]). The institutes are 
connected via tracks (formed by secured connections and legal frameworks) and statistical 
analyses (trains) are executed on the local data, instead of centralizing patient data, thereby 
negating privacy and regulatory concerns.
Previously, we have developed a normal tissue complication probability (NTCP) model 
predicting Grade ≥2 acute esophageal toxicity (AET) for locally-advanced non-small cell lung 
cancer (LA-NSCLC) patients receiving (chemo-)radiotherapy (Wijsman et al. 2015 [10]). This 
single institute based training cohort was modest in size (n=149). The model was validated 
in five healthcare institutes (Dankers et al. 2018 [11]). It successfully validated in three 
cohorts but poor performance was observed in two cohorts, which included patients with 
substantially different treatments.
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In this study, we aim to improve our existing NTCP model for prediction of Grade ≥2 AET 
by increasing the training cohort size through the combination of multi-institutional data 
and using the privacy-preserving PHT infrastructure (TRIPOD statement 2b study [12]). We 
hypothesize that this will significantly enhance the predictive performance of the model as 
measured by the root mean square error (RMSE) and the Wilcoxon signed-rank test for all 
participating institutes.
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Materials and Methods
Wijsman et al. (2015) model and training cohort
The published and externally validated multivariable logistic regression model by Wijsman 
et al. (2015) predicts the chance of Grade ≥2 AET [10,11]. Individual patient predictions are 
calculated using the logistic regression model containing four variables with corresponding 
coefficients:
• Gender: 1.204 (male = 0, female = 1)
• Clinical tumor stage (cT): 0.994 (<cT3 = 0, ≥cT3 = 1)
• Concurrent chemoradiotherapy (CCR): 2.645 (no = 0, yes = 1)
• Mean esophagus dose (MED): 0.117 (per Gy increase)
A detailed description of the model’s training cohort regarding inclusion and exclusion 
criteria has been published previously [10]. In short, the training cohort of model was 
based on 149 irresectable LA-NSCLC patients that received (chemo-)radiotherapy (60-66 
Gy) at Radboudumc (Nijmegen, The Netherlands). Radiotherapy was administered either 
via intensity-modulated radiation therapy (IMRT) or via VMAT. Chemotherapy was given 
sequentially, concurrently, or not at all. AET was scored based on the Radiation Therapy 
Oncology Group (RTOG) acute radiation morbidity scoring criteria (weekly during treatment 
and continued after treatment until acute toxicity resolved) [13].
New data cohorts
Four new NSCLC cohorts were supplied by Dutch radiation oncology institutes by 
retrospectively collecting data from routine clinical care systems. The data collection was 
performed according to national guidelines for research ethics committees and informed 
consent (see Table 1). An extensive description of the characteristics of the new data 
cohorts is provided in Supplementary Material S1. All cohorts comprised stage III LA-NSCLC 
patients that were treated by (chemo-)radiotherapy following conventional fractionation 
(range 1.5-2.75 Gy per fraction). For most institutes the median prescribed radiation dose 
was 66 Gy (interquartile range (IQR): 60-66 Gy) and was administered via IMRT or VMAT. For 
all cohorts, AET was scored at least every other week during treatment and continued after 
treatment until toxicity resolved (typically until 12 weeks after treatment). Predominantly, 
cancer staging was performed using the AJCC TNM 7th edition and AET was scored using the 
Common Toxicity Criteria for Adverse Events (CTCAE) v4.0 [14].
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Table 1: Cohort characteristics of the Wijsman et al. (2015) data and the new data cohorts.
Wijsman et al. 
(2015) data New data
Characteristics Radboudumc MAASTRO clinic Erasmus MC NKI Radboudumc
Number of patients 147 228 194 171 47
Inclusion start date Mar 2008 May 2012 2008 Jan 2013 Jun 2013
Inclusion end date Jun 2013 Dec 2016 2013 Jun 2018 Dec 2014
TNM staging edition 7 7 8 7 & 8 7
Physical dose or EQD2 EQD2 physical physical EQD2 EQD2
Toxicity scoring criteria RTOG CTCAE CTCAE CTCAE RTOG
Abbreviations: EQD2 = equivalent dose in 2 Gy fractions using α/β=10 Gy, RTOG = Radiation Therapy 
Oncology Group, CTCAE = Common Toxicity Criteria Adverse Effects.
Personal Health Train infrastructure for distributed learning
The four participating institutes were connected using the PHT infrastructure. Extensive 
details regarding the PHT have been discussed previously [8]. The four institutes hosted their 
data adhering to FAIR guiding principles by applying a common data model [15] based on 
Semantic Web technology [16] and public ontologies [17,18]. The data are thus converted 
to triples and saved in a Resource Description Framework (RDF) store which is queried using 
SPARQL (SPARQL Protocol And RDF Query Language).
The institutes are connected to a distributed learning platform called the Varian Learning 
Portal (VLP, Varian Medical Systems, Palo Alto, CA, USA). The VLP forms a cloud-based 
communications hub and allows the distribution of researcher applications, which are sent 
to locally installed connectors at each institute.
Distributed applications
In this study, three main types of applications are sent between the institutes using the VLP. 
Each application has a master-part that runs on the VLP and that can initiate site-parts that 
run locally at the institutes.
• Discovery: performs a cohort discovery resulting in summary statistics of all the 
data available in the network. The application centralizes counts per level for 
categorical variables, and calculates basic statistics for continuous variables 
(minimum, maximum, mean, etc.). Continuous variables are not tested for 
statistically significant differences, as using rank-based tests would require sharing 
individual patient measurements, and would violate the privacy regulations of the 
platform.
• Retraining: randomly samples the distributed data into training and validation splits 
and trains a logistic regression model on the distributed training data using the 
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iterative Newton-Rhapson method (NR) [19]. After a finite number of iterations, 
it converges to a (near-)identical solution as if the data were centralized, i.e. it 
finds similar regression coefficients. There is a small chance that the algorithm 
diverges if it is initialized too far from the optimal solution. To avoid this, we 
initialize the algorithm at the medians of the locally fitted regression coefficients. 
At each iteration, the algorithm centralizes the current regression coefficients, the 
covariance matrix of coefficients, the gradients for the coefficient update and the 
total number of patients per institute [19]. The continuous model variable MED is 
normalized during training to meet algorithm requirements, but the normalization 
is undone afterwards to retain the conventional interpretation of a logistic 
regression coefficient (i.e. the increase in log odds with a 1 Gy increase in MED).
• Validation: validates a logistic regression model over distributed validation data by 
calculating the root mean square error (RMSE). This metric is adopted since it can 
be readily calculated from the distributed data, using:
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =  √
1
𝑁𝑁
∑ (?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖)2
𝑁𝑁
𝑖𝑖=1 = √
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ (?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖)2
𝑁𝑁𝑠𝑠
𝑖𝑖=1𝑠𝑠  , (1)
with i running over available patients, yi the observed outcome of an individual 
patient, ŷi the predicted probability, N the total number of patients, s the institutes 
(data station) and Ns the number of patients per institute. It is clear from Equation 
1 that only the summed square errors and total patient numbers per institute need 
to be centralized on the VLP for calculation of the central RMSE. Additionally, mean 
absolute error (MAE) and mean log-likelihood (MLL) are calculated (equations 
given in Supplementary Material S2). Area under the curve (AUC) of the receiver 
operating characteristic and average calibration plots are also calculated. AUCs and 
calibration plots are determined per institute since they can only be calculated for 
all data if patient outcomes and predictions are centralized, which would violate 
the patient-level data privacy requirements of the platform.
Applications are implemented in MATLAB R2018a (MathWorks, Natick, MA, USA). All 
applications are initiated, and their results downloaded, by communicating with the VLP 
through its application programming interface using Python scripts (version 2.7.15). Code 
and documentation are open-source [15].
Data pre-processing and imputation
The site-parts of the applications that are sent to the institutes first perform a SPARQL query 
[15] to locally retrieve the data from the RDF store. The clinical T, N, and M stage and clinical 
cancer stage are imputed following logic rules (implementation described previously [8], in 
the current study only the logical rules are used and probabilistic imputation is deactivated) 
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based on AJCC TNM cancer staging editions [20]. For a given patient, missing cancer stage(s) 
are only imputed if they can be unequivocally derived from the other stages available 
for this patient. Data leakage between training and validation data is not an issue with 
imputation based solely on logic rules. This approach ensures we maximize available data 
for the distributed applications.
The data are filtered by removing patients with missing values for the model variables, the 
outcome (AET) and clinical cancer stage. The subset of LA-NSCLC patients is collected by 
filtering for stage III clinical cancer stage. Finally, the model variables gender (male = 0, 
female = 1), CCR (no = 0, yes = 1) and cT (<T3 = 0, ≥cT3 = 1) are dichotomized for the model 
validation and retraining applications.
Monte Carlo cross-validation for model validation and model retraining
To reliably estimate the out-of-sample RMSE, a 1000-times repeated distributed Monte 
Carlo cross-validation (MCCV) is performed. During each repetition, the original Wijsman 
et al. (2015) training data is enhanced with a random subsample (67%) from each new data 
cohort and together form the training split. The choice to assign the original data to the 
training split for all repetitions complies best with the hypothesis that increasing training 
cohort size improves the original model. The remaining 33% from each new data cohort 
together form the validation split (see Figure 1). Random sampling at each institute is 
implemented while retaining the incidence of the outcome in both training and validation 
splits (stratified splits). For a given repetition, no patients in the training split are reused in 
the corresponding validation split.
The retraining application is run for each repetition by retraining new regression coefficients 
for the variables of the original Wijsman et al. (2015) model on the training splits. The 
validation application then calculates central RMSE (and secondary metrics: MAE, MLL, 
and AUC per institute) for each of the 1000 regression models on the validation splits. The 
validation application is rerun with the logistic regression model reported in Wijsman et al. 
(2015) on the same 1000 validation splits to pairwise compare prediction improvements 
of the retrained models, and tested using a one-tailed Wilcoxon signed-rank test with 
significance level chosen at 0.01 (H0: performance of the retrained model is the same or 
worse than of the Wijsman et al. (2015) model versus H1: performance of the retrained 
model is better than of the Wijsman et al. (2015) model). For RMSE and MAE smaller values 
are superior and a left-tailed test is performed, for MLL and AUC larger values are superior 
and a right-tailed test is performed.
Finally, a final model is trained on all available data in the network (Wijsman et al. 
(2015) cohort and new data) using the retraining algorithm. No validation metrics can be 
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computed for this model, but the MCCV results serve as an indication of the performance 
of the final model.
Figure 1: Distributed Monte Carlo cross-validation (MCCV) setup using 1000 repetitions to estimate 
prediction improvement with additional training data. The new data is randomly sampled into 
stratified training and validation splits. The training split is always extended with the original Wijsman 
et al. (2015) data. The retraining application retrains the model coefficients on the training split; the 
validation application computes performance metrics on the validation split for the retrained models 
and the original model by Wijsman et al. (2015), and allows pairwise comparison of the prediction 
performance.
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Results
The discovery application reported a total of 1617 patients available in the network for this 
study. After our imputation strategy, patients with clinical cancer stage other than stage 
III (LA-NSCLC) were excluded (22.8%). For the remaining patients (n=1248), missing values 
(15.5% missing CCR, 29.8% missing MED (mainly in one institute for technical reasons), and 
7.9% missing AET) were observed in 461 patients, which resulted in a total number of 787 
complete cases available for modeling. From this cohort, 147 patients from Radboudumc 
formed the original training cohort of Wijsman et al. (2015) (two patients less than the 
originally reported number, since these patients had clinical cancer stage IIB and are now 
excluded).
In Table 2 the patient characteristics after data pre-processing are shown per institute 
for comparison. Notable differences are the fraction of patients receiving concurrent 
chemotherapy – an important predictor in the Wijsman et al. (2015) model – which was 
large for Erasmus MC and NKI (89.2% and 81.9%, respectively) compared to the other 
institutes (70.2%, 68.0% and 62.6%). Planning target volumes (PTV) are greatest for Erasmus 
MC and Radboudumc (median values of 548 cm3 and 524 cm3, respectively, versus 485 cm3 
and 374 cm3 for other institutes). The mean esophagus dose was also greatest for Erasmus 
MC and Radboudumc, with median values of 28.3 Gy and 27.6 Gy, respectively (compared 
to 24.2 Gy, 23.3 Gy and 22.9 Gy for the other institutes). Finally, the fraction of patients 
with AET Grade ≥2 was again greatest for Erasmus MC and Radboudumc (61.3% and 70.2%, 
versus 49.2%, 47.3% and 35.3%).
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The retraining application fitted 1000 new models in the MCCV using the Wijsman et al. 
(2015) model variables. Convergence of the algorithm using the Newton-Rhapson method 
was reached in 7 iterations for most repetitions (16 out of 1000 repetitions required 8 
iterations).
Figure 2 displays the distributions of regression coefficients trained in the 1000 repetitions 
of the MCCV (n=573), the final model trained on all data in the network (Wijsman et al. 
(2015) data and new data, n=787), and the original coefficients reported by Wijsman et al. 
(2015) (n=149). All coefficients move closer to zero in the final model compared to Wijsman 
et al. (2015). Table 3 shows the model coefficients retrained on all available data versus the 
coefficients reported by Wijsman et al. (2015). The coefficients for the intercept, CCR, and 
gender approximately halve in value. The T stage (≥cT3) coefficient reduces from 0.994 to 
near zero (-0.028). In absolute terms, the intercept displays the most variation in the MCCV 
results (i.e. it has the widest distribution). The relative standard deviation (the standard 
deviation divided by its mean), is greatest for T stage with 1.6.
Figure 2: Distributions of regression coefficients of the retrained models derived for the 1000 
repetitions of the distributed MCCV. Note the presence of the y-axis break (from 430 to 870) due to 
nearly all values of the mean esophagus dose being located in a single bin. 
Abbreviations: MCCV = Monte Carlo cross-validation.
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Table 3: Model coefficients for the original model reported by Wijsman et al. (2015) and for the single 
model retrained on all data available in the network.
 Wijsman et al. (2015) model
Retrained model 
(all data)
Coefficient n=149 n=787
Intercept -6.418 -3.233
Gender (male = 0, female = 1) 1.204 0.692
T stage (<cT3 = 0, ≥cT3 = 1) 0.994 -0.028
Concurrent chemoradiotherapy (no = 0, yes = 1) 2.645 1.080
Mean esophagus dose (per Gy) 0.117 0.086
The validation application computed performance metrics for the Wijsman et al. (2015) 
model and the 1000 new models. Figure 3 displays the distribution of the pairwise difference 
in RMSE between the retrained models and the Wijsman et al. (2015) model computed 
in the MCCV. The median RMSE difference is -0.03 corresponding to a 5.4% decrease of 
the error after retraining. The pairwise RMSE differences vary from -0.04 to 0.00 and their 
median is statistically significantly less than zero, indicating significant improvement of 
the retrained models (p<0.01, left-tailed Wilcoxon signed-rank test). Table 4 displays the 
pairwise differences for the secondary performance metrics, i.e. MAE, MLL and AUC per 
institute. Note that lower values of RMSE and MAE, but greater values of MLL and AUC, 
indicate better models. MLL and AUCs for three out of four institutes improve significantly 
for the retrained models. AUC for Radboudumc did not improve significantly, with a median 
pairwise difference of exactly zero. MAE deteriorates (increases) with 0.02 or 4.2% indicating 
worse performance of the retrained models. Significant deterioration of MAE was observed 
for the retrained models (p<0.01, right-tailed Wilcoxon signed-rank test). Histograms for the 
secondary performance metrics and average calibration plots are given in Supplementary 
Material S3 and S4, respectively.
Additionally, Table 4 shows the Wijsman et al. (2015) model performance on the current 
cohorts and therefore provides further evidence of the validation performance of this model, 
and allows for a comparison with the validation results obtained in the previous study by 
Dankers et al. (2018) [11]. This comparison is provided in the Supplementary Material S5.
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Figure 3: Histogram of paired differences in RMSE between the retrained models and the model 
reported by Wijsman et al. (2015). The RMSEs are calculated on the 1000 validation splits of the 
distributed MCCV. Values lower than zero indicate improved performance by the retrained models (as 
indicated by the ‘Improved’/’Deteriorated’ labels). Statistical significance at the 0.01 level according 
to a left-tailed Wilcoxon signed-rank test is indicated by †. 
Abbreviations: RMSE = root mean square error, MCCV = Monte Carlo cross-validation.
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Table 4: Average MCCV performance metrics for the original Wijsman et al. (2015) model and the 
retrained models on the 1000 MCCV validation splits (each containing 33% of the total data). Pairwise 
differences and percentage pairwise differences are calculated between the Wijsman et al. (2015) 
model and the retrained model for identical validation splits. Significant improvement of retrained 
models over the Wijsman et al. (2015) model is tested using one-sided Wilcoxon signed-rank tests. 
Smaller RMSE and MAE are superior, and larger MLL and AUC are superior. Numbers are reported as 
median value and interquartile range in parentheses.
  
Wijsman et 
al. (2015) 
model
Retrained 
models
Pairwise 
difference  
Percentage 
pairwise 
difference
Significant 
improvement
  Median (IQR) Median (IQR) Median (IQR) p Median (IQR) +/0
Centralized
RMSE 0.49 (0.02) 0.46 (0.02) -0.03 (0.01) <0.01† -5.4 (1.4) +
MAE 0.40 (0.03) 0.42 (0.01) 0.02 (0.02) 1.00‡ 4.2 (6.0) 0
MLL -0.73 (0.06) -0.62 (0.03) 0.10 (0.03) <0.01† 14.2 (3.1) +
AUC per institute*
MAASTRO 
clinic
0.71 (0.07) 0.73 (0.06) 0.02 (0.02) <0.01† 2.7 (3.4) +
Erasmus MC 0.64 (0.08) 0.66 (0.08) 0.02 (0.03) <0.01† 3.7 (4.5) +
NKI 0.67 (0.08) 0.69 (0.08) 0.02 (0.03) <0.01† 3.7 (5.0) +
 Radboudumc 0.89 (0.11) 0.91 (0.11) 0.00 (0.04) 0.18 0.0 (4.3) 0
Abbreviations: MCCV = Monte Carlo cross-validation, RMSE = root mean square error, MAE = mean 
absolute error, MLL = mean log-likelihood, AUC = area under the curve of the receiver operating 
characteristic, IQR = interquartile range.
† Significant improvement of the retrained models at the 0.01 level (Wilcoxon signed-rank test: left-
tailed for RMSE and MAE, right-tailed for MLL and AUC).
‡ MAE significantly deteriorated (p<0.01, right-tailed Wilcoxon signed-rank test).
* AUC values per site for the parts of the validation splits (33% of the total data of a site).
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Discussion
The results of this study confirmed our hypothesis: increasing training data size significantly 
improved the prediction performance as measured by the RMSE when compared to the 
original model by Wijsman et al. (2015) [10]. While RMSE improved, MAE showed the 
opposite behavior and was better for the original model. This means that the retrained 
models produced probabilities that were on average (slightly) further away from the true 
outcomes (resulting in larger MAE for the retrained models), but produced fewer extreme 
mispredictions (smaller RMSE). The decrease in RMSE is in line with the fact that training a 
logistic regression model disproportionally penalizes large deviations via the log-likelihood 
(similar to RMSE, which squares the errors). Note that the MLL also improved significantly 
(see Table 4 and Supplementary Material S3).
Additionally, AUCs of the retrained models improved significantly for three out of four 
institutes compared to the Wijsman et al. (2015) model (see Table 4), demonstrating better 
discrimination of patients developing Grade ≥2 AET. The retrained models might discriminate 
better for three out of four institutes because they were trained on 67% of the available 
new data from each institute additional to 147 Radboudumc patients, whereas the original 
model was trained on only 149 Radboudumc patients. It has to be noted that the AUC 
estimates per institute are less reliable since they are based on only the available patients 
of the respective institute, whereas the other performance metrics can be calculated on the 
entire validation split (all patients combined).
The inability to calculate an AUC on all patients combined, or test for significant differences 
between cohorts for continuous variables, could be viewed as a limitation of distributed 
learning compared to centralized learning (i.e. the conventional way of collecting multiple 
institutes’ data in one location and analyzing it). However, this is an unfair comparison. If our 
goal is to enable data analysis while fully preserving patient privacy, no centralized analysis 
is possible at all, but distributed learning still allows data analyses (e.g., cohort comparisons 
through summary statistics, model training and validation) with some exceptions (like an 
AUC on all patients). If the patient privacy conditions could be relaxed only for patient-level 
outcomes and model predictions (i.e. centralizing patient outcomes and model predictions), 
then an AUC on all patients could be calculated while still preserving patient privacy for the 
remaining individual variables. In summary, where centralized learning allows any type of 
data analysis at the cost of fully sharing patient-level data, distributed learning facilitates a 
varying range of data analyses given the desired rigor of patient privacy.
Since we have nearly quadrupled the amount of training data (the models were trained on 
147 Wijsman et al. (2015) training patients plus 67% of 640 new patients = 576 patients) 
the improvement in RMSE is small and might be considered to be of little clinical relevance. 
Therefore, we think that the predictive potential of the current four model variables has 
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been reached and likely cannot be improved further by training the model on more patients. 
The selection of model variables might be too restricted to explain the outcome, a situation 
that is commonly referred to as a model having high bias. Instead, future studies should 
investigate additional variables now that we have established the Personal Health Train 
infrastructure and have access to more clinical data.
The MCCV reveals some variance for the regression coefficients for the retrained models, 
which questions their significance. The histogram of T stage is located around zero implying 
that this variable is not relevant anymore. The histogram of mean esophagus dose (MED) is 
also close to zero. However, here we should not conclude that MED is irrelevant because: 
1) this coefficient measures the increased probability of the outcome per Gray increase, 
and 2) the histogram does not overlap with zero. Consider the following typical patient (see 
Table 2): male, ≥cT3, concurrent chemo and a MED of 25 Gy. If the MED increases by 3 Gy 
the probability of this patient to develop Grade ≥2 AET, according to the retrained model on 
all data (Table 3), would increase from 49% to 56%. This change in probability may still be 
clinically relevant.
However, we have to be cautious overinterpreting individual model coefficients. If we compare 
the individual retrained model coefficients with the Wijsman et al. (2015) model, we see 
that they all shrink and move closer to zero (see Figure 2 and Table 3), yet the RMSE hardly 
changes. Lower coefficients indicate that the model variables (e.g., a patient having ≥cT3, 
or concurrent chemotherapy) have become less important for predicting acute esophagitis 
in the cohorts of the four institutes. Even though we see that the model coefficients have 
shrunk substantially, the predicted probabilities per patient for the retrained models and 
the Wijsman et al. (2015) model change much less. In the MCCV, calculating the absolute 
differences in patient-level AET predictions between the retrained models and the Wijsman 
et al. (2015) model shows an average change of only 10.3 percentage points. This may 
explain why just modest changes in the performance metrics are observed. If dissimilar 
models, i.e. having wildly different coefficients, have near equal performance, then this 
questions their interpretability.
The present study contains a number of limitations. Firstly, the routine clinical care data was 
retrospectively collected from electronic health records by the participating institutes and 
showed considerable amounts of missing data for the model parameters (in 461 of 1248 
patients, or 36.9%; mostly due to missing MED in a single institute). For some institutes, 
relevant variables were not stored in a structured manner and were derived from related 
data elements, which may have had a negative impact on the data quality. For instance, 
chemotherapy timing (categorized as concurrent, sequential or none) was derived by 
comparing administration dates of chemotherapy cycles with the known radiotherapy time 
interval.
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Secondly, institutes used different versions of the AJCC TNM cancer staging edition resulting 
in different tumor stage and clinical cancer stage classifications. This may have affected 
patient inclusion when filtering for locally advanced (stage III) lung cancer patients: going 
from the TNM 6th edition to the 7th edition, a stage IIB can become a stage IIIA, and a stage 
IV can turn into a stage III or vice versa [22,23]. Additionally, the use of multiple AJCC TNM 
cancer staging editions adds uncertainty to the dichotomization of T stage (≥cT3) used in 
the model.
Thirdly, several institutes provided physical dose for the mean esophagus dose, instead of 
equivalent dose in 2 Gy fractions as recommended by the Wijsman et al. (2015) model. 
However, the effect is expected to be small: for the combined Radboudumc data for which 
both doses were available, the average difference between physical and equivalent mean 
esophagus dose was only -1.0 ± 0.3 Gy (one standard deviation).
Finally, two different toxicity scoring criteria are used by the participating institutes to score 
esophageal toxicity (RTOG vs CTCAE). As was discussed previously in our external validation 
study of the Wijsman et al. (2015) model (Dankers et al. (2018), [11]), some outcomes scored 
as Grade 1 according to RTOG can change to a Grade 2 using CTCAE (e.g., RTOG distinguishes 
between the use of non-narcotic and narcotic analgesics whereas CTCAE does not, and soft 
diet is considered Grade 1 in RTOG but Grade 2 in CTCAE).
In conclusion, we retrained an existing model by Wijsman et al. (2015) [10] for predicting 
acute esophageal toxicity (Grade 2 and greater). The retrained model is now based on 787 
patients from four institutes compared to 149 patients from a single institute for the original 
model. Using a Monte Carlo cross-validation, the decrease in root mean square error (RMSE) 
was found to be significant and an improvement of 5.4% was observed. As this model is now 
based on multi-institutional data and the RMSE improved significantly, we recommend the 
retrained model over the existing model for independent validation. However, given that 
we greatly increased the training cohort but observed only a small decrease in RMSE, we 
conclude that training the model on even more patients will be unlikely to yield further 
improvements. Instead, we recommend investigating additional predictors. This multi-
institutional machine learning study has been conducted without patient data leaving the 
institutes by using the Personal Health Train infrastructure.
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Supplementary Material
S1. Detailed cohort characteristics of the new data cohorts
The first cohort (n=228) was treated at MAASTRO clinic (Maastricht, The Netherlands) 
between May 2012 and December 2016. If given, sequential or concurrent chemotherapy 
consisted of 2 courses of a platinum-based doublet. Radiotherapy was administered with 
VMAT. Radiation dose prescription was heterogeneous: 100 patients received 30 Gy in 1.5 
Gy twice-daily fractions, followed by a sequential boost to the tumor of 2 Gy per fraction 
in 8-12 fractions (depending on dose to the organs-at-risk). The remaining 128 patients 
received either 24 fractions of 2.75 Gy (patients with no or sequential chemotherapy) or 30 
to 44 fractions of 1.8 Gy (again depending on organ-at-risk dose). Reported mean esophagus 
dose was physical (not biological equivalent dose). Patients receiving re-irradiations or 
treatment plan adaptations were excluded. Cancer staging was performed using the AJCC 
TNM 7th edition and AET was scored using the Common Toxicity Criteria for Adverse Events 
(CTCAE) v4.0 [14].
The second cohort (n=194) was treated with chemoradiotherapy at Erasmus MC (Rotterdam, 
The Netherlands) between 2008 and 2013. Chemotherapy was predominantly administered 
concurrently, consisting of 3 or 4 cycles of etoposide and cisplatinum, but some patients 
received sequential chemotherapy, and some patients received prior surgery. Radiotherapy 
was administered via 3-dimensional conformal radiotherapy (3D-CRT). Radiation 
prescription consisted of 30-33 fractions of 2 Gy for concurrent chemotherapy patients, and 
15-20 fractions of 3 Gy for sequential chemotherapy patients. Physical mean esophagus 
dose was reported. Cancer staging was updated for all patients conforming to the AJCC TNM 
8th edition and AET was scored using CTCAE v4.0.
The third cohort (n=171) was treated at The Netherlands Cancer Institute (NKI, Amsterdam, 
The Netherlands) between January 2014 and June 2018. The majority received concurrent 
chemotherapy consisting of daily low-dose cisplatin (6 mg/m2). The prescription dose was 
66 Gy delivered in 24 fractions of 2.75 Gy. Since 2016 dose to the mediastinal lymph nodes 
was lowered from 2.75 Gy to 2.42 Gy. Reported mean esophagus dose was converted to 
biologically equivalent dose in 2 Gy fractions with α/β = 10 Gy. Cancer staging was performed 
according to the AJCC TNM 7th edition for the majority of patients, but a small portion of the 
most recent patients were staged using the 8th edition. AET was scored using the Common 
Toxicity Criteria for Adverse Events (CTCAE) v4.0 (during treatment: in week 2, 4 and 5, after 
treatment: in week 1, 3, 6-8 and then every 3 months). Re-irradiated patients and patients 
with treatment plan adaptations were excluded.
The fourth cohort (n=47) was treated at Radboudumc – the same institute where the 
original model was developed – between June 2013 and December 2014. There were no 
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overlapping patients between the Radboudumc cohorts. Cohort inclusion criteria, treatment 
characteristics and follow-up were identical to the Wijsman et al. (2015) training cohort [10]. 
Cancer staging was performed using the AJCC TNM 7th edition and AET was scored based on 
the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria.
S2. Equations for mean absolute error and mean log-likelihood
The validation application not only calculates root mean square error (RMSE), but additionally 
calculates mean absolute error (MAE) and mean log-likelihood (MLL) according to:
𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
1
𝑁𝑁
∑ |?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖|
𝑁𝑁
𝑖𝑖=1 =
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ |?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖|
𝑁𝑁
𝑖𝑖=1𝑠𝑠  
𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
1
𝑁𝑁
∑ 𝑦𝑦𝑖𝑖𝑙𝑙𝑙𝑙𝑙𝑙?̂?𝑦𝑖𝑖 − (1 − 𝑦𝑦𝑖𝑖)𝑙𝑙𝑙𝑙𝑙𝑙(1 − ?̂?𝑦𝑖𝑖)
𝑁𝑁
𝑖𝑖=1  
=
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ 𝑦𝑦𝑖𝑖𝑙𝑙𝑙𝑙𝑙𝑙?̂?𝑦𝑖𝑖 − (1 − 𝑦𝑦𝑖𝑖)𝑙𝑙𝑙𝑙𝑙𝑙(1 − ?̂?𝑦𝑖𝑖)
𝑁𝑁
𝑖𝑖=1𝑠𝑠  
(S.1)
𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
1
𝑁𝑁
∑ |?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖|
𝑁𝑁
𝑖𝑖=1 =
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ |?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖|
𝑁𝑁
𝑖𝑖=1𝑠𝑠  
𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
1
𝑁𝑁
∑ 𝑦𝑦𝑖𝑖𝑙𝑙𝑙𝑙𝑙𝑙?̂?𝑦𝑖𝑖 − (1 − 𝑦𝑦𝑖𝑖)𝑙𝑙𝑙𝑙𝑙𝑙(1 − ?̂?𝑦𝑖𝑖)
𝑁𝑁
𝑖𝑖=1  
=
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ 𝑦𝑦𝑖𝑖𝑙𝑙𝑙𝑙𝑙𝑙?̂?𝑦𝑖𝑖 − (1 − 𝑦𝑦𝑖𝑖)𝑙𝑙𝑙𝑙𝑙𝑙(1 − ?̂?𝑦𝑖𝑖)
𝑁𝑁
𝑖𝑖=1𝑠𝑠  
𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
1
𝑁𝑁
∑ |?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖|
𝑁𝑁
𝑖𝑖=1 =
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ |?̂?𝑦𝑖𝑖 − 𝑦𝑦𝑖𝑖|
𝑁𝑁
𝑖𝑖=1𝑠𝑠  
𝑀𝑀𝑀𝑀𝑀𝑀𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =
1
𝑁𝑁
∑ 𝑦𝑦𝑖𝑖𝑙𝑙𝑙𝑙𝑙𝑙?̂?𝑦𝑖𝑖 − (1 − 𝑦𝑦𝑖𝑖)𝑙𝑙𝑙𝑙𝑙𝑙(1 − ?̂?𝑦𝑖𝑖)
𝑁𝑁
𝑖𝑖=1  
=
1
∑ 𝑁𝑁𝑠𝑠𝑠𝑠
∑ ∑ 𝑦𝑦𝑖𝑖𝑙𝑙𝑙𝑙𝑙𝑙?̂?𝑦𝑖𝑖 − (1 − 𝑦𝑦𝑖𝑖)𝑙𝑙𝑙𝑙𝑙𝑙(1 − ?̂?𝑦𝑖𝑖)
𝑁𝑁
𝑖𝑖=1𝑠𝑠  (S.2)
with i running over available patients, yi the observed outcome of an individual patient, ŷi 
the predicted probability, N the total number of patients, s the institutes and Ns the number 
of patients per institute.
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S3. Improvements of secondary performance metrics
Histograms for paired differences of performance metrics between the 1000 retrained models from 
the MCCV and the model by Wijsman et al. (2015) [10]. The metrics are calculated on the validation 
splits of the MCCV. The dashed line indicates the median value for the paired differences, and the 
solid line at x=0 indicates no change. Statistical significance at the 0.01 level according to a one-tailed 
Wilcoxon signed-rank test is indicated by † (left-tailed for MAE, right-tailed for MLL and AUC). MAE and 
MLL histograms are calculated for all institutes combined, whereas the AUC histograms are calculated 
per institute. Direction of improvement of retrained models versus the Wijsman et al. (2015) model 
depends on the metric and is indicated by the labels ‘Improved’ and ‘Deteriorated’. 
Abbreviations: MCCV = Monte Carlo cross-validation, MAE = mean absolute error, MLL = mean log-
likelihood, AUC = area under the curve of the receiver operating characteristic.
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S4. Average calibration plots per institute
  
Average calibration plots per institute of the retrained models (triangles) and the original model 
(circles) by Wijsman et al. (2015) calculated on the validation splits in the MCCV. The quantiles 
(triangles and circles) indicate grouped predicted probabilities of Grade ≥2 AET by the models versus 
grouped observed frequencies. For both the retrained models and the Wijsman et al. (2015) model, 
corresponding quantiles are averaged over the 1000 repetitions from the MCCV. Perfect predictions 
should lie on the dashed y = x reference line. Double histograms of patients with and without Grade 
≥2 AET, binned according to the predicted probabilities, are displayed at the bottom of the plots for 
both the retrained models and the Wijsman et al. (2015) model (again averaged over 1000 MCCV 
repetitions for corresponding bins). 
Abbreviations: MCCV = Monte Carlo cross-validation, AET = acute esophageal toxicity.
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S5. Comparison of Wijsman et al. (2015) model performance in the current study 
with the performance reported in the previous validation study by Dankers et al. 
(2018)
The Wijsman et al. (2015) model [10] was previously validated in a study by Dankers et al. 
(2018) on five patient cohorts from four institutes [11]. Three of the four institutes of the 
current study also provided data for the study conducted by Dankers et al. (2018). While the 
current study is focused towards improving the model by increasing training cohort size with 
multi-institutional data, the Wijsman et al. (2015) model is also validated on the patient 
cohorts from this study (in a 1000 times repeated Monte Carlo cross-validation) so that 
improvements can be quantified. These results provide further evidence of the validation 
performance of this model and allow for a comparison with the previous validation results. 
The table below shows the validation performance of the Wijsman et al. (2015) model on 
the patient cohorts from the current study and the previous cohorts from Dankers et al. 
(2018).
Comparison of Wijsman et al. (2015) model performance on validation cohorts from Dankers et al. 
(2018) and on validation cohorts from the current study. For Dankers et al. (2018) the AUC is calculated 
on the entire cohort and the 95% CI is given (based on the standard error). For the current study 
cohorts the AUC is reported as median and IQR based on the 1000 times repeated MCCV.
Cohort AUC Inclusion time interval Patients in total
Cross-
validation
Current study cohorts
MAASTRO clinic 0.71 (0.07) May 2012 –  Dec 2016 228 Yes
Erasmus MC 0.64 (0.08) 2008 – 2013 194 Yes
NKI 0.67 (0.08) Jan 2014  – Jun 2018 171 Yes
Radboudumc 0.89 (0.11) Jun 2013 – Dec 2014 47 Yes
Dankers et al. (2018)
MAASTRO Clinic 0.63 (0.55-0.71) Apr 2006 – Oct 2013 182 No
Radiotherapiegroep 0.81 (0.70-0.91) Jan 2013 – Mar 2016 73 No
NKI  (3D-CRT) 0.84 (0.75-0.94) Dec 1998 – Mar 2003 129 No
NKI  (IMRT) 0.64 (0.55-0.72) Jan 2008 – Nov 2010 172 No
Radboudumc 0.89 (0.80-0.98) Jun 2013 – Dec 2014 47 No
Abbreviations: AUC = area under the curve of the receiver operating characteristic, CI = confidence 
interval, IQR = interquartile range, MCCV = Monte Carlo cross-validation. 
A limited amount of overlap in data between the current study and the validation study 
by Dankers et al. (2018) is present. The time intervals for the MAASTRO cohorts overlap 
slightly (April 2006 until October 2013 versus May 2012 until December 2016), but exact 
determination of the overlap is impossible due to the privacy-preserving design of the 
Personal Health Train infrastructure. The time interval of the NKI cohort in this study does 
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not overlap with the two NKI cohorts used by Dankers et al. (2018) and therefore the NKI 
data in the current study constitutes new data. The new Radboudumc cohort (n=47) is 
identical in both studies.
The Wijsman et al. (2015) model performance has improved for MAASTRO clinic with 
the newer data. The model performance on the NKI cohort is in between the reported 
performance of the older NKI cohorts in Dankers et al. (2018). Since the Radboudumc cohort 
is identical in both studies the average AUC in the MCCV of the current study is identical to 
the AUC reported in Dankers et al. (2018).

Chapter 9
General discussion and future 
perspectives
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Machine learning interest has grown dramatically in the past decade. Its potential to 
transform healthcare practices and radiation oncology is vast. The previous chapters 
have demonstrated implementations of machine learning and distributed learning for 
radiotherapy outcomes in lung cancer patients. In this chapter, the pitfalls of current machine 
learning research in radiation oncology are discussed and recommendations are provided. 
Furthermore, the difficulties of distributed learning and future perspectives regarding its 
ability to overcome the common machine learning challenges are illustrated.
The reproducibility crisis in scientific research
Healthcare in general and radiation oncology specifically are prime areas where machine 
learning research is currently thriving, as is demonstrated by the large number of research 
publications on the subject. Simultaneously, we have to acknowledge that successful machine 
learning applications in routine clinical care are still highly scarce. The scientific results that 
are reported are often overly optimistic and frequently irreproducible [1]. This situation is 
commonly referred to as the reproducibility crisis [2], and is one of the main challenges in 
current scientific research. A common driver is a publisher’s desire to distribute positive, 
exciting and innovative findings. This contributes to pressures exerted on researchers to 
generate these positive results using the newest techniques, ultimately leading to selective 
reporting and publication bias. We should create an environment in which it is easier and 
more rewarding to publish results that show negative outcomes (as was done in Chapter 
5 [3]). Publishing a more balanced distribution of research studies with regards to their 
scientific results, should lead to a reduction of the number of irreproducible studies [4]. The 
added benefit of public knowledge of negative results is that there is less chance of multiple 
research groups pursuing the same unfruitful research line. This can clearly save valuable 
time and research money.
Another possibility to improve reproducibility is to preregister studies. By clearly detailing 
the research questions and intended methods, similarly to how clinical trials are registered 
before they are initiated, the researcher essentially has fewer options to (unintentionally) 
tweak results afterwards. For example, we preregistered our large scale distributed learning 
study (Chapter 7 [5]) on clinicaltrials.gov [6], before we initiated the research. If a research 
question is relevant and the proposed methodology statistically sound, and assessed as such 
through peer review, it can be argued that the results should be published no matter the 
outcome of the study (presuming the ultimate publication again adheres to the scientific 
reporting standards). In recent years, several journals have updated their range of article 
types with preregistered studies [7,8].
Common machine learning pitfalls and recommendations
Other major reasons for the high number of irreproducible results are methodological 
in nature. In many studies, also in machine learning based research, a combination of 
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unfavorable methodological factors are regularly observed, resulting in unduly optimistic 
findings and irreproducible outcomes. Among the common pitfalls in machine learning, the 
most prevalent are the simultaneous use of small cohorts, overly complex algorithms, an 
excessive number of input variables, and multiple testing.
The goal of machine learning for prediction modeling is to produce models that generalize 
well outside the training set (i.e. out-of-sample performance). To achieve this goal it is 
essential that the training set is a representative sample of the true, underlying distribution. 
The chances of having a representative sample evidently decreases with smaller datasets. 
Bootstrapping and repeated cross-validation techniques are recommended when dealing 
with small datasets to investigate the accuracy of the estimated performance metrics (see 
implementations in the studies presented in Chapter 3 [9], 6 [10], and 8 [11], and see 
relevant theory in Chapter 2 [12]).
In recent literature, the use of more complex algorithms, such as deep neural networks, has 
become increasingly popular, and it seems that we are risking a publication bias favoring 
added complexity for the wrong reasons. While these techniques have been very successful 
for a wide range of tasks, they are not the ultimate algorithms suitable for all machine 
learning problems. Complex algorithms are inherently more opaque; their inner workings 
can be extremely hard to untangle, which is why they received the unenviable black box 
qualification. They can contain many hyperparameters (i.e. tunable algorithm settings, 
such as the number and type of layers forming a neural network) which make them more 
flexible and able to better fit the data. The downside is that this also increases the chances 
of overfitting and subsequently reducing reproducibility (bias-variance tradeoff, Chapter 2 
[12]). Additionally, the increased flexibility of complex algorithms also presents opportunities 
for them to be manipulated. Deep neural networks with excellent performance on the public 
ImageNet or MNIST databases have been found to classify objects (with very high predicted 
probabilities) in images that are indistinguishable from noise to humans [13]. Additionally, 
they have also been shown to be vulnerable to attacks by adversarial examples: by applying 
minute manipulations to input images, again unobservable to humans, object classifications 
can be completely altered [14].
All of this is not to say that we should steer away from complex algorithms; arguing the 
opposite position also has merit. Simpler algorithms can impose too much bias, i.e. by 
assuming linear/logistic relations between inputs and outcome, risking underfitting of the 
data and potentially wasting valuable information. Evaluating different algorithms for the 
task at hand is therefore a commended approach. It is paramount that this is performed 
using statistically sound methods, by using, for example, the nested cross-validation 
approach employed in Chapter 6 [10]. In that study we compared six classifiers for predicting 
a range of radiotherapy outcomes using clinical, dosimetric and blood biomarkers. The 
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results showed equal prediction performance between relatively simple regularized logistic 
regression models and more complex and flexible random forest models. The increased bias 
for the logistic regression models was apparently nullified by a lower variance, resulting in 
similar algorithm performance. Regularized logistic regression models even outperformed 
other flexible algorithms, such as support-vector machines and single-hidden-layer neural 
networks. It would be valuable for future studies proposing complex machine learning 
models, to include comparisons with simpler alternative modeling algorithms. In this manner, 
their added benefit can be proven and their use warranted, but needlessly overcomplicated 
approaches can be prevented.
Another common pitfall is the use of large numbers of input variables to explore their 
predictive qualities for the outcome under investigation. Researchers regularly collect a 
large number of variables simply because they are available (e.g., in the electronic health 
record or treatment planning system), and they do not want to risk excluding worthwhile 
predictors. In other situations the statistical analyses themselves result in a large number 
of input variables, e.g., by calculating a large set of pre-engineered variables or by using 
modeling techniques, such as deep learning, that can produce many ‘hidden’ variables by 
themselves. The danger lies in the fact that having many variables increases the probability 
of encountering chance correlations between some input variables and the outcome 
(overfitting). Variables with chance correlations in the training dataset have no predictive 
power and turn out to be useless when validated on new data.
Consider the following simulation example using purely random data for variables and 
outcome: a cohort of 300 patients with 20% incidence (i.e. the outcome is observed in a 
fifth of the patients) is split (stratified) into training (n=200, 67%) and validation cohorts 
(n=100, 33%). There are a total of 1000 input variables. Both the variables and the outcome 
are created using a uniformly distributed random number generator. A logistic regression 
model is fitted using the five variables that show maximum correlation (Pearson correlation 
coefficient) with the random outcome. The model performance is evaluated in both the 
training and validation cohorts. The entire process is repeated 5000 times to attain a good 
estimate of the average model performance (generating new random variable and outcome 
data for each repetition, splitting into training and validation cohorts, and fitting using the 
five most correlated variables). The simulation results are displayed in Figure 1.
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Figure 1: A 5000 times repeated simulation using uniformly distributed random input and outcome 
data. Training and validation cohorts contain 200 and 100 patients respectively. The incidence is 20% 
in both cohorts and there are 1000 input variables. 5000 models are fitted in the training cohort 
using the five variables that show maximum correlation with the output in each repetition. The top 
panels show median ROC plots and 68%/95% confidence bands. AUC distributions are displayed in 
the bottom panels. The complementary cumulative distribution functions, i.e. the probabilities of 
encountering AUCs exceeding specific values, are shown in red (normalized to the panel height). An 
AUC of 0.50 is indicated in all panels by the dashed lines. 
Abbreviations: ROC = receiver operating characteristic, AUC = area under the curve of the receiver 
operating characteristic, CI = confidence interval, ‘P(AUC > x)’ = probability of the complementary 
cumulative distribution function of the AUCs.
Chance correlations between the input variables and the outcome occur, even though the 
simulation data is completely random. This is apparent from the average training cohort 
AUC, which equals 0.80 on average. This value is clearly a function of the number of input 
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variables; with more input variables there is an increased risk of chance correlations with the 
outcome leading to better training cohort performance (since the five variables with highest 
correlation are selected). Training cohort AUCs often demonstrate inflated and unrealistic 
performance, and for this reason model performances need to be evaluated in validation 
cohorts (Chapter 4 [15]). The distribution of AUCs in the validation cohort is centered 
around 0.50, which intuitively makes sense since this (random) data was unobserved 
during the model fitting step. However, even in the validation set there is a probability that 
an elevated AUC is observed due to chance correlations. This probability can be derived 
from the complementary cumulative distribution function (1 – the cumulative distribution 
function), which demonstrates the probability of observing AUCs exceeding specific values. 
For the current simulation experiment the chance of observing an AUC greater than 0.60, 
which is a value regularly encountered in radiation oncology prediction modeling literature, 
equals 8.6% (i.e. P(AUC > 0.60) = 8.6%).
The simulation demonstrates the risk of performing statistical analyses on small datasets 
combined with a large input variable space. Fortunately, this risk is easily reduced by 
increasing cohort sizes (both training and validation) and by remaining conservative with 
regards to the number of input variables. Traditionally, 10 events per candidate variable 
has been the rule of thumb for determining the number of input variables to maximally 
consider in logistic regression modeling [16]. For the simulation this would mean that only 4 
candidate variables should be considered instead of 1000 (200 patients with 20% incidence 
results in 40 events, leading to only 4 candidate variables). This rule is often misinterpreted 
as 10 events per final model variable. This is clearly wrong: as the simulation experiment 
shows, the risk of chance correlations between input variables and outcome is increased by 
considering more input variables, even though only a limited number of variables is selected 
for the final model. It has been argued that this rule is too conservative [17], and the 
drawbacks of this rule have been demonstrated along with improved alternative guidelines 
[18]. It is however, generally good advice to err on the side of caution and keep the number 
of variables limited to prevent overfitting. An alternative approach is to use robust feature 
selection techniques (such as regularization) combined with proper methods (Chapter 2 
[12] and 6 [10]).
Another recommendation is to include multiple validation cohorts. For the simulation 
example, the probability of observing an AUC greater than 0.60 in two independent cohorts 
simultaneously is only 0.7% (0.0862). This leads us to one of the most common and dangerous 
machine learning pitfalls: multiple testing. Multiple testing is the (unintentional) practice of 
cherry picking results from multiple performance metrics, or from multiple validation sets. 
There are methods for dealing with multiple testing, for example by applying a Bonferroni 
correction (Chapter 6 [10]), or by controlling the false discovery rate [19]. If multiple testing 
is not taken into account correctly, this is analogous to rolling a dice several times to increase 
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the probability of rolling a six at least once. Revisiting the simulation experiment; the chance 
of observing an AUC greater than 0.60 in at least one of the two independent cohorts is 
16.5% (one minus the chance of not observing 0.60 in both cohorts, or 1 – (1 – 0.086)2), 
which is nearly double! If multiple metrics are calculated, or multiple cohorts are collected, 
all results should be presented by the researcher so that they can be correctly interpreted 
by the reader.
In summary, we would do well to keep our models as simple as possible (but not too 
simple), so that we maximize generalizability to new data. As a first step, researchers should 
investigate how much their models improve by using larger training and validation cohorts 
before they turn to algorithms that are more flexible and complex. In Chapter 8, we retrained 
the published model from Chapter 3 using a training cohort that was nearly quadrupled in 
size [9,11]. The model performance improved significantly, although in an absolute sense, 
not by much. In Chapter 7, we trained a simple model (logistic regression) with a limited 
number of variables on approximately 15 000 patients [5]. Increasing training cohort size 
in this case is also not likely to yield substantial improvements. Both chapters are examples 
where follow-up studies on these datasets, focusing on exploring new variables or more 
advanced modeling techniques, are indicated. Finally, a very important recommendation 
for machine learning studies is to improve the quality of the data, e.g. by storing data in a 
structured manner and according to broadly accepted standards and scoring guidelines. The 
performance gains by improving data quality could exceed the gains that can be achieved by 
resorting to more advanced machine learning algorithms.
Recommendations for reporting on modeling studies 
There are clear recommendations for the reporting of prediction modeling studies that aim 
to advance study transparency and assist readers in assessing the utility of prediction models. 
The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or 
Diagnosis (TRIPOD) Initiative generated the TRIPOD Statement with this goal in mind [20]. In 
practice, these recommendations are still regularly neglected, and the quality of reporting 
in modeling studies frequently lacks necessary details. This hampers the interpretation 
of the results and again negatively affects reproducibility. Where possible, the original 
data should be made available, although admittedly, this is often difficult in healthcare 
research due to privacy concerns. All details regarding the employed methods should be 
clearly presented, and should preferably be published to the readers, for example, through 
software development hosting platforms such as GitHub (as was done in Chapters 6 [10], 
7 [5], and 8 [11]). Finally, the prediction model itself should also be provided, even if it is a 
complex or black box type model. The presented results cannot be verified or replicated if 
the model itself is not published, and taking results at face value clearly is not very scientific.
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“The proof of the pudding is in the eating” (William Camden, Remaines of a Greater Worke, 
Concerning Britaine, 1605). This famous proverb applies particularly well to the field of 
machine learning. The true value of the plethora of models presented in literature can 
only be established by testing them on new cohorts and evaluating their generalizability. 
Publications on model validation studies, preferably performed by research groups 
other than the original model developers, would form the best approach to tackling the 
reproducibility crisis. Currently, the balance between studies on new model development 
versus model validation is heavily skewed towards new models. The scientific community 
in a broad sense, and this includes publishers of scientific studies, has to become more 
accepting towards studies on reproducibility and validation of existing models.
Distributed learning as an enabling technology
The reason that we observe so many small cohorts in machine learning research is 
predominantly driven by the fact that acquiring and curating data is very labor-intensive. 
Additionally, sharing data to increase patient numbers is difficult due to increasingly stringent, 
but necessary, privacy regulations (e.g., the EU’s General Data Protection Regulation (GDPR) 
[21]). Distributed (machine) learning can play a pivotal role in circumventing privacy concerns 
in healthcare studies, and additionally enable research that overcomes the previously 
described machine learning pitfalls.
In the conventional centralized learning approach, data is collected at a single hub before 
data analyses are performed. This is in stark contrast with distributed learning; the data 
remains at the source and data analyses are brought to the data. Privacy concerns are 
effectively negated with this approach, and research on larger datasets becomes possible. 
Distributed learning can therefore be a solution for the common machine learning pitfall of 
small patient cohorts. Model development using a variety of machine learning algorithms 
(e.g., Bayesian networks [22], support vector machines [23], regularized logistic regression 
[24], and deep neural networks [25]) is feasible in a distributed setting. Furthermore, we 
have shown in Chapter 7 that the technology scales to large patient numbers and can be 
implemented in a short timeframe [5]. In Chapter 8, we demonstrated that the technology 
is suitable for clinical model validation and updating [11]. These results illustrate that 
distributed learning could be the driving technology that will enable a truly rapid learning 
healthcare system [26]. With the recent introduction of proton therapy in the Netherlands, 
and the advent of MRI-guided radiotherapy, a distributed learning network could provide us 
with the means to evaluate innovations while they are being implemented.
The challenges of distributed learning
As discussed, distributed learning has the potential to overcome some of the current machine 
learning challenges in healthcare research. However, a distributed learning approach also 
presents itself with several new challenges.
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Firstly, since the data is located in the hospitals and is not allowed to leave, the algorithms 
have to be converted so that they produce the same results as if the data were centralized. 
Typically, this involves implementing an optimization process where algorithms repeatedly 
visit the hospitals and they iteratively converge to the central solution. Converting data 
analyses to function in a distributed setting can be time consuming, and in some situations, 
not even be possible at all. Strictly speaking, a single receiver operator characteristic curve 
(ROC) and its area under the curve (AUC) cannot be calculated for distributed data. The 
outcomes and model probabilities of the individual patients would need to be centralized (to 
enable the necessary ranking of these values) and this could hypothetically be traced back 
to a specific patient in special cases. Centralizing patient-level data breaks the requirements 
of the distributed learning platform that is employed in Chapters 7 and 8 [5,11]. For this 
reason, we choose to calculate the root mean square error (RMSE) instead of the AUC 
in Chapter 8, which does not have this problem. This challenge also exists for other data 
analyses, such as the Wilcoxon rank-sum test to compare parameter distributions across 
hospitals.
In the distributed learning studies presented in this thesis (Chapters 7 and 8 [5,11]), we 
choose to use semantic web technologies, open ontologies and FAIR data guidelines 
(Findable, Accessible, Interoperable, Reusable) [27], to enhance data interpretability and 
reusability. These data characteristics are extremely important in a distributed setting where 
the researcher does not have direct access to the data. The data conditioning techniques used 
in this thesis revolved around Semantic Web technology [28]. They consisted of, amongst 
others, mapping data to triples using ontologies (resource data framework (RDF) statements 
of the form subject–predicate–object), storing data in graph databases, and querying data 
using SPARQL (SQL equivalent for graph databases). These standards are mostly unfamiliar 
to the hospitals’ IT staff, and knowledge and implementation of these technologies almost 
solely resides with the researcher. Similar to the algorithm conversions that are necessary in 
a distributed learning infrastructure, using data conditioning adds another significant time-
consuming component to the research. 
Furthermore, imposing advanced but unfamiliar IT technologies on participating hospitals 
not only hampers the acceptance and rollout of the distributed learning infrastructure, but 
it also threatens the sustainability of existing networks and application of new methods 
when research projects are finished. In addition, distributed learning networks require 
maintenance to remain available, but there is little incentive for this once a research 
project has ended and the employed methods are not implemented in the clinic as a part of 
routine practice. Ongoing research within our group is focused towards improving the ease 
of use of performing distributed learning research, for example by designing web-based 
user interfaces where programming knowledge is not required. While there is a growing 
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publication base for distributed learning implementations, there is still a long way to go 
before its use will have become commonplace.
Distributed learning is often directly compared with conventional centralized learning. 
If centralized learning is possible, i.e. the main hurdles regarding sharing the data and 
patient privacy are surmountable, it is arguably the easier approach for performing 
the research. Additionally, the inability to perform certain calculations in a distributed 
learning infrastructure is another argument in favor of centralized learning. However, the 
comparison is somewhat flawed and incomplete. If we fully share patient data to enable any 
analysis via centralized learning, the exact same results could have been obtained through 
distributed learning while only sharing the minimally necessary data. Distributed learning 
therefore aligns nicely with the ‘minimum necessary’ axiom as prescribed in HIPAA (Health 
Insurance Portability and Accountability Act [29], United States Department of Health 
and Human Services). On the contrary, if no sharing of patient-level data is authorized, 
distributed learning still enables a range of available data analyses, where otherwise no 
analyses would have been possible at all. For example, the study presented in Chapter 
7 (distributed learning on more than 20 000 patients [5]) would not have been possible 
without distributed learning, as the participating hospitals would have not been very willing 
to share that amount of data for centralized analysis. Ultimately, it is not the choice between 
a distributed or centralized learning approach, but the desired level of patient privacy that 
determines which data analyses are possible.
Conclusion and future perspectives
Radiation oncology has a strong history of using sophisticated computational techniques 
to provide the best possible care for our patients. Radiation treatments have drastically 
improved since the introduction of (fully automated) inverse treatment planning. Collection 
of imaging, segmentation and dosimetric information forms an integral part of the treatment 
resulting in large amounts of data. Furthermore, technical innovations, such as MRI-guided 
radiotherapy, are developed and introduced at a rapid pace. These examples illustrate that 
radiation oncology is well-suited to be one of the leading fields for machine learning research 
in medicine, and act as a frontrunner in translating research findings to clinical practice.
There is currently a strong acceptance towards machine learning studies in healthcare 
research. The potential (but also the expectations) of machine learning to provide 
meaningful applications are exceptionally high. We should seize this opportunity to not only 
focus on producing new prediction models using advanced algorithms, but also on creating 
a sustainable environment for future machine learning research. The distributed learning 
infrastructure that was developed to perform two machine learning studies (Chapter 7 [5] 
and 8 [11]) is an attempt to create such an environment.
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Additionally, if we can improve our machine learning methods this will enhance the 
reproducibility of our research. For this reason, the presented esophageal toxicity model 
(Chapter 3 [9]) has been thoroughly investigated in follow-up studies (Chapter 4 [15] and 
8 [11]). Hypotheses were tested and negative results were also published (Chapter 5 [3]). 
Finally, different machine learning algorithms were compared on a large collection of 
radiation oncology datasets in a robust manner (Chapter 6 [10]).
With this work, we have aimed to contribute to the goal of sustainable machine learning 
research in healthcare and radiation oncology specifically. In a utopian vision all radiotherapy 
institutes are continuously connected. This will enable fast prediction model development 
and validation while innovations, such as proton or MRI-guided radiotherapy, are being 
introduced. Such an environment can also provide us with the means to conduct the 
necessary quality assurance for safe applications of machine learning in clinical practice. 
It can lead to the implementation of true decision support and turn this into a reliable 
resource for both patients and physicians. While admittedly this vision is still a ways off from 
being realized, it is a worthy goal to pursue.
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Summary
There is a growing interest for prediction modeling of radiation oncology treatment 
outcomes. Prediction models have the potential to assist patients and physicians in making 
personalized treatment decisions. This thesis deals with prediction modeling and distributed 
learning for radiotherapy outcomes in lung cancer patients.
In Chapter 2, an introduction to prediction modeling methodology was provided. A brief 
overview was given on the underlying theory, e.g., modeling techniques, performance 
metrics for evaluation, and model validation approaches.
The majority of normal-tissue complication probability (NTCP) models for the prediction of 
side-effects in locally advanced stage non-small cell lung cancer (NSCLC) patients treated 
with (chemo-)radiotherapy are based on conventional three-dimensional conformal 
radiotherapy (3D-CRT). Contemporary radiation techniques, such as intensity-modulated 
radiation therapy (IMRT) or volumetric modulated arc radiotherapy (VMAT), allow more 
conformal dose distributions. The changes in dose distributions that arise due to the 
transition from 3D-CRT to IMRT/VMAT requires the NTCP models to be updated. In Chapter 3, 
a multivariable logistic regression prediction model was developed for prediction of acute 
esophageal toxicity (AET) in lung cancer patients undergoing (chemo-)radiotherapy. The 
prediction model consisted of the following variables: concurrent chemotherapy, gender, 
clinical tumor stage, and mean dose to the esophagus. A bootstrapping methodology was 
applied to internally validate the performance of the model. The area under the receiver 
operating characteristic curve (AUC) was 0.82 after correcting for optimism.
External validation of prediction models is of paramount importance to assess their 
generalizability. In Chapter 4, the model that was developed in Chapter 3 was externally 
validated using five cohorts collected from four Dutch institutes (603 patients in total). The 
cohorts differed substantially in terms of the incidence of AET, the toxicity scoring system 
that was applied, and the administration of concurrent chemotherapy. Discrimination 
performance of the model was excellent in three out of five cohorts (AUC ≥ 0.80), but poor 
in two cohorts that included patients receiving substantially different treatment compared 
to the training cohort. These results illustrate the importance of validating the performance 
of models in local cohorts before they are implemented in clinical practice.
Using conventional dose-volume histogram parameters (including the mean radiation dose) 
omits spatial information of the dose distribution. The esophagus is a tubular organ and 
spatial information regarding the dose distribution of the esophagus wall may be valuable 
for the prediction of AET after (chemo-)radiotherapy. In Chapter 5, the added value 
of incorporating spatial dose information in the prediction model that was presented in 
Chapter 3 was investigated. Dose-surface histograms and polar dose-surface maps were 
222 CHAPTER 10
generated, and dosimetric variables were derived that included spatial information. 
Unfortunately, no improvement in model performance was observed over the original 
model that omitted spatial dosimetric information. It was sufficient to only consider the 
mean dose to the esophagus (in conjunction with the clinical variables) for the prediction of 
AET after (chemo-)radiotherapy.
General machine learning studies have investigated the performance of a wide range of 
classification algorithms, but there is no consensus on the optimal algorithm. It is unclear 
if results from the general machine learning literature are directly applicable to the field 
of radiation oncology. In Chapter 6, the performance of six common binary classification 
algorithms (decision tree, random forest, neural network, support vector machine, elastic 
net logistic regression, LogitBoost) on (chemo-)radiotherapy datasets was investigated using 
a nested cross-validation approach. The developed code and documentation was made 
publicly available. Twelve datasets (3484 patients) from prior studies on toxicity, survival, 
and tumor control were collected from multiple institutes, containing a variety of clinical, 
dosimetric, or blood biomarker variables and for different tumor sites (i.e. (non-)small 
cell lung cancer, head and neck cancer, and meningioma). On average, elastic net logistic 
regression and random forest provided a small but significant improvement in discrimination 
performance over the other classification algorithms. The results indicated that an informed 
pre-selection of classification algorithms improved the performance over random selection.
Large amounts of patient data are required in order to develop accurate prediction 
models that can be safely implemented in clinical practice. The conventional approach of 
aggregating data in a central location for statistical analyses is challenging for a variety of 
reasons (e.g., administrative, political, ethical, or technical). One possible resolution is to 
develop and validate prediction models using distributed learning; algorithms are sent 
to the data instead of aggregating the data in a central location. In Chapters 7 and 8, a 
distributed learning infrastructure was developed to enable privacy-preserving machine 
learning studies across healthcare institutes. Algorithms and implementations were made 
publicly available in both studies. In Chapter 7, eight international healthcare institutes 
(Amsterdam, Cardiff, Maastricht, Manchester, Nijmegen, Rome, Rotterdam, Shanghai) were 
connected to perform a pre-registered prediction modeling study that demonstrated the 
feasibility of reaching large patient numbers (23 203 NSCLC patients). Additionally, this 
study was performed in only 4 months highlighting that the technology can be implemented 
in a short time frame to answer specific research questions.
In Chapter 8, the prediction model for AET after (chemo-)radiotherapy that was presented 
in Chapter 3, was retrained using a privacy-preserving distributed learning infrastructure. 
Data on locally advanced NSCLC patients was collected in four Dutch healthcare institutes, 
which resulted in a (distributed) dataset that contained four times more patients for model 
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updating (787 patients in total). The improvement of the retrained model over the existing 
model was tested for significance using a Monte Carlo cross-validation. The root mean 
square error showed a significant but modest improvement, by 5.4% on average.
A general discussion on the common pitfalls in machine learning research in radiation 
oncology was presented in Chapter 9, and recommendations for future studies were 
provided. The challenges of distributed learning were illustrated and the ability of this 
technology to improve future machine learning research in healthcare was hypothesized.
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Nederlandse samenvatting
Er is een groeiende interesse in de ontwikkeling van predictiemodellen voor de voorspelling 
van radiotherapie behandeluitkomsten. Predictiemodellen hebben de potentie om 
patiënten en artsen te ondersteunen bij het maken van gepersonaliseerde keuzes omtrent 
de behandeling. Dit proefschrift behandelt de ontwikkeling van predictiemodellen en 
gedistribueerd leren voor radiotherapie behandeluitkomsten bij longkankerpatiënten.
In Hoofdstuk 2 werd een introductie omtrent de methodologie van de ontwikkeling van 
predictiemodellen geschetst. Er werd een kort overzicht gegeven van de onderliggende 
theorie, waaronder modelleringstechnieken, maatstaven voor modelevaluatie, en methodes 
voor validatie.
Het merendeel van de predictiemodellen voor de voorspelling van bijwerkingen (NTCP) 
in patiënten met loco-regionaal gevorderd stadium niet-kleincellig longkanker (NSCLC) 
die behandeld worden met (chemo)radiotherapie zijn gebaseerd op conventionele 
3-dimensionale conformatie radiotherapie (3D-CRT). Moderne bestralingstechnieken, 
zoals intensiteits-gemoduleerde radiotherapie (IMRT) of volumetrisch-gemoduleerde 
radiotherapie (VMAT), staan dosisverdelingen toe die nog “conformeler” zijn. De 
veranderingen van de dosisverdeling die optreden bij de transitie van 3D-CRT naar IMRT/
VMAT maken het noodzakelijk dat de NTCP modellen worden herzien. In Hoofdstuk 3 
werd een multivariabel logistisch regressiemodel ontwikkeld voor predictie van acute 
slokdarm toxiciteit (AET) bij longkankerpatiënten die (chemo)radiotherapie ondergaan. Het 
predictiemodel bestond uit de variabelen: concomitante chemotherapie, geslacht, klinisch 
tumorstadium, en gemiddelde dosis in de slokdarm. Met een bootstrapping techniek werd 
de prestatie van het model intern gevalideerd. De oppervlakte onder de receiver operating 
characteristic curve (AUC) bedroeg 0.82 na correctie voor optimisme.
Externe validatie van predictiemodellen is essentieel om hun generaliseerbaarheid aan te 
tonen. In Hoofdstuk 4 werd het model dat was ontwikkeld in Hoofdstuk 3 extern gevalideerd 
in vijf cohorten afkomstig uit vier Nederlandse ziekenhuizen (603 patiënten in totaal). De 
cohorten verschilden substantieel van elkaar met betrekking tot de incidentie van AET, het 
gebruikte systeem voor het scoren van de toxiciteit, en de toepassing van concomitante 
chemotherapie. Het discriminerend vermogen van het model was uitstekend in drie van 
de vijf cohorten (AUC ≥ 0.80), maar matig in twee van de cohorten die patiënten bevatten 
die een substantieel andere behandeling kregen dan het trainingscohort. Deze resultaten 
illustreren het belang van het valideren van modelprestaties in lokale cohorten voordat 
modellen worden geïmplementeerd in de klinische praktijk.
Het gebruik van conventionele dosis-volume histogram parameters (inclusief de gemiddelde 
bestralingsdosis) laat spatiële informatie van de dosisverdeling buiten beschouwing. 
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De slokdarm is een hol orgaan en spatiële informatie omtrent de dosisverdeling op de 
slokdarmwand kan waardevol zijn bij de voorspelling van AET na (chemo)radiotherapie. In 
Hoofdstuk 5 werd de toegevoegde waarde van het meenemen van spatiële dosisinformatie 
in het predictiemodel van Hoofdstuk 3 onderzocht. Dosis-oppervlakte histogrammen en 
polaire dosis-oppervlakte afbeeldingen werden vervaardigd, en er werden dosimetrische 
parameters afgeleid die spatiële informatie meenemen. Er werd helaas geen verbetering van 
de kwaliteit van het model waargenomen ten opzichte van het originele model dat spatiële 
dosisinformatie buiten beschouwing liet. Het bleek voldoende om alleen de gemiddelde 
dosis in de slokdarm in ogenschouw te nemen (samen met de klinische variabelen) voor de 
predictie van AET na (chemo)radiotherapie.
Algemene machine learning studies hebben de prestaties onderzocht van een breed scala 
aan verschillende classificatie algoritmes, maar er is geen consensus over het optimale 
algoritme. Het is onduidelijk in hoeverre de resultaten van algemene machine learning 
studies van toepassing zijn binnen de radiotherapie. In Hoofdstuk 6 werden de prestaties van 
zes veelvoorkomende classificatie algoritmes (decision tree, random forest, neural network, 
support vector machine, elastic net logistic regression, LogitBoost) op (chemo)radiotherapie 
datasets onderzocht met behulp van een geneste cross-validatie aanpak. Twaalf datasets 
(3484 patiënten) van eerdere studies naar toxiciteit, overleving, en tumor controle werden 
verzameld afkomstig uit verschillende instituten, bestaande uit klinische, dosimetrische 
en bloed biomarker variabelen en voor verschillende tumor doelgebieden (i.e. (niet-)
kleincellig longkanker, hoofd-halskanker, en meningeomen). Gemiddeld genomen toonden 
elastic net logistic regression en random forest een kleine maar significante verbetering 
in discriminerend vermogen ten opzichte van de andere algoritmes. De resultaten gaven 
aan dat een geïnformeerde voorselectie van het classificatie algoritme (op basis van onze 
empirische studie) een verbeterde prestatie gaf dan een random selectie van het algoritme.
Er zijn grote hoeveelheden patiëntendata nodig om nauwkeurige predictiemodellen te 
ontwikkelen die veilig kunnen worden geïmplementeerd in de kliniek. De conventionele 
aanpak om data centraal te verzamelen voorafgaand aan statische analyses is uitdagend 
vanwege een verscheidenheid van redenen (e.g., administratief, politiek, ethisch, of technisch). 
Een mogelijke oplossing hiervoor is het ontwikkelen en valideren van predictiemodellen 
middels distributed learning: algoritmes worden naar de data toegezonden in tegenstelling 
tot het verzamelen van de data op één centrale locatie. In de Hoofdstukken 7 en 8 werd een 
distributed learning infrastructuur ontwikkeld en geïmplementeerd die het mogelijk maakt 
om machine learning studies uit te voeren over meerdere instituten zonder schending van 
patiënt-privacy. De ontwikkelde algoritmes werden openbaar beschikbaar gesteld in beide 
studies. In Hoofdstuk 7 werden acht internationale zorginstituten (Amsterdam, Cardiff, 
Maastricht, Manchester, Nijmegen, Rome, Rotterdam, Shanghai) verbonden om een vooraf 
geregistreerde modeleringsstudie uit te voeren met als doel de haalbaarheid aan te tonen 
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tot het bereiken van grote patiënten aantallen (23 203 NSCLC patiënten). De studie werd 
uitgevoerd in slechts 4 maanden, wat demonstreerde dat de technologie in een korte tijd 
kan worden geïmplementeerd om specifieke onderzoeksvragen te beantwoorden.
In Hoofdstuk 8 werd het predictiemodel voor AET na (chemo)radiotherapie, dat was 
gepresenteerd in Hoofdstuk 3, opnieuw getraind met behoud van patiënt-privacy 
door gebruik te maken van de distributed learning infrastructuur uit Hoofdstuk 7. Data 
van patiënten met loco-regionaal gevorderd stadium NSCLC werd verzameld in vier 
Nederlandse zorginstituten, wat resulteerde in een (gedistribueerde) dataset die vier keer 
meer data bevatte voor updaten van het model (787 patiënten in totaal). De verbetering 
van het opnieuw getrainde model ten opzichte van het originele model werd getoetst op 
significantie middels een Monte Carlo cross-validatie. De root mean square error vertoonde 
een significante maar kleine verbetering, met 5.4% gemiddeld.
Een algemene discussie over de meest voorkomende valkuilen van machine learning in 
de radiotherapie werd gepresenteerd in Hoofdstuk 9, en aanbevelingen voor toekomstige 
studies werden gegeven. De uitdagingen van distributed learning werden uiteengezet en 
de potentie van deze technologie om toekomstige machine learning studies in de zorg te 
verbeteren werd beschouwd.
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